

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21 CAS patent coverage to include exemplified prophetic
substances identified in English-, French-, German-,
and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26 MARPAT enhanced with FSORT command
NEWS 4 NOV 26 CHEMSAFE now available on STN Easy
NEWS 5 NOV 26 Two new SET commands increase convenience of STN
searching
NEWS 6 DEC 01 ChemPort single article sales feature unavailable
NEWS 7 DEC 12 GBFULL now offers single source for full-text
coverage of complete UK patent families
NEWS 8 DEC 17 Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 11 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 14 FEB 10 COMPENDEX reloaded and enhanced
NEWS 15 FEB 11 WTEXTILES reloaded and enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 21:35:45 ON 17 FEB 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 21:35:52 ON 17 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 FEB 2009 HIGHEST RN 1107125-97-2
DICTIONARY FILE UPDATES: 16 FEB 2009 HIGHEST RN 1107125-97-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10574676.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

8-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

4-7 5-9 7-8 8-9 10-14 11-12

exact bonds :

8-10 10-11 12-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 10 :

G1:O,S,N,Cy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 21:36:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4019 TO ITERATE

100.0% PROCESSED 4019 ITERATIONS

1763 ANSWERS

SEARCH TIME: 00.00.01

L2 1763 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

185.88

186.10

FILE 'CAPLUS' ENTERED AT 21:36:25 ON 17 FEB 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Feb 2009 VOL 150 ISS 8
FILE LAST UPDATED: 16 Feb 2009 (20090216/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l2 full
L3 24 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:25215 CAPLUS
DOCUMENT NUMBER: 150:119716
TITLE: Anti-insulin-like growth factor 1 receptor therapy
INVENTOR(S): Wang, Yan; Pachter, Jonathan A.; Hailey, Judith Anne;
Brams, Peter; Williams, Denise; Srinivasan, Mohan;
Feingersh, Mary Diane
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 129pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009005673	A1	20090108	WO 2008-US7920	20080625
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-946803P P 20070628

AB The authors disclose the preparation and functional characterization of human antibodies to the type 1 insulin-like growth factor receptor. In one example, the growth of a human neuroblastoma was shown to be inhibited by an anti-IGF1R antibody in a xenograft model.


IT 937174-76-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination therapy with anti-IGF1R antibodies)

RN 937174-76-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

17


THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1211343 CAPLUS
 DOCUMENT NUMBER: 149:440339
 TITLE: Methods of use for inhibitors of Akt activity
 INVENTOR(S): Kumar, Rakesh
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 62pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008121685	A1	20081009	WO 2008-US58383	20080327
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			


PRIORITY APPLN. INFO.: US 2007-908468P P 20070328
 AB Invented is the use of 1H-imidazo[4,5-c]pyridin-2-yl compds. in the treatment of specified cancers.
 IT 937174-84-0P 937174-88-4P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (antitumor Akt inhibitors)
 RN 937174-84-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2S)-2-thiomorpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 937174-88-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2S)-2-morpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 937174-76-0P 937174-85-1P 937174-92-0P
 937174-94-2P 937174-95-3P 937174-96-4P
 937175-07-0P 937175-08-1P 1068100-49-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antitumor Akt inhibitors)

RN 937174-76-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 937174-85-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2S)-2-thiomorpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,

hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


RN 937174-92-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(3-pyrrolidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 937174-91-9


CMF C20 H25 N7 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 937174-94-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-1-methyl-3-piperidiny]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 937174-95-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-4-methyl-2-thiomorpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-96-4 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-4-methyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 937175-07-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-6-methyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 937175-08-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-4-ethyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 1068100-49-1 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2R)-2-morpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 937233-64-2

CMF C20 H25 N7 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 937233-66-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(antitumor Akt inhibitors)


RN 937233-66-4 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-6-methyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
(CA INDEX NAME)


Absolute stereochemistry.



IT 842144-07-4P 842149-46-6P 937174-74-8P
 937174-75-9P 937174-78-2P 937174-83-9P
 937174-86-2P 937174-87-3P 937174-89-5P
 937174-90-8P 937174-93-1P 937175-05-8P
 937175-06-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (antitumor Akt inhibitors)
 RN 842144-07-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-
 c]pyridin-2-yl)- (CA INDEX NAME)




RN 842149-46-6 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-
 ethyl- (CA INDEX NAME)



RN 937174-74-8 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-
 chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-,
 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-75-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-78-2 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-83-9 CAPLUS

CN 4-Thiomorpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-86-2 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-87-3 CAPLUS


CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 937174-89-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 937174-90-8 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 937174-93-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-7-[[[(3S)-1-methyl-3-piperidinyl]methoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937175-05-8 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-6-methyl-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937175-06-9 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-6-methyl-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1101728 CAPLUS
DOCUMENT NUMBER: 149:347465
TITLE: Amelioration of cellular stress response by decreasing
RALc protein expression
INVENTOR(S): Mallet, William; Tindell, Charles
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 128pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008109560	A2	20080912	WO 2008-US55714	20080303
WO 2008109560	A3	20081211		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2007-892806P P 20070302

AB The present invention is directed to compns. and methods useful for treating cancer and for amelioration of cellular stress response triggered by chemotherapy. The present invention relates to the role of RALc in the stress responses of cancerous cells. In one aspect, the invention provides a method of ameliorating cellular stress response in a cell comprising contacting the cell, preferably a cancer cell, more preferably a prostate cancer tumor cell, with a compound that decreases or blocks RALc expression or activity in the cell. In one embodiment, the cellular stress response is induced by a chemotherapeutic agent. Preferably, the compound increases the sensitivity of the cell to the chemotherapeutic agent.

IT 937174-76-0, GSK 690693 937174-76-0D, GSK 690693, analogs and derivs.


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amelioration of cellular stress response in cancerous cells by decreasing RALc protein expression and use of chemotherapeutic agents)

RN 937174-76-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 937174-76-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



ACCESSION NUMBER: 2008:1042188 CAPLUS

DOCUMENT NUMBER: 149:323057

TITLE: Identification of
4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-3-piperidinylmethyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase

AUTHOR(S): Heerding, Dirk A.; Rhodes, Nelson; Leber, Jack D.; Clark, Tammy J.; Keenan, Richard M.; Lafrance, Louis V.; Li, Mei; Safonov, Igor G.; Takata, Dennis T.; Venslavsky, Joseph W.; Yamashita, Dennis S.; Choudhry, Anthony E.; Copeland, Robert A.; Lai, Zhihong; Schaber, Michael D.; Tummino, Peter J.; Strum, Susan L.; Wood, Edgar R.; Duckett, Derek R.; Eberwein, Derek; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Zhang, Shu Yun; Minthorn, Elisabeth A.; Concha, Nestor O.; Warren, Gregory L.; Kumar, Rakesh

CORPORATE SOURCE: Oncology Center of Excellence for Drug Discovery, GlaxoSmithKline, Collegeville, PA, 19426, USA

SOURCE: Journal of Medicinal Chemistry (2008), 51(18), 5663-5679

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 149:323057

GI



I

AB Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant neg. AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693, I). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC₅₀ values of 2, 13, and 9 nM against AKT1, 2, and 3, resp. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP

binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3 β . I.p. administration of 3g in immunocompromised mice results in the inhibition of GSK3 β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.


IT 607373-68-2P 937174-76-0P 937174-92-0P
 1052112-20-5P 1052112-22-7P 1052112-56-7P
 1052112-58-9P 1052112-60-3P 1052112-62-5P
 1052112-63-6P 1052112-64-7P 1052112-65-8P
 1052112-66-9P 1052112-67-0P 1052112-68-1P
 1052112-71-6P 1052112-73-8P 1052112-75-0P
 1052112-77-2P 1052112-78-3P 1052112-79-4P
 1052149-91-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(oxadiazolyl imidazopyridines as antitumor AKT kinase inhibitors)

RN 607373-68-2 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 937174-76-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 937174-92-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(3-pyrrolidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)
 CM 1
 CRN 937174-91-9
 CMF C20 H25 N7 O3



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 1052112-20-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 842146-17-2


CMF C19 H21 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-22-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(3-amino-1-propyn-1-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:3) (CA INDEX NAME)

CM 1

CRN 842148-42-9


CMF C16 H20 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-56-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1052112-55-6


CMF C17 H20 N8 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1052112-58-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 1052112-57-8
 CMF C17 H19 N7 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1052112-60-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(1H-pyrrol-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 1052112-59-0
 CMF C17 H20 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-62-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 1052112-61-4


CMF C16 H19 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-63-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(2-cyclopropylethynyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 842148-44-1


CMF C18 H21 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-64-7 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 842148-35-0


CMF C18 H23 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-65-8 CAPLUS

CN 2-Propyn-1-ol, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 842148-40-7


CMF C16 H19 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-66-9 CAPLUS

CN 3-Butyn-1-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 842148-46-3


CMF C17 H21 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1052112-67-0 CAPLUS

CN 3-Butyn-2-ol, 4-[7-(4-aminobutoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 842148-19-0


CMF C19 H25 N7 O3



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1052112-68-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 842148-38-3
 CMF C21 H27 N7 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 1052112-71-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[7-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate
 (1:1) (CA INDEX NAME)


CM 1

CRN 1052112-70-5
 CMF C17 H21 N7 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 1052112-73-8 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3S)-3-amino-4-phenylbutoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 1052112-72-7
CMF C25 H29 N7 O3

Absolute stereochemistry. Rotation (-).



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 1052112-75-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinyl-
 piperidinyloxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 1052112-74-9
 CMF C20 H25 N7 O3



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 1052112-77-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3R)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 1052112-76-1
 CMF C21 H27 N7 O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 1052112-78-3 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[3-[[2-(4-methoxyphenyl)ethyl]amino]propoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 842149-45-5
CMF C27 H33 N7 O4

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 1052112-79-4 CAPLUS
CN 1,2-Propanediol, 3-[[[3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 1052149-91-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 607373-68-2


CMF C15 H19 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 607372-46-3 607373-29-5 607373-66-0
701907-70-2 750568-75-3 762238-15-3
1052112-19-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)


(oxadiazolyl imidazopyridines as antitumor AKT kinase inhibitors)

RN 607372-46-3 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-4-piperidinyl- (CA INDEX NAME)




RN 607373-29-5 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-piperazinyl- (CA INDEX NAME)



RN 607373-66-0 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 701907-70-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-piperidinyl- (CA INDEX NAME)




RN 750568-75-3 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-
 c]pyridin-7-yl][(3R)-3-amino-1-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 762238-15-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-4-piperidinyl- (CA INDEX NAME)



RN 1052112-19-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(methylamino)ethyl]- (CA
 INDEX NAME)



IT 1052112-48-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxadiazolyl imidazopyridines as antitumor AKT kinase inhibitors)
 RN 1052112-48-7 CAPLUS
 CN Carbamic acid, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[3-[[1,1-dimethylethoxy)carbonyl]amino]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-propyn-1-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 607370-99-0P 607373-60-4P 842143-99-1P
 842144-00-7P 842144-07-4P 842144-08-5P
 842146-03-6P 842146-04-7P 842149-07-9P


842149-46-6P 936941-25-2P 937174-74-8P
 937174-75-9P 937174-89-5P 937174-90-8P
 1052112-21-6P 1052112-24-9P 1052112-26-1P
 1052112-27-2P 1052112-28-3P 1052112-29-4P
 1052112-30-7P 1052112-31-8P 1052112-32-9P
 1052112-33-0P 1052112-34-1P 1052112-35-2P
 1052112-36-3P 1052112-37-4P 1052112-38-5P
 1052112-39-6P 1052112-40-9P 1052112-41-0P
 1052112-42-1P 1052112-43-2P 1052112-44-3P
 1052112-46-5P 1052112-47-6P 1052112-53-4P
 1052112-54-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(oxadiazolyl imidazopyridines as antitumor AKT kinase inhibitors)


RN 607370-99-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)




RN 607373-60-4 CAPLUS

CN Carbamic acid, [4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-
 oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842143-99-1 CAPLUS

CN Carbamic acid, [4-(1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-
 oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842144-00-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842144-07-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 842144-08-5 CAPLUS

CN Carbamic acid, [4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842146-03-6 CAPLUS

CN Carbamic acid, [4-(4-chloro-1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842146-04-7 CAPLUS

CN Carbamic acid, [4-(1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842149-07-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842149-46-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-7-yl, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl- (CA INDEX NAME)



RN 936941-25-2 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-bromopropoxy)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 937174-74-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-75-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 937174-89-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 937174-90-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-21-6 CAPLUS

CN Carbamic acid, N-[4-[7-(3-aminopropoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-24-9 CAPLUS

CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-26-1 CAPLUS

CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-cyclopropylethynyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-27-2 CAPLUS

CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-28-3 CAPLUS

CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-1-propyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-29-4 CAPLUS

CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-hydroxy-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-30-7 CAPLUS

CN Carbamic acid, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052112-31-8 CAPLUS


CN Carbamic acid, N-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052112-32-9 CAPLUS


CN Carbamic acid, N-[(1S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1052112-33-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052112-34-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1052112-35-2 CAPLUS

CN Carbamic acid, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-36-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052112-37-4 CAPLUS

CN Carbamic acid, N-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-38-5 CAPLUS

CN Carbamic acid, N-[(1S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-


hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-(phenylmethyl)propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 1052112-39-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-40-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 1052112-41-0 CAPLUS
 CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052112-42-1 CAPLUS
 CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 1052112-43-2 CAPLUS
 CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-[1-[tris(1-methylethyl)silyl]-1H-pyrrol-3-yl]-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052112-44-3 CAPLUS


CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1052112-46-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-7-[3-[[2-(4-methoxyphenyl)ethyl]amino]propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1052112-47-6 CAPLUS
CN 1,2-Propanediol, 3-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1052112-53-4 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-7-[(3R)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 1052112-52-3
 CMF C16 H20 Cl N7 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 1052112-54-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-[1-[tris(1-methylethyl)silyl]-1H-pyrrol-3-yl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:771165 CAPLUS
DOCUMENT NUMBER: 149:102715
TITLE: Methods of treating cancer using IGF1R inhibitors
INVENTOR(S): Wang, Yan; Zong, Chen; Seidel-Dugan, Cynthia; Wang, Yaolin; Yao, Siu-Long; Lu, Brian Der-Hua; Ladha, Mohamed H.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 103pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076278	A2	20080626	WO 2007-US25398	20071211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:
US 2006-874589P P 20061213
US 2006-870937P P 20061220
US 2007-946011P P 20070625
US 2007-979274P P 20071011


AB The present invention provides IGF1R inhibitors and combinations thereof that are effective at treating or preventing cancer. More specifically the IGF1R inhibitors are pyrrolo[2,3-d]pyrimidine derivs. or antibodies. The IGF1R inhibitors can be used in combination with other anticancer therapies, antiemetic agents, antianemic agents, or antimucositis agents.

IT 937174-76-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GSK 690693, codrug; methods of treating cancer using IGF1R inhibitors)

RN 937174-76-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L3 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:640545 CAPLUS
DOCUMENT NUMBER: 149:1429
TITLE: Erb family inhibitor combination with PI3 kinase
inhibitor or akt inhibitor for cancer treatment
INVENTOR(S): Rusnak, David; Rhodes, Clifford Nelson, II; Gilmer,
Tona M.
PATENT ASSIGNEE(S): Smithkline Beecham (Cork) Limited, Ire.
SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008063853	A2	20080529	WO 2007-US83680	20071106
WO 2008063853	A3	20080807		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2006-866616P P 20061121
US 2007-948747P P 20070710

AB The invention discloses a method for treating cancer in a mammal, as well as pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer. Preparation of e.g. lapatinib is described.

IT 937174-76-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(erb family inhibitor combination with PI3 kinase inhibitor or akt inhibitor for cancer treatment)

RN 937174-76-0 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 1029067-05-7, GSK 690693C
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (erb family inhibitor combination with PI3 kinase inhibitor or akt
 inhibitor for cancer treatment)
 RN 1029067-05-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-
 piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



● HCl


IT 842144-07-4P 842149-46-6P 937174-75-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (erb family inhibitor combination with PI3 kinase inhibitor or akt
 inhibitor for cancer treatment)
 RN 842144-07-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-

c]pyridin-2-yl)- (CA INDEX NAME)



RN 842149-46-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl- (CA INDEX NAME)



RN 937174-75-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:409006 CAPLUS

DOCUMENT NUMBER: 148:553129

TITLE: Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

AUTHOR(S): Rhodes, Nelson; Heerding, Dirk A.; Duckett, Derek R.; Eberwein, Derek J.; Knick, Victoria B.; Lansing, Timothy J.; McConnell, Randy T.; Gilmer, Tona M.; Zhang, Shu-Yun; Robell, Kimberly; Kahana, Jason A.; Geske, Robert S.; Kleymenova, Elena V.; Choudhry, Anthony E.; Lai, Zhihong; Leber, Jack D.; Minthorn, Elisabeth A.; Strum, Susan L.; Wood, Edgar R.; Huang, Pearl S.; Copeland, Robert A.; Kumar, Rakesh

CORPORATE SOURCE: Oncology Biology, GlaxoSmithKline, Collegeville, PA, USA

SOURCE: Cancer Research (2008), 68(7), 2366-2374

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Akt kinases 1, 2, and 3 are important regulators of cell survival and have been shown to be constitutively active in a variety of human tumors. GSK690693 is a novel ATP-competitive, low-nanomolar pan-Akt kinase inhibitor. It is selective for the Akt isoforms vs. the majority of kinases in other families; however, it does inhibit addnl. members of the AGC kinase family. It causes dose-dependent redns. in the phosphorylation state of multiple proteins downstream of Akt, including GSK3 β , PRAS40, and Forkhead. GSK690693 inhibited proliferation and induced apoptosis in a subset of tumor cells with potency consistent with intracellular inhibition of Akt kinase activity. In immune-compromised mice implanted with human BT474 breast carcinoma xenografts, a single i.p. administration of GSK690693 inhibited GSK3 β phosphorylation in a dose- and time-dependent manner. After a single dose of GSK690693, >3 μ mol/L drug concentration in BT474 tumor xenografts correlated with a sustained decrease in GSK3 β phosphorylation. Consistent with the role of Akt in insulin signaling, treatment with GSK690693 resulted in acute and transient increases in blood glucose level. Daily administration of GSK690693 produced significant antitumor activity in mice bearing established human SKOV-3 ovarian, LNCaP prostate, and BT474 and HCC-1954 breast carcinoma xenografts. Immunohistochem. anal. of tumor xenografts after repeat dosing with GSK690693 showed redns. in phosphorylated Akt substrates in vivo. These results support further evaluation of GSK690693 as an anticancer agent.

IT 937174-76-0


RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GSK 690693; characterization of Akt kinase inhibitor with potent pharmacodynamic and antitumor activity)

RN 937174-76-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

42

THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:43490 CAPLUS

DOCUMENT NUMBER: 148:135980

TITLE: Blood levels of insulin-like growth factor-binding protein 2 as a marker for monitoring the effectiveness of inhibitors of insulin-like growth factor I receptors in cancer therapy

INVENTOR(S): Wang, Yan

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 133pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008005469	A2	20080110	WO 2007-US15423	20070629
WO 2008005469	A3	20080228		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

US 20080112888	A1	20080515	US 2007-771454	20070629
----------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2006-818004P P 20060630

AB The present invention provides method for quickly and conveniently determining if a given treatment regimen of insulin-like growth factor I receptor (IGF1R) inhibitor is sufficient, e.g., to saturate IGF1 R receptors in the body of a subject. Blood levels of insulin-like growth factor-binding protein 2 (IGFBP2) are shown to be strongly correlated with the effectiveness of IGF1R receptor therapy. Several clin. relevant detns. may be made based on this point, including, for example, whether the dosage of the regimen is sufficient or should be increased. The relationship is demonstrated using animal xenograft models of neuroblastoma. Treatment with monoclonal antibodies to IGFR1 lowered the blood levels of IGFBP2. The level of IGFBP2 correlated with the tumor size.


IT 937174-76-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cancer therapy using; blood levels of IGBP2 as marker for monitoring effectiveness of inhibitors of IGF1 receptors in cancer therapy)

RN 937174-76-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L3 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:991296 CAPLUS

DOCUMENT NUMBER: 147:497625

TITLE: Dual Enzyme-Linked Immunosorbent Assay System for Detection of Endogenous Kinase Activities of Mitogen- and Stress-Activated Protein Kinase-1/2

AUTHOR(S): Ishii, Tsuyoshi; Sootome, Hiroshi; Toyoda, Hiroko; Suda, Mikiya; Noumi, Takato; Yamashita, Keizo

CORPORATE SOURCE: GlaxoSmithKline K.K., Ibaraki, Japan

SOURCE: Assay and Drug Development Technologies (2007), 5(4), 523-534

CODEN: ADDTAR; ISSN: 1540-658X

PUBLISHER: Mary Ann Liebert, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The kinase signaling cascades related to mitogen- and stress-activated protein kinase-1 and -2 (MSK1 and MSK2, resp.) are attractive targets for pharmaceutical intervention, especially for neural injury. Therefore, we have developed a high throughput and cost-effective detection platform for measuring selective activity of MSK1/MSK2 in cells. Through the serial monitoring of both the p38 mitogen-activated protein kinase (stress-activated protein kinase 2B)-MSK1/MSK2- cAMP response element binding protein (CREB)/activating transcription factor 1 (ATF1) pathway and the p38-mammalian heat shock protein 27 (Hsp27) pathway in HeLa cells treated with anisomycin, two selective MSK1 inhibitors showed inhibition of CREB (Ser-133) and ATF1 (Ser-63) phosphorylation and no interference with Hsp-27 phosphorylation (Ser-82). On the other hand, the p38 inhibitor SB-220025 showed equipotent inhibition of CREB/ATF1 and Hsp27 phosphorylation. This study demonstrated that the specific inhibition of a target kinase could be subsequently monitored by a secondary assay that measures the intervention arising from the modulation of off-target kinases. Our established system is applicable to inhibitor screening and drug discovery related to MSK1/MSK2.

IT 607372-50-9, SB 745651B

RL: BSU (Biological study, unclassified); BIOL (Biological study) (SB 745651B; screening method for MSK1/2 inhibitors and simultaneously monitoring endogenous phosphorylation of CREB/ATF1 and Hsp27 in HeLa cells treated with anisomycin)

RN 607372-50-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1-piperazinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




IT 701907-70-2, SB 761113B

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(SB 761113B; screening method for MSK1/2 inhibitors and simultaneously monitoring endogenous phosphorylation of CREB/ATF1 and Hsp27 in HeLa cells treated with anisomycin)

RN 701907-70-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-piperidinyl- (CA INDEX NAME)



REFERENCE COUNT:

32

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:566890 CAPLUS

DOCUMENT NUMBER: 147:180515

TITLE: Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors

AUTHOR(S): Vadivelan, S.; Sinha, Barij Nayan; Irudayam, Sheeba Jem; Jagarlapudi, Sarma A. R. P.

CORPORATE SOURCE: GVK Biosciences Pvt. Ltd., Hyderabad, 500037, India

SOURCE: Journal of Chemical Information and Modeling (2007), 47(4), 1526-1535

CODEN: JCISD8; ISSN: 1549-9596

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The cell division cycle is controlled by cyclin-dependent kinases (CDK), which consist of a catalytic subunit (CDK1-CDK8) and a regulatory subunit (cyclin A-H). Pharmacophore anal. indicates that the best inhibitor model consists of (1) two hydrogen bond acceptors, (2) one hydrogen bond donor, and (3) one hydrophobic feature. The HypoRefine pharmacophore model gave an enrichment factor of 1.31 and goodness of fit score of 0.76. Docking studies were carried out to explore the structural requirements for the CDK2-cyclin A inhibitors and to construct highly predictive models for the design of new inhibitors. Docking studies demonstrate the important role of hydrogen bond and hydrophobic interactions in determining the inhibitor-receptor binding affinity. The validated pharmacophore model is further used for retrieving the most active hits/lead from a virtual library of mols. Subsequently, docking studies were performed on the hits, and novel series of potent leads were suggested based on the interaction energy between CDK2-cyclin A and the putative inhibitors.


IT 607368-87-6

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(virtual screening studies to design CDK2-cyclin A inhibitors)

RN 607368-87-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



REFERENCE COUNT:

51

THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:565116 CAPLUS

DOCUMENT NUMBER: 147:9921

TITLE: Preparation of imidazopyridines as inhibitors of AKT activity

INVENTOR(S): Heerding, Dirk A.; Clark, Tammy J.; Leber, Jack Dale; Safonov, Igor

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 47pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2007058879	A2	20070524	WO 2006-US43617	20061109
WO 2007058879	A3	20080103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1954286	A2	20080813	EP 2006-837230	20061109
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
US 20080269131	A1	20081030	US 2008-93175	20080509
PRIORITY APPLN. INFO.:			US 2005-735938P	P 20051110
			WO 2006-US43617	W 20061109
OTHER SOURCE(S):	MARPAT 147:9921			
GI				



CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[2-[(2S)-2-pyrrolidinyl]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 937203-17-3 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[2-[(2S)-2-pyrrolidinyl]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 937203-16-2

CMF C21 H27 N7 O3


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 937203-18-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[2-[(2S)-2-piperidinyl]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 937203-19-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[2-(3-thiomorpholinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 937203-30-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[2-(2S)-2-piperidinylethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



IT 842144-07-4P 842149-46-6P 937203-21-9P
 937203-22-0P 937203-24-2P 937203-25-3P
 937203-28-6P 937203-29-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of novel imidazopyridinyl compds. as protein kinase B
 inhibitors useful in treatment of cancer and arthritis)
 RN 842144-07-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-
 c]pyridin-2-yl)- (CA INDEX NAME)




RN 842149-46-6 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-
 ethyl- (CA INDEX NAME)



RN 937203-21-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-

chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-,
1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937203-22-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937203-24-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 2-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937203-25-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 2-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 937203-28-6 CAPLUS

CN 4-Thiomorpholinecarboxylic acid, 3-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 937203-29-7 CAPLUS

CN 4-Thiomorpholinecarboxylic acid, 3-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L3 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:564566 CAPLUS
 DOCUMENT NUMBER: 147:23730
 TITLE: 1H-imidazo[4,5-c]pyridin-2-yl derivatives as
 inhibitors of AKT activity and their therapeutic uses
 INVENTOR(S): Heerding, Dirk A.; Clark, Tammy J.; Leber, Jack Dale;
 Safonov, Igor
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 72pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007058850	A2	20070524	WO 2006-US43513	20061109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006315805	A1	20070524	AU 2006-315805	20061109
CA 2629429	A1	20070524	CA 2006-2629429	20061109
EP 1948188	A2	20080730	EP 2006-837170	20061109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20080076763	A1	20080327	US 2007-823415	20070627
IN 2008DN03428	A	20080725	IN 2008-DN3428	20080425
MX 200806170	A	20080522	MX 2008-6170	20080509
KR 2008067646	A	20080721	KR 2008-711158	20080509
NO 2008002414	A	20080805	NO 2008-2414	20080528
PRIORITY APPLN. INFO.:			US 2005-735955P	P 20051110
			US 2006-772289P	P 20060210
			US 2006-826928P	P 20060926
			WO 2006-US43513	W 20061109
OTHER SOURCE(S):	MARPAT 147:23730			
GI				



IT 937174-84-0P 937174-88-4P
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(1H-imidazo[4,5-c]pyridin-2-yl derivs. as inhibitors of AKT activity and their therapeutic uses)


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2S)-2-thiomorpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

CC(C)(C)C1=CC=C2C(=C1)N=C(N2)C(=N3C(=C(N=C3O)N)N)N(Et)C4=CC=C(C=C4)O[C@H]5CNCCS5

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2S)-2-


morpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 937174-76-0P 937174-79-3P 937174-85-1P
937174-92-0P 937174-94-2P 937174-95-3P
937174-96-4P 937175-07-0P 937175-08-1P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(1H-imidazo[4,5-c]pyridin-2-yl derivs. as inhibitors of AKT activity
and their therapeutic uses)
RN 937174-76-0 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-
piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX
NAME)

Absolute stereochemistry. Rotation (-).



RN 937174-79-3 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2R)-2-
morpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 937174-85-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(2S)-2-thiomorpholinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 937174-92-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(3-pyrrolidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 937174-91-9
CMF C20 H25 N7 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 937174-94-2 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-1-methyl-3-piperidinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 937174-95-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-4-methyl-2-thiomorpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 937174-96-4 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-4-methyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 937175-07-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-6-methyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 937175-08-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2S)-4-ethyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 842144-07-4P 842149-46-6P 937174-74-8P
 937174-75-9P 937174-78-2P 937174-83-9P
 937174-86-2P 937174-87-3P 937174-89-5P
 937174-90-8P 937174-93-1P 937175-05-8P
 937175-06-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(1H-imidazo[4,5-c]pyridin-2-yl derivs. as inhibitors of AKT activity
 and their therapeutic uses)


RN 842144-07-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-
 c]pyridin-2-yl)- (CA INDEX NAME)



RN 842149-46-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-
 ethyl- (CA INDEX NAME)



RN 937174-74-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-75-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-78-2 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-83-9 CAPLUS

CN 4-Thiomorpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-86-2 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937174-87-3 CAPLUS


CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 937174-89-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 937174-90-8 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 937174-93-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-7-[[[(3S)-1-methyl-3-piperidinyl]methoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 937175-05-8 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-6-methyl-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 937175-06-9 CAPLUS


CN 4-Morpholinecarboxylic acid, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-6-methyl-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 937175-11-6
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (1H-imidazo[4,5-c]pyridin-2-yl derivs. as inhibitors of AKT activity
 and their therapeutic uses)
 RN 937175-11-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(2R)-6-
 methyl-2-morpholinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:563378 CAPLUS
DOCUMENT NUMBER: 146:514732
TITLE: 1H-imidazo[4,5-c]pyridin-2-yl derivatives as
inhibitors of AKT activity and their therapeutic uses
INVENTOR(S): Leber, Jack Dale; Heerding, Dirk A.; Clark, Tammy J.;
Safonov, Igor; Li, Mei
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 74pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007058852	A2	20070524	WO 2006-US43518	20061109
WO 2007058852	A3	20071227		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1948185	A2	20080730	EP 2006-837174	20061109
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			
PRIORITY APPLN. INFO.:			US 2005-735536P	P 20051110
			WO 2006-US43518	W 20061109
OTHER SOURCE(S):			CASREACT 146:514732; MARPAT 146:514732	
GI				



AB Novel 1H-imidazo[4,5-c]pyridin-2-yl compds. (I; R1-6 = H, F, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydro-2H-thiopyran, C1-4-alkyl, etc.; R7,R8 = H, cyclopropyl, cyclobutyl, cyclopentyl, C1-4-alkyl, etc.) and their pharmaceutically acceptable salts, hydrates, solvates, and prodrugs, which are inhibitors of protein kinase B/Akt, are disclosed. The I compds. may be used in the treatment of cancer and arthritis. The synthesis of I (R1, R1', R2, R2',

R3, and R3' = H; R4 and R5 form a 6-membered heterocycle with N), as well as 17 other similar compds., are described. This compound inhibited human Akt1 and growth of breast carcinoma cells in vitro with submicromolar IC50's.


IT 936941-27-4P 936941-29-6P 936941-31-0P
 936941-34-3P 936941-36-5P 936941-39-8P
 936941-42-3P 936941-45-6P 936941-48-9P
 936941-50-3P 936941-54-7P 936941-58-1P
 936941-62-7P 936941-65-0P 936941-68-3P
 936941-71-8P 936941-75-2P 936941-80-9P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(1H-imidazo[4,5-c]pyridin-2-yl derivs. as inhibitors of AKT activity and their therapeutic uses)


RN 936941-27-4 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[3-(1-piperidinyl)propoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 936941-29-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[3-(1-pyrrolidinyl)propoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 936941-31-0 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[3-(cyclopentylamino)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 936941-34-3 CAPLUS


CN 3-Butyn-2-ol, 4-[7-[[(3R)-3-amino-4-methylpentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 936941-36-5 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[3-(cyclobutylamino)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 936941-39-8 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(2S)-3-(cyclopropylamino)-2-methylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 936941-42-3 CAPLUS


CN 3-Butyn-2-ol, 4-[7-(3-amino-2,2-dimethylpropoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 936941-45-6 CAPLUS

CN 3-Butyn-2-ol, 4-[7-[(2S)-3-amino-2-methylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 936941-48-9 CAPLUS


CN 3-Butyn-2-ol, 4-[7-[(3S)-3-aminobutoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 936941-50-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[3-[(cyclopropylmethyl)amino]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 936941-54-7 CAPLUS

CN 3-Butyn-2-ol, 4-[7-[[2-(aminomethyl)pentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 936941-58-1 CAPLUS

CN 3-Butyn-2-ol, 4-[7-[[2-(aminomethyl)-4-methylpentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 936941-62-7 CAPLUS

CN 3-Butyn-2-ol, 4-[7-[[2-(aminomethyl)hexyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 936941-65-0 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[3-amino-3-(tetrahydro-2H-thiopyran-4-yl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 936941-68-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[7-[[1-(aminomethyl)cyclopropyl]methoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 936941-71-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[7-[1-(2-aminoethyl)butoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 936941-75-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[7-(3-amino-2-fluoropropoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 936941-80-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[7-(3-amino-1-cyclohexylpropoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

INDEX NAME)




IT 842144-07-4P 842149-46-6P 936941-25-2P
 936941-26-3P 936941-28-5P 936941-30-9P
 936941-33-2P 936941-35-4P 936941-37-6P
 936941-38-7P 936941-40-1P 936941-41-2P
 936941-43-4P 936941-44-5P 936941-46-7P
 936941-47-8P 936941-49-0P 936941-51-4P
 936941-52-5P 936941-53-6P 936941-55-8P
 936941-57-0P 936941-59-2P 936941-60-5P
 936941-61-6P 936941-63-8P 936941-64-9P
 936941-66-1P 936941-67-2P 936941-69-4P
 936941-70-7P 936941-73-0P 936941-74-1P
 936941-77-4P 936941-78-5P 936941-79-6P
 936941-81-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(1H-imidazo[4,5-c]pyridin-2-yl derivs. as inhibitors of AKT activity and their therapeutic uses)


RN 842144-07-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 842149-46-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl- (CA INDEX NAME)



RN 936941-25-2 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-bromopropoxy)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Br-(CH₂)₃-O


RN 936941-26-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-7-[3-(1-piperidinyl)propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 936941-28-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-7-[3-(1-pyrrolidinyl)propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 936941-30-9 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-7-[3-(cyclopentylamino)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 936941-33-2 CAPLUS


CN Carbamic acid, N-[(1R)-1-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-2-methylpropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 936941-35-4 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-7-[3-(cyclobutylamino)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 936941-37-6 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[(2R)-3-bromo-2-methylpropoxy]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 936941-38-7 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-7-[(2S)-3-(cyclopropylamino)-2-methylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936941-40-1 CAPLUS
 CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 936941-41-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-amino-2,2-dimethylpropoxy)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 936941-43-4 CAPLUS

CN Imidodicarbonic acid, N-[(2S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-2-methylpropyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)


Absolute stereochemistry.



RN 936941-44-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[(2S)-3-amino-2-methylpropoxy]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 936941-46-7 CAPLUS

CN Carbamic acid, N-[(1S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-methylpropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 936941-47-8 CAPLUS


CN Carbamic acid, N-[(1S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-methylpropyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 936941-49-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-7-[3-[(cyclopropylmethyl)amino]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-(CA INDEX NAME)

CCN1C=NC2=C(N1)N=CN=C2C3=CC=C(N)C=C3C4=CC=CC=C4C5=CC=CC=C5C6=CC=CC=C6C7=CC=CC=C7C8=CC=CC=C8C9=CC=CC=C9C10=CC=CC=C10C11=CC=CC=C11C12=CC=CC=C12C13=CC=CC=C13C14=CC=CC=C14C15=CC=CC=C15C16=CC=CC=C16C17=CC=CC=C17C18=CC=CC=C18C19=CC=CC=C19C20=CC=CC=C20C21=CC=CC=C21C22=CC=CC=C22C23=CC=CC=C23C24=CC=CC=C24C25=CC=CC=C25C26=CC=CC=C26C27=CC=CC=C27C28=CC=CC=C28C29=CC=CC=C29C30=CC=CC=C30C31=CC=CC=C31C32=CC=CC=C32C33=CC=CC=C33C34=CC=CC=C34C35=CC=CC=C35C36=CC=CC=C36C37=CC=CC=C37C38=CC=CC=C38C39=CC=CC=C39C40=CC=CC=C40C41=CC=CC=C41C42=CC=CC=C42C43=CC=CC=C43C44=CC=CC=C44C45=CC=CC=C45C46=CC=CC=C46C47=CC=CC=C47C48=CC=CC=C48C49=CC=CC=C49C50=CC=CC=C50C51=CC=CC=C51C52=CC=CC=C52C53=CC=CC=C53C54=CC=CC=C54C55=CC=CC=C55C56=CC=CC=C56C57=CC=CC=C57C58=CC=CC=C58C59=CC=CC=C59C60=CC=CC=C60C61=CC=CC=C61C62=CC=CC=C62C63=CC=CC=C63C64=CC=CC=C64C65=CC=CC=C65C66=CC=CC=C66C67=CC=CC=C67C68=CC=CC=C68C69=CC=CC=C69C70=CC=CC=C70C71=CC=CC=C71C72=CC=CC=C72C73=CC=CC=C73C74=CC=CC=C74C75=CC=CC=C75C76=CC=CC=C76C77=CC=CC=C77C78=CC=CC=C78C79=CC=CC=C79C80=CC=CC=C80C81=CC=CC=C81C82=CC=CC=C82C83=CC=CC=C83C84=CC=CC=C84C85=CC=CC=C85C86=CC=CC=C86C87=CC=CC=C87C88=CC=CC=C88C89=CC=CC=C89C90=CC=CC=C90C91=CC=CC=C91C92=CC=CC=C92C93=CC=CC=C93C94=CC=CC=C94C95=CC=CC=C95C96=CC=CC=C96C97=CC=CC=C97C98=CC=CC=C98C99=CC=CC=C99C100=CC=CC=C100C101=CC=CC=C101C102=CC=CC=C102C103=CC=CC=C103C104=CC=CC=C104C105=CC=CC=C105C106=CC=CC=C106C107=CC=CC=C107C108=CC=CC=C108C109=CC=CC=C109C110=CC=CC=C110C111=CC=CC=C111C112=CC=CC=C112C113=CC=CC=C113C114=CC=CC=C114C115=CC=CC=C115C116=CC=CC=C116C117=CC=CC=C117C118=CC=CC=C118C119=CC=CC=C119C120=CC=CC=C120C121=CC=CC=C121C122=CC=CC=C122C123=CC=CC=C123C124=CC=CC=C124C125=CC=CC=C125C126=CC=CC=C126C127=CC=CC=C127C128=CC=CC=C128C129=CC=CC=C129C130=CC=CC=C130C131=CC=CC=C131C132=CC=CC=C132C133=CC=CC=C133C134=CC=CC=C134C135=CC=CC=C135C136=CC=CC=C136C137=CC=CC=C137C138=CC=CC=C138C139=CC=CC=C139C140=CC=CC=C140C141=CC=CC=C141C142=CC=CC=C142C143=CC=CC=C143C144=CC=CC=C144C145=CC=CC=C145C146=CC=CC=C146C147=CC=CC=C147C148=CC=CC=C148C149=CC=CC=C149C150=CC=CC=C150C151=CC=CC=C151C152=CC=CC=C152C153=CC=CC=C153C154=CC=CC=C154C155=CC=CC=C155C156=CC=CC=C156C157=CC=CC=C157C158=CC=CC=C158C159=CC=CC=C159C160=CC=CC=C160C161=CC=CC=C161C162=CC=CC=C162C163=CC=CC=C163C164=CC=CC=C164C165=CC=CC=C165C166=CC=CC=C166C167=CC=CC=C167C168=CC=CC=C168C169=CC=CC=C169C170=CC=CC=C170C171=CC=CC=C171C172=CC=CC=C172C173=CC=CC=C173C174=CC=CC=C174C175=CC=CC=C175C176=CC=CC=C176C177=CC=CC=C177C178=CC=CC=C178C179=CC=CC=C179C180=CC=CC=C180C181=CC=CC=C181C182=CC=CC=C182C183=CC=CC=C183C184=CC=CC=C184C185=CC=CC=C185C186=CC=CC=C186C187=CC=CC=C187C188=CC=CC=C188C189=CC=CC=C189C190=CC=CC=C190C191=CC=CC=C191C192=CC=CC=C192C193=CC=CC=C193C194=CC=CC=C194C195=CC=CC=C195C196=CC=CC=C196C197=CC=CC=C197C198=CC=CC=C198C199=CC=CC=C199C200=CC=CC=C200C201=CC=CC=C201C202=CC=CC=C202C203=CC=CC=C203C204=CC=CC=C204C205=CC=CC=C205C206=CC=CC=C206C207=CC=CC=C207C208=CC=CC=C208C209=CC=CC=C209C210=CC=CC=C210C211=CC=CC=C211C212=CC=CC=C212C213=CC=CC=C213C214=CC=CC=C214C215=CC=CC=C215C216=CC=CC=C216C217=CC=CC=C217C218=CC=CC=C218C219=CC=CC=C219C220=CC=CC=C220C221=CC=CC=C221C222=CC=CC=C222C223=CC=CC=C223C224=CC=CC=C224C225=CC=CC=C225C226=CC=CC=C226C227=CC=CC=C227C228=CC=CC=C228C229=CC=CC=C229C230=CC=CC=C230C231=CC=CC=C231C232=CC=CC=C232C233=CC=CC=C233C234=CC=CC=C234C235=CC=CC=C235C236=CC=CC=C236C237=CC=CC=C237C238=CC=CC=C238C239=CC=CC=C239C240=CC=CC=C240C241=CC=CC=C241C242=CC=CC=C242C243=CC=CC=C243C244=CC=CC=C244C245=CC=CC=C245C246=CC=CC=C246C247=CC=CC=C247C248=CC=CC=C248C249=CC=CC=C249C250=CC=CC=C250C251=CC=CC=C251C252=CC=CC=C252C253=CC=CC=C253C254=CC=CC=C254C255=CC=CC=C255C256=CC=CC=C256C257=CC=CC=C257C258=CC=CC=C258C259=CC=CC=C259C260=CC=CC=C260C261=CC=CC=C261C262=CC=CC=C262C263=CC=CC=C263C264=CC=CC=C264C265=CC=CC=C265C266=CC=CC=C266C267=CC=CC=C267C268=CC=CC=C268C269=CC=CC=C269C270=CC=CC=C270C271=CC=CC=C271C272=CC=CC=C272C273=CC=CC=C273C274=CC=CC=C274C275=CC=CC=C275C276=CC=CC=C276C277=CC=CC=C277C278=CC=CC=C278C279=CC=CC=C279C280=CC=CC=C280C281=CC=CC=C281C282=CC=CC=C282C283=CC=CC=C283C284=CC=CC=C284C285=CC=CC=C285C286=CC=CC=C286C287=CC=CC=C287C288=CC=CC=C288C289=CC=CC=C289C290=CC=CC=C290C291=CC=CC=C291C292=CC=CC=C292C293=CC=CC=C293C294=CC=CC=C294C295=CC=CC=C295C296=CC=CC=C296C297=CC=CC=C297C298=CC=CC=C298C299=CC=CC=C299C300=CC=CC=C300C301=CC=CC=C301C302=CC=CC=C302C303=CC=CC=C303C304=CC=CC=C304C305=CC=CC=C305C306=CC=CC=C306C307=CC=CC=C307C308=CC=CC=C308C309=CC=CC=C309C310=CC=CC=C310C311=CC=CC=C311C312=CC=CC=C312C313=CC=CC=C313C314=CC=CC=C314C315=CC=CC=C315C316=CC=CC=C316C317=CC=CC=C317C318=CC=CC=C318C319=CC=CC=C319C320=CC=CC=C320C321=CC=CC=C321C322=CC=CC=C322C323=CC=CC=C323C324=CC=CC=C324C325=CC=CC=C325C326=CC=CC=C326C327=CC=CC=C327C328=CC=CC=C328C329=CC=CC=C329C330=CC=CC=C330C331=CC=CC=C331C332=CC=CC=C332C333=CC=CC=C333C334=CC=CC=C334C335=CC=CC=C335C336=CC=CC=C336C337=CC=CC=C337C338=CC=CC=C338C339=CC=CC=C339C340=CC=CC=C340C341=CC=CC=C341C342=CC=CC=C342C343=CC=CC=C343C344=CC=CC=C344C345=CC=CC=C345C346=CC=CC=C346C347=CC=CC=C347C348=CC=CC=C348C349=CC=CC=C349C350=CC=CC=C350C351=CC=CC=C351C352=CC=CC=C352C353=CC=CC=C353C354=CC=CC=C354C355=CC=CC=C355C356=CC=CC=C356C357=CC=CC=C357C358=CC=CC=C358C359=CC=CC=C35




RN 936941-52-5 CAPLUS

CN Imidodicarbonic acid, N-[2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]pentyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 936941-53-6 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[2-(aminomethyl)pentyl]oxy]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 936941-55-8 CAPLUS

CN 1-Pentanol, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-4-methyl-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)


PAGE 1-A





PAGE 2-A




RN 936941-57-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[2-(aminomethyl)-4-methylpentyl]oxy]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 936941-59-2 CAPLUS
 CN 1-Hexanol, 2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)



RN 936941-60-5 CAPLUS
 CN Imidodicarbonic acid, N-[2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]hexyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 936941-61-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[2-(aminomethyl)hexyl]oxy]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 936941-63-8 CAPLUS


CN Carbamic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-(tetrahydro-2H-thiopyran-4-yl)propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 936941-64-9 CAPLUS


CN Carbamic acid, N-[(1S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-(tetrahydro-2H-thiopyran-4-yl)propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 936941-66-1 CAPLUS

CN Carbamic acid, N-[[1-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]cyclopropyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 936941-67-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[1-(aminomethyl)cyclopropyl]methoxy]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 936941-69-4 CAPLUS
 CN 1-Hexanol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 936941-70-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[1-(2-aminoethyl)butoxy]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 936941-73-0 CAPLUS

CN Imidodicarbonic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-2-fluoropropyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)





RN 936941-74-1 CAPLUS

CN Imidodicarbonic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-2-fluoropropyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 936941-77-4 CAPLUS

CN Cyclohexanepropanol, γ -[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1-(4-methylbenzenesulfonate) (CA INDEX NAME)




RN 936941-78-5 CAPLUS

CN Imidodicarbonic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-3-cyclohexylpropyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



CN Imidodicarbonic acid, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-3-cyclohexylpropyl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



CN Carbamic acid, N-[(1R)-3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-(tetrahydro-2H-thiopyran-4-yl)propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

CC1=CC=C2C(=C1)N=C(N2C(=O)OCC[C@H](C3CCCCC3)C(=O)N(C)C)C(=O)N4C=CC(=N4)N

L3 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:35391 CAPLUS

DOCUMENT NUMBER: 146:243783

TITLE: Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities

AUTHOR(S): Doe, Chris; Bentley, Ross; Behm, David J.; Lafferty, Robert; Stavenger, Robert; Jung, David; Bamford, Mark; Panchal, Terry; Grygielko, Eugene; Wright, Lois L.; Smith, Gary K.; Chen, Zunxuan; Webb, Christine; Khandekar, Sanjay; Yi, Tracey; Kirkpatrick, Robert; Dul, Edward; Jolivet, Larry; Marino, Joseph P., Jr.; Willette, Robert; Lee, Dennis; Hu, Erding

CORPORATE SOURCE: Department of Investigational Biology, Discovery Research, GlaxoSmithKline Pharmaceuticals Inc., King of Prussia, PA, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 320(1), 89-98

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis. We hypothesized that potent and selective ROCK inhibitors with novel structural motifs would help elucidate the functional role of ROCK and further explore the therapeutic potential of ROCK inhibition for hypertension. In this article, we characterized two aminofurazan-based inhibitors, GSK269962A [N-(3-{[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]-oxy}benzamide] and SB-772077-B [4-(7-{[(3S)-3-amino-1-pyrrolidinyl]carbonyl}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine], as members of a novel class of compds. that potently inhibit ROCK enzymic activity. GSK269962A and SB-772077-B have IC50 values of 1.6 and 5.6 nM toward recombinant human ROCK1, resp. GSK269962A also exhibited more than 30-fold selectivity against a panel of serine/threonine kinases. In lipopolysaccharide-stimulated monocytes, these inhibitors blocked the generation of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor- α . Furthermore, both SB-772077-B and GSK269962A induced vasorelaxation in precontracted rat aorta with an IC50 of 39 and 35 nM, resp. Oral administration of either GSK269962A or SB-772077-B produced a profound dose-dependent reduction of systemic blood pressure in spontaneously hypertensive rats. At doses of 1, 3, and 30 mg/kg, both compds. induced a reduction in blood pressure of approx. 10, 20, and 50 mm Hg. In addition, administration of SB-772077-B also dramatically lowered blood pressure in DOCA salt-induced hypertensive rats. SB-772077-B and GSK269962A represent a novel class of ROCK inhibitors that have profound effects in the vasculature and may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases.

IT 785774-34-7, SB 772077-B 850664-21-0, GSK 269962A


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities)

RN 785774-34-7 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][(3S)-3-amino-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 850664-21-0 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



REFERENCE COUNT:

39

THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1324378 CAPLUS

DOCUMENT NUMBER: 146:220117

TITLE: Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

AUTHOR(S): Stavenger, Robert A.; Cui, Haifeng; Dowdell, Sarah E.; Franz, Robert G.; Gaitanopoulos, Dimitri E.; Goodman, Krista B.; Hilfiker, Mark A.; Ivy, Robert L.; Leber, Jack D.; Marino, Joseph P., Jr.; Oh, Hye-Ja; Viet, Andrew Q.; Xu, Weiwei; Ye, Guosen; Zhang, Daohua; Zhao, Yongdong; Jolivet, Larry J.; Head, Martha S.; Semus, Simon F.; Elkins, Patricia A.; Kirkpatrick, Robert B.; Dul, Edward; Khandekar, Sanjay S.; Yi, Tracey; Jung, David K.; Wright, Lois L.; Smith, Gary K.; Behm, David J.; Doe, Christopher P.; Bentley, Ross; Chen, Zunxuan X.; Hu, Erding; Lee, Dennis

CORPORATE SOURCE: Department of Medicinal Chemistry, GlaxoSmithKline, King of Prussia, PA, 19406, USA

SOURCE: Journal of Medicinal Chemistry (2007), 50(1), 2-5
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:220117

AB The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.


IT 607368-87-6P 607373-85-3P 607373-88-6P
765268-50-6P 788820-06-4P 850663-66-0P
850663-91-1P 850664-21-0P 850665-01-9P
850665-21-3P 850665-76-8P 850665-94-0P
850666-29-4P 850667-31-1P 850667-48-0P
850667-59-3P 925213-74-7P 925213-75-8P
925213-76-9P 925213-77-0P 925213-78-1P
925213-79-2P 925213-80-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity)

RN 607368-87-6 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 607373-85-3 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-

yl)- (CA INDEX NAME)




RN 607373-88-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-6-phenoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 765268-50-6 CAPLUS

CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 788820-06-4 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850663-66-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(3-aminophenoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850663-91-1 CAPLUS

CN Ethanone, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-21-0 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 850665-01-9 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-21-3 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- (CA INDEX NAME)




RN 850665-76-8 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)- (CA INDEX NAME)




RN 850665-94-0 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 850666-29-4 CAPLUS

CN Benzamide, 4-(aminomethyl)-N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850667-31-1 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 850667-48-0 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(dimethylamino)methyl]- (CA INDEX NAME)



RN 850667-59-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-(methylsulfonyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 925213-74-7 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 850665-01-9


CMF C23 H19 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 925213-75-8 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 850665-21-3


CMF C25 H24 N8 O3



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 925213-76-9 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 925213-77-0 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(dimethylamino)methyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 850667-48-0
 CMF C26 H26 N8 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 925213-78-1 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinylmethyl)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 850667-31-1
 CMF C28 H28 N8 O4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 925213-79-2 CAPLUS
CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(dimethylamino)ethoxy]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 850665-94-0
CMF C27 H28 N8 O4




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 925213-80-5 CAPLUS
CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-

c[pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]-, hydrochloride
(1:3) (CA INDEX NAME)



● 3 HCl


IT 850663-86-4P 850664-74-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of
Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity)


RN 850663-86-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(6-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
(CA INDEX NAME)



RN 850664-74-3 CAPLUS

CN Benzenesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methyl- (CA INDEX NAME)



REFERENCE COUNT:

21

THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:1124305 CAPLUS

DOCUMENT NUMBER: 145:471527

TITLE: Imidazopyridinyl compounds as inhibitors of AKT activity and their preparation, pharmaceutical compositions and use in the treatment of cancer and arthritis

INVENTOR(S): Heerding, Dirk A.; Rouse, Meagan B.; Seefeld, Mark Andrew

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 198pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113837	A2	20061026	WO 2006-US14807	20060420
WO 2006113837	A3	20070830		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1874768	A2	20080109	EP 2006-758426	20060420
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008536938	T	20080911	JP 2008-507851	20060420
US 20080318947	A1	20081225	US 2008-911892	20080630
PRIORITY APPLN. INFO.:			US 2005-673120P	P 20050420
			WO 2006-US14807	W 20060420
OTHER SOURCE(S):	MARPAT 145:471527			
GI				



I




II


AB Disclosed in the invention are 1H-imidazo[4,5-c]pyridin-2-yl compds. of formula I, the use of such compds. as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis. Compds. of formula I wherein Het is (un)substituted aminoxadiazolyl, (un)substituted pyridinyl, (un)substituted aminoisoxazolyl, (un)substituted pyrazinyl, and (un)substituted aminopyrimidinyl; R1 is H, (un)substituted alkyl, (un)substituted (hetero)cycloalkyl, (un)substituted C1-12 aryl, etc.; R4 and R7 are independently H, halo, (un)substituted alkyl, (un)substituted alkoxy, acetamide, CN, (un)substituted urea, (un)substituted aryl, oxo, OH, etc.; R15 is halo, (un)substituted alkyl, (un)substituted alkoxy, acetamide, CN, (un)substituted urea, (un)substituted aryl, oxo, OH, etc.; and their pharmaceutically acceptable salts, hydrates, solvates, and prodrugs are claimed. Example compound II was prepared by palladium-catalyzed coupling of 4-(6-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine with 2-hydroxy-2-methyl-3-butyne. All the invention compds. were evaluated for their protein kinase B inhibitory activity. From the assay, it was determined that some of the tested compds. exhibited IC50 valued of less than or equal to 0.5 μ M against AKT1, AKT2 and AKT3.

IT 913640-21-8P 913641-47-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of imidazopyridinyl compds. as protein kinase B activity inhibitors useful in treatment of cancer and arthritis)

RN 913640-21-8 CAPLUS
 CN Phenol, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyne-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]- (CA INDEX NAME)



RN 913641-47-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(3-methoxyphenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




IT 913640-04-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of imidazopyridinyl compds. as protein kinase B activity inhibitors useful in treatment of cancer and arthritis)

RN 913640-04-7 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



IT	913640-03-6P	913640-05-8P	913640-06-9P
	913640-07-0P	913640-08-1P	913640-09-2P
	913640-11-6P	913640-13-8P	913640-15-0P
	913640-17-2P	913640-18-3P	913640-19-4P
	913640-22-9P	913640-24-1P	913640-26-3P
	913640-28-5P	913640-29-6P	913640-30-9P
	913640-31-0P	913640-32-1P	913640-34-3P
	913640-36-5P	913640-37-6P	913640-39-8P
	913640-40-1P	913640-41-2P	913640-43-4P
	913640-44-5P	913640-45-6P	913640-47-8P
	913640-48-9P	913640-49-0P	913640-50-3P
	913640-51-4P	913640-52-5P	913640-53-6P
	913640-54-7P	913640-55-8P	913640-56-9P
	913640-57-0P	913640-58-1P	913640-59-2P
	913640-60-5P	913640-61-6P	913640-62-7P
	913640-63-8P	913640-64-9P	913640-65-0P
	913640-66-1P	913640-67-2P	913640-68-3P
	913640-69-4P	913640-70-7P	913640-71-8P
	913640-72-9P	913640-73-0P	913640-74-1P
	913640-75-2P	913640-76-3P	913640-77-4P
	913640-78-5P	913640-79-6P	913640-80-9P
	913640-81-0P	913640-82-1P	913640-83-2P
	913640-84-3P	913640-85-4P	913640-86-5P
	913640-87-6P	913640-88-7P	913640-89-8P
	913640-90-1P	913640-91-2P	913640-92-3P
	913640-93-4P	913640-94-5P	913640-95-6P
	913640-96-7P	913640-97-8P	913640-98-9P
	913640-99-0P	913641-00-6P	913641-01-7P
	913641-02-8P	913641-03-9P	913641-04-0P
	913641-05-1P	913641-06-2P	913641-07-3P
	913641-08-4P	913641-09-5P	913641-10-8P
	913641-11-9P	913641-12-0P	913641-13-1P
	913641-14-2P	913641-15-3P	913641-16-4P
	913641-17-5P	913641-18-6P	913641-19-7P
	913641-20-0P	913641-21-1P	913641-22-2P
	913641-23-3P	913641-24-4P	913641-25-5P
	913641-26-6P	913641-27-7P	913641-28-8P
	913641-29-9P	913641-30-2P	913641-31-3P
	913641-32-4P	913641-33-5P	913641-34-6P
	913641-35-7P	913641-36-8P	913641-37-9P
	913641-38-0P	913641-39-1P	913641-40-4P


913641-41-5P 913641-42-6P 913641-43-7P
 913641-44-8P 913641-45-9P 913641-46-0P
 913641-48-2P 913641-49-3P 913641-50-6P
 913641-51-7P 913641-52-8P 913641-53-9P
 913641-54-0P 913641-55-1P 913641-56-2P
 913641-57-3P 913641-58-4P 913641-59-5P
 913641-60-8P 913641-61-9P 913641-62-0P
 913641-63-1P 913641-64-2P 913641-65-3P
 913641-66-4P 913641-67-5P 913641-68-6P
 913641-69-7P 913641-70-0P 913641-71-1P
 913641-72-2P 913641-73-3P 913641-74-4P
 913641-75-5P 913641-76-6P 913641-77-7P
 913641-79-9P 913641-80-2P 913641-81-3P
 913641-82-4P 913641-83-5P 913641-84-6P
 913641-85-7P 913641-86-8P 913641-87-9P
 913641-88-0P 913641-89-1P 913641-90-4P
 913641-91-5P 913641-92-6P 913641-93-7P
 913641-94-8P 913641-95-9P 913641-96-0P
 913641-97-1P 913641-98-2P 913641-99-3P
 913642-00-9P 913642-01-0P 913642-02-1P
 913642-03-2P 913642-04-3P 913642-05-4P
 913643-53-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of imidazopyridinyl compds. as protein kinase B
 activity inhibitors useful in treatment of cancer and arthritis)


RN 913640-03-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-
 methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]-2-methyl- (CA INDEX
 NAME)




RN 913640-05-8 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(2-aminophenyl)-1-
 ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-06-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-(aminomethyl)phenyl]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-07-0 CAPLUS
 CN Benzonitrile, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]- (CA INDEX NAME)



RN 913640-08-1 CAPLUS
 CN Benzenemethanol, 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]- (CA INDEX NAME)




RN 913640-09-2 CAPLUS
 CN Acetamide, N-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 913640-11-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(1H-indol-5-yl)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-13-8 CAPLUS

CN Acetamide, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]phenyl]- (CA INDEX NAME)




RN 913640-15-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-(aminomethyl)phenyl]-1-ethyl-4-(1H-pyrrol-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913640-17-2 CAPLUS
 CN Acetamide, 2-amino-N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]phenyl]- (CA INDEX NAME)



RN 913640-18-3 CAPLUS
 CN Acetamide, 2-amino-N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]phenyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 913640-17-2
 CMF C23 H24 N8 O3




CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 913640-19-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-22-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[3-(3-aminopropoxy)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-24-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-(2-aminoethoxy)phenyl]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-26-3 CAPLUS
 CN Phenol, 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]- (CA INDEX NAME)




RN 913640-28-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(4-aminobutoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-29-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-30-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(5-aminopentyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-31-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(4-piperidinyloxy)]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-32-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(3-pyrrolidinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-34-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-36-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(2-morpholinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-37-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(3-pyrrolidinyloxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-39-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(3S)-3-pyrrolidinyloxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-40-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(3R)-3-pyrrolidinyloxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-41-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-(3-thienyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-43-4 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(1H-indol-3-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-44-5 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[[(1R,2S)-2-aminocyclopentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-45-6 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(methylamino)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-47-8 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[[(1S,2R)-2-aminocyclopentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-48-9 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(phenylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-49-0 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-50-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(2-(3-piperidinyl)ethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-51-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(3-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-52-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(1H-indol-3-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-53-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(2R)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-54-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(2S)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-55-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(1H-indol-3-yl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-56-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(4-amino-2-methylbutoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-57-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-2-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-58-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-2-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-59-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-60-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-61-6 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-methylbutoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-62-7 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]- (CA INDEX NAME)



RN 913640-63-8 CAPLUS


CN 2-Propyn-1-ol, 3-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]- (CA INDEX NAME)



RN 913640-64-9 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-azetidinylmethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-65-0 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[[(1R,2S)-2-aminocyclohexyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-66-1 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[[(1S,2R)-2-aminocyclohexyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-67-2 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[[(1R,2R)-2-aminocyclohexyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 913640-68-3 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(2-morpholinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-69-4 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[3-(2S)-2-pyrrolidinylpropoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-70-7 CAPLUS


CN 6H-Imidazo[4,5-c]pyridin-6-one, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1,5-dihydro-4-(3-hydroxy-3-methyl-1-butyn-1-yl)- (CA INDEX NAME)



RN 913640-71-8 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-aminopropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-72-9 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-methylbutoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-73-0 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[[2-amino-4-methylpentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-74-1 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[[(2S)-2-amino-4-methylpentyl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-75-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-aminopropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-76-3 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-cyclohexylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-77-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-4-phenylbutoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-78-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[6-(2-aminoethoxy)-1-ethyl-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 913640-79-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(1H-imidazol-5-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-80-9 CAPLUS

CN 2-Pyrrolidinone, 5-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-81-0 CAPLUS


CN 2-Pyrrolidinone, 5-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-82-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(1-pyrrolidinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-83-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[2-[[4-(methoxyphenyl)methyl]amino]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-84-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[2-[[4-(trifluoromethyl)phenyl]methyl]amino]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-85-4 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-86-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(4-morpholinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-87-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(phenylamino)ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-88-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(1-methyl-1H-indol-3-yl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913640-89-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-[(phenylmethyl)thio]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-90-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-(3-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913640-91-2 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-4-phenylbutoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913640-92-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(2-amino-1-phenylethoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-93-4 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(aminomethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-94-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(methylamino)methyl]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-95-6 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[(phenylmethyl)amino]methyl]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-96-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminopropyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-97-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(2-aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913640-98-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-morpholinylmethyl)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913640-99-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[methyl(phenylmethyl)amino]methyl]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-00-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[methyl(2-phenylethyl)amino]methyl]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-01-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1R)-2-amino-1-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-02-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-(methylamino)-1-phenylethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-03-9 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(2-amino-1-cyclohexylethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-04-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(tetrahydro-2H-pyran-4-yl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-05-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(3-pyridinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-06-2 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(2-amino-1-cyclopropylethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-07-3 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(1,3-benzodioxol-4-yl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-08-4 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(1R)-2-amino-1-(1,3-benzodioxol-4-yl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-09-5 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(1S)-2-amino-1-(1,3-benzodioxol-4-yl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-10-8 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-(dimethylamino)-1-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-11-9 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[[[(1R,2S)-1-amino-2,3-dihydro-1H-inden-2-yl]oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 913641-12-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(S)-(2R)-2-morpholinylphenylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-13-1 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(R)-(2S)-2-morpholinylphenylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-14-2 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(1-pyrrolidinylmethyl)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-15-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(dimethylamino)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-16-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(1-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-17-5 CAPLUS
 CN Acetamide, N-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]methyl]-N-methyl- (CA INDEX NAME)




RN 913641-18-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-(4-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-19-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1S)-2-amino-1-phenylethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913641-20-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(2-amino-1-methylethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-21-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[1-(aminomethyl)-2-phenylethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-22-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-amino-1-phenylpropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-23-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1S)-3-amino-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-24-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1R)-3-amino-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 913641-25-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(3-amino-1-cyclohexylpropoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-26-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(4-pyridinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-27-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(2-pyridinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-28-8 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[1-(aminomethyl)-3-phenylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-29-9 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-amino-1-phenylbutoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-30-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1R,2R)-1-amino-1,2,3,4-tetrahydro-2-naphthalenyl]oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 913641-31-3 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(S)-phenyl(2S)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-32-4 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(R)-phenyl(2R)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-33-5 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[2-amino-1-(4-piperidinyl)ethoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)





RN 913641-34-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(1-methyl-4-piperidinyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-35-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[3-amino-1-(4-methyl-1-piperidinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-36-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(1-methyl-4-piperidinyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



Chemical structure of compound 10: A complex molecule featuring a cyclohexyl group, a chiral center with a hydroxyl group, a propargyl group, and a 4-ethyl-2-(4-aminophenyl)-1H-imidazole-5-yl group.


RN	913641-39-1	CAPLUS
CN	3-Butyn-2-ol, 4-[6-[(1S)-2-amino-1-cyclohexylethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)	

Absolute stereochemistry.



RN 913641-40-4 CAPLUS


CN 1-Pentyn-3-ol, 1-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-3-methyl- (CA INDEX NAME)



RN 913641-41-5 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(1R,2S)-2-amino-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-42-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[3-(methylamino)-1-phenylpropoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-43-7 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[3-(dimethylamino)-1-phenylpropoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)





RN 913641-44-8 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(4-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-45-9 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(3-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


CCN1C=NC2=C1N(C)C=C2Oc3cc4nc5c(c3)C#CC(C)(C)C(O)c5c4SCCSCCOC

RN	913641-49-3	CAPLUS
CN	3-Butyn-2-ol, 4-[6-[3-amino-1-(2-fluoro-3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)	




RN 913641-50-6 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-51-7 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(2-fluoro-3-methoxyphenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-52-8 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(2-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-53-9 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(4-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-54-0 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-55-1 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-[2-(trifluoromethyl)phenyl]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-56-2 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(4-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-57-3 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-58-4 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-chlorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-59-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-[3-(trifluoromethyl)phenyl]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-60-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-61-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2R)-2-amino-3-[4-(trifluoromethyl)phenyl]propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-62-0 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-benzo[b]thien-2-ylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913641-63-1 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-cyclohexylpropoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-64-2 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-amino-3-phenylpropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-65-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-amino-2-phenylpropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-66-4 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(3-chlorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-67-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(2-chlorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-68-6 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(4-chlorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-69-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(3-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-70-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(4-fluorophenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-71-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(2-fluorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-72-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(3-fluorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-73-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(4-fluorophenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-74-4 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-(4-fluoro-3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-75-5 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[2-amino-1-(4-fluoro-3-methoxyphenyl)ethoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)



RN 913641-76-6 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-furanyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-77-7 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-furanyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 913641-76-6
 CMF C22 H25 N7 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 913641-79-9 CAPLUS
 CN Phenol, 3-[2-amino-1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]ethyl]-,
 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 913641-78-8
 CMF C23 H25 N7 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-80-2 CAPLUS

CN Phenol, 4-[(2R)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 913641-81-3 CAPLUS


CN Phenol, 4-[(2R)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-80-2

CMF C24 H27 N7 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-82-4 CAPLUS

CN Phenol, 4-[(2S)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-(CA INDEX NAME)

Absolute stereochemistry.



RN 913641-83-5 CAPLUS


CN Phenol, 4-[(2S)-2-amino-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-82-4

CMF C24 H27 N7 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-84-6 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-85-7 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-84-6

CMF C25 H27 N7 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-86-8 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-87-9 CAPLUS


CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(3-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-86-8

CMF C25 H29 N7 O4


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 913641-88-0 CAPLUS

CN Phenol, 3-[3-amino-1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-(CA INDEX NAME)




RN 913641-89-1 CAPLUS

CN Phenol, 3-[3-amino-1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 913641-88-0


CMF C24 H27 N7 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 913641-90-4 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-91-5 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[2-[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]ethoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1


CRN 913641-90-4

CMF C26 H29 N7 O3

Absolute stereochemistry.


CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN	913641-92-6	CAPLUS
CN	3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-(3-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)	

Absolute stereochemistry.




RN	913641-93-7	CAPLUS
CN	3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2S)-2-amino-3-(4-pyridinyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)	

Absolute stereochemistry.




RN 913641-94-8 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(4-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-95-9 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2S)-2-amino-3-(2-furanyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA
 INDEX NAME)

Absolute stereochemistry.




RN 913641-96-0 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-[(2R)-2-amino-3-(2-methoxyphenyl)propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 913641-97-1 CAPLUS
 CN 3-Butyn-2-ol, 4-[6-(3-amino-3-cyclohexylpropoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913641-98-2 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(3R)-3-amino-3-(tetrahydro-2H-pyran-4-yl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 913641-99-3 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(3S)-3-amino-3-(tetrahydro-2H-pyran-4-yl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 913642-00-9 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[[(3S)-1,2,3,4-tetrahydro-3-isoquinolinyl]methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 913642-01-0 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[2-(aminomethyl)-4-phenylbutoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913642-02-1 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-[(3-methoxyphenyl)methyl]propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913642-03-2 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[3-amino-1-(3-thienylmethyl)propoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913642-04-3 CAPLUS

CN 3-Butyn-2-ol, 4-[6-[3-amino-1-[(3,4-dimethoxyphenyl)methyl]propoxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913642-05-4 CAPLUS

CN 3-Butyn-2-ol, 4-[6-(2-aminoethoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913643-53-5 CAPLUS
 CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-[(2,3-dihydro-1H-indol-2-yl)methoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




IT 913642-06-5P 913642-12-3P 913642-16-7P
 913642-17-8P 913642-18-9P 913642-19-0P
 913642-20-3P 913642-21-4P 913642-22-5P
 913642-23-6P 913642-24-7P 913642-25-8P
 913642-26-9P 913642-27-0P 913642-28-1P
 913642-29-2P 913642-30-5P 913642-32-7P
 913642-33-8P 913642-34-9P 913642-35-0P
 913642-36-1P 913642-37-2P 913642-38-3P
 913642-50-9P 913642-51-0P 913642-52-1P
 913642-64-5P 913642-65-6P 913642-72-5P
 913642-73-6P 913642-75-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of imidazopyridinyl compds. as protein kinase B
 activity inhibitors useful in treatment of cancer and arthritis)

RN 913642-06-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(6-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 913642-12-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(4,6-dichloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 913642-16-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(3-aminophenyl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913642-17-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-(aminomethyl)phenyl]-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913642-18-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-(aminomethyl)phenyl]-1-ethyl-4-[1-[tris(1-methylethyl)silyl]-1H-pyrrol-3-yl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 913642-19-0 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)




RN 913642-20-3 CAPLUS

CN Carbamic acid, [2-[[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 913642-21-4 CAPLUS

CN Carbamic acid, [3-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]phenoxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 913642-22-5 CAPLUS

CN 6H-Imidazo[4,5-c]pyridin-6-one, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1,5-dihydro- (CA INDEX NAME)




RN 913642-23-6 CAPLUS

CN Carbamic acid, [4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 913642-24-7 CAPLUS

CN Carbamic acid, [4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 913642-25-8 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-ethyl-6-(phenylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 913642-26-9 CAPLUS

CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-[(4-methoxyphenyl)methoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)


NAME)



RN 913642-27-0 CAPLUS

CN Carbamic acid, [(1S)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913642-28-1 CAPLUS


CN Carbamic acid, [(1S)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 913642-29-2 CAPLUS

CN Carbamic acid, [2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 913642-30-5 CAPLUS

CN Carbamic acid, [2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 913642-32-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(4-chloro-6-ethenyl-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 913642-33-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-methanol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl- (CA INDEX NAME)




RN 913642-34-9 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]- (CA INDEX NAME)




RN 913642-35-0 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]methyl]- (CA INDEX NAME)




RN 913642-36-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-methanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-N-methyl- (CA INDEX NAME)




RN 913642-37-2 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]propyl]- (CA INDEX NAME)




RN 913642-38-3 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]propyl]- (CA INDEX NAME)




RN 913642-50-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-6-methanol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-α-phenyl- (CA INDEX NAME)




RN 913642-51-0 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]phenylmethoxy]ethyl]- (CA INDEX NAME)




RN 913642-52-1 CAPLUS
 CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butyn-1-yl)-1H-imidazo[4,5-c]pyridin-6-yl]phenylmethoxy]ethyl]- (CA INDEX NAME)




RN 913642-64-5 CAPLUS
 CN Carbamic acid, [(1R)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-(2-furanylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913642-65-6 CAPLUS
 CN Carbamic acid, [(1R)-2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1-(2-furanylmethyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 913642-72-5 CAPLUS

CN 2(1H)-Isoquinolinecarboxylic acid,
3-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-
c]pyridin-6-yl]oxy]ethyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 913642-73-6 CAPLUS


CN Carbamic acid, [(1S)-1-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-
hydroxy-3-methyl-1-butynyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-2-(3-
pyridinyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 913642-75-8 CAPLUS

CN Imidodicarbonic acid, N-[2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-
ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]methyl]-4-phenylbutyl]-,
C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



L3 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:544601 CAPLUS

DOCUMENT NUMBER: 143:224753

TITLE: (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors

AUTHOR(S): Bamford, Mark J.; Bailey, Nicholas; Davies, Susannah; Dean, David K.; Francis, Leann; Panchal, Terence A.; Parr, Christopher A.; Sehmi, Sanjeet; Steadman, Jon G.; Takle, Andrew K.; Townsend, James T.; Wilson, David M.

CORPORATE SOURCE: Neurology & GI Centre of Excellence for Drug Discovery, New Frontiers Science Park, GlaxoSmithKline Pharmaceuticals, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(14), 3407-3411

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:224753

AB The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here the authors report on its optimization for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases.


IT 607368-93-4 607368-97-8 607369-16-4
607369-21-1 607369-29-9 607369-33-5
607369-34-6 607369-41-5 607370-81-0
607370-83-2 607372-49-6 607372-50-9
607372-56-5 607373-74-0 862599-59-5
862599-60-8 862599-61-9 862599-62-0
862599-63-1 862599-64-2

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

((imidazopyridin-2-yl)oxadiazol-3-ylamine N1-, C4- and C7- derivs. optimization and preparation as protein kinase MSK1-selective inhibitors in relation to other protein kinases)


RN 607368-93-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607368-97-8 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclohexyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607369-16-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607369-21-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-propanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 607369-29-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-butanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)- (CA INDEX NAME)




RN 607369-33-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-propanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-
(CA INDEX NAME)




RN 607369-34-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-piperidiny1)-1H-imidazo[4,5-c]pyridin-2-yl]-
(CA INDEX NAME)




RN 607369-41-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-
(CA INDEX NAME)




RN 607370-81-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(aminomethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-
(CA INDEX NAME)




RN 607370-83-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-(aminomethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-49-6 CAPLUS

CN 4-Piperidinamine, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]- (CA INDEX NAME)




RN 607372-50-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1-piperazinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-56-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1-piperidin-4-ylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-74-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 862599-59-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1,4-diethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 862599-60-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-4-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 862599-61-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(4-ethoxy-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 862599-62-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-4-phenoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 862599-63-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-(1-pyrrolidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 862599-64-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-ethanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)- β -methyl- (CA INDEX NAME)




IT 607368-87-6
 RL: BSU (Biological study, unclassified); PRP (Properties); RCT
 (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 ((imidazopyridin-2-yl)oxadiazol-3-ylamine N1-, C4- and C7- derivs.
 optimization and preparation as protein kinase MSK1-selective inhibitors in
 relation to other protein kinases)
 RN 607368-87-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA
 INDEX NAME)




IT 607373-73-9P
 RL: BSU (Biological study, unclassified); PRP (Properties); RCT
 (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent)
 ((imidazopyridin-2-yl)oxadiazol-3-ylamine N1-, C4- and C7- derivs.
 optimization and preparation as protein kinase MSK1-selective inhibitors in
 relation to other protein kinases)
 RN 607373-73-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
 yl)- (CA INDEX NAME)




IT 607370-99-0P 607372-46-3P 607373-75-1P
 RL: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 ((imidazopyridin-2-yl)oxadiazol-3-ylamine N1-, C4- and C7- derivs.
 optimization and preparation as protein kinase MSK1-selective inhibitors in relation to other protein kinases)
 RN 607370-99-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)




RN 607372-46-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-4-piperidinyl- (CA INDEX NAME)




RN 607373-75-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-4-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)



IT 607372-47-4P 607372-48-5P 607373-72-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 ((imidazopyridin-2-yl)oxadiazol-3-ylamine N1-, C4- and C7- derivs.
 optimization and preparation as protein kinase MSK1-selective inhibitors in
 relation to other protein kinases)
 RN 607372-47-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxaldehyde,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA INDEX NAME)




RN 607372-48-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-
 1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]-, 1,1-dimethylethyl ester (CA
 INDEX NAME)



RN 607373-72-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-5-oxido-1H-imidazo[4,5-c]pyridin-2-yl)-
(CA INDEX NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:544600 CAPLUS

DOCUMENT NUMBER: 143:229795

TITLE: (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors

AUTHOR(S): Bamford, Mark J.; Alberti, Michael J.; Bailey, Nicholas; Davies, Susannah; Dean, David K.; Gaiba, Alessandra; Garland, Stephen; Harling, John D.; Jung, David K.; Panchal, Terence A.; Parr, Christopher A.; Steadman, Jon G.; Takle, Andrew K.; Townsend, James T.; Wilson, David M.; Witherington, Jason

CORPORATE SOURCE: Neurology and GI Centre of Excellence for Drug Discovery, New Frontiers Science Park, GlaxoSmithKline Pharmaceuticals, Essex, CM19 5AW, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(14), 3402-3406

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:229795

AB A novel series of imidazo[4,5-c]pyridines bearing a 1,2,5-oxadiazol-3-ylamine functionality has been developed. These are potent inhibitors of mitogen and stress-activated protein kinase-1.

IT 607368-87-6P 607368-93-4P 607368-95-6P

607368-97-8P 607369-16-4P 607369-29-9P

607369-41-5P 862814-98-0P 862814-99-1P


862815-00-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivs. as potent MSK-1-inhibitors)


RN 607368-87-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607368-93-4 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607368-95-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607368-97-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclohexyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607369-16-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-piperidiny1)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-29-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-butanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-
 (CA INDEX NAME)




RN 607369-41-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA
 INDEX NAME)



RN 862814-98-0 CAPLUS
 CN Acetamide, N-[4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]- (CA INDEX NAME)




RN 862814-99-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine, 2-(4-chloro-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA
 INDEX NAME)



RN 862815-00-7 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(3H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)

NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:451189 CAPLUS
DOCUMENT NUMBER: 142:476214
TITLE: Erb family inhibitor and PI3K and/or Akt inhibitor for cancer treatment
INVENTOR(S): Dev, Inderjit Jumar; Gilmer, Tana Morgan; Rhodes, Clifford Nelson, III; Tansik, Robert L.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046678	A1	20050526	WO 2004-US37027	20041105
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1682123	A1	20060726	EP 2004-810446	20041105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
JP 2007510667	T	20070426	JP 2006-538522	20041105
US 20070161665	A1	20070712	US 2006-595691	20060505
PRIORITY APPLN. INFO.:			US 2003-518212P	P 20031107
			WO 2004-US37027	W 20041105

OTHER SOURCE(S): MARPAT 142:476214

AB The invention discloses a method for treating cancer in a mammal, as well as pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer. Preparation of inhibitors is described.

IT 607373-66-0P 607373-68-2P 842144-79-0P

842146-05-8P 842146-10-5P 842146-12-7P


842146-18-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(erb family inhibitor and PI3K and/or Akt inhibitor for cancer treatment)


RN 607373-66-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607373-68-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842144-79-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-N-[2-[(phenylmethyl)amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 842144-78-9


CMF C28 H27 Cl N8 O2



CRN 76-05-1
CMF C2 H F3 O2




RN 842146-05-8 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-10-5 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CRN 842146-09-2

CMF C22 H24 Cl N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842146-12-7 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-aminobutoxy)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842146-11-6
CMF C20 H22 Cl N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842146-18-3 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842146-17-2
CMF C19 H21 N7 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 852023-81-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(erb family inhibitor and PI3K and/or Akt inhibitor for cancer treatment)
RN 852023-81-5 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

IT 607370-99-0P 607373-60-4P 607373-65-9P
 607373-67-1P 842143-99-1P 842144-00-7P
 842144-07-4P 842144-08-5P 842146-03-6P
 842146-04-7P 852023-76-8P 852023-77-9P
 852023-78-0P 852023-79-1P 852023-80-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (erb family inhibitor and PI3K and/or Akt inhibitor for cancer
 treatment)


RN 607370-99-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)




RN 607373-60-4 CAPLUS


CN Carbamic acid, [4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-
 oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607373-65-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-
 (CA INDEX NAME)



RN 607373-67-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842143-99-1 CAPLUS
 CN Carbamic acid, [4-(1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842144-00-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842144-07-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 842144-08-5 CAPLUS


CN Carbamic acid, [4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 842146-03-6 CAPLUS


CN Carbamic acid, [4-(4-chloro-1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-

yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842146-04-7 CAPLUS

CN Carbamic acid, [4-(1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 852023-76-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-4-chloro-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 852023-77-9 CAPLUS

CN Imidodicarbonic acid, N-[4-[7-bromo-4-chloro-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-yl]-, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 852023-78-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
4-chloro-1-(cyclopropylmethyl)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]-
1,2,5-oxadiazol-3-yl]- (CA INDEX NAME)




RN 852023-79-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
4-(3-chlorophenyl)-1-(cyclopropylmethyl)-2-[4-[(1,1-
dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]- (CA INDEX NAME)



RN 852023-80-4 CAPLUS

CN Carbamic acid, [4-[4-(3-chlorophenyl)-1-(cyclopropylmethyl)-7-[[[2-
[(phenylmethyl)amino]ethyl]amino]carbonyl]-1H-imidazo[4,5-c]pyridin-2-yl]-
1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:369223 CAPLUS
 DOCUMENT NUMBER: 142:430270
 TITLE: Preparation of 1,7-disubstituted azabenzimidazoles as
 Rho-kinase inhibitors, and their pharmaceutical
 compositions and methods of use
 INVENTOR(S): Lee, Dennis; Stavenger, Robert; Goodman, Krista B.;
 Hilfiker, Mark A.; Cui, Haifeng; Marino, Joseph P.
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037198	A2	20050428	WO 2004-US32825	20041006
WO 2005037198	A3	20050609		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1689393	A2	20060816	EP 2004-809870	20041006
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007507547	T	20070329	JP 2006-534265	20041006
US 20070123561	A1	20070531	US 2006-574675	20060404
PRIORITY APPLN. INFO.:			US 2003-508893P	P 20031006
			US 2003-532085P	P 20031223
			WO 2004-US32825	W 20041006
OTHER SOURCE(S):	CASREACT 142:430270; MARPAT 142:430270			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of novel azabenzimidazoles I, which are inhibitors of Rho-kinases. In compds. I, R1 is (un)substituted alkyl, Ph, heteroaryl, NH2, etc.; R2 is H, halo, (un)substituted alkyl, Ph, heteroaryl, heterocyclyl, CONH2, SONH2, NH2, etc. The invention also relates to the preparation of I, pharmaceutical compns. containing I as active ingredients, as well as to the use of the compns. for the treatment of disorders involving Rho-kinases. For instance, invention compound II was prepared in 8 steps: (1) chlorination of 3-nitro-4-pyridinol with POCl3, (2) substitution of the resultant chloride with 4-methoxyaniline, (3) hydrogenation of nitro to amino, (4) cyclocondensation of the diamine with Et cyanoacetate to give imidazopyridine derivative III, (5) treatment of III with HCl, NaNO2, NaOH, and NH2OH, to give the furazan derivative IV, (6) O-demethylation of IV, (7) Mitsunobu reaction of the resultant phenol with N-BOC-4-hydroxypiperidine, and (8) removal of BOC with TFA. Eight addnl. prepns. are given, and 72 specific examples of I are claimed by name.



ROCK kinase inhibitory activity was determined using human recombinant ROCK1 kinase domain (amino acid 2-543) expressed in Sf9 cells (no data).

IT 850850-56-5P, 1,1-Dimethylethyl
(3R)-3-[[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]amino]methyl]-1-pyrrolidinecarboxylate 850850-61-2P,
1,1-Dimethylethyl 4-[[4-[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]-1-piperidinecarboxylate 850850-68-9P,
4-[1-[4-(4-Piperidinyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-81-6P, Methyl
[4-[[4-[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]-1-piperidinyloxy]acetate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 1,7-disubstituted azabenzimidazoles as Rho-kinase inhibitors)
RN 850850-56-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 850850-61-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)





RN 850850-68-9 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(4-piperidinyloxy)phenyl]-1H-imidazo[4,5-

c]pyridin-2-yl]- (CA INDEX NAME)



RN 850850-81-6 CAPLUS

CN 1-Piperidineacetic acid, 4-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-, methyl ester (CA INDEX NAME)



II 850850-30-5P, 4-[1-Ethyl-7-[[3-(methyloxy)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-31-6P, Phenylmethyl 4-[[4-[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]-1-piperidinecarboxylate 850850-32-7P, 4-[1-[4-[[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-33-8P, 4-[1-[4-[[2-(4-Chlorophenyl)-1,3-thiazol-4-yl]methyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-34-9P, 4-[1-[4-[[5-Phenyl-1,2,4-oxadiazol-3-yl]methyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-35-0P, 4-[1-[4-[[5-Methyl-3-isoxazolyl]methyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-36-1P, 4-[1-[4-[[Methylsulfonyl]methyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-37-2P, 2-(4-Aminofurazan-3-yl)-1-ethyl-N-[4-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-7-amine 850850-38-3P, 2-(4-Aminofurazan-3-yl)-1-ethyl-N-(4-piperidinylmethyl)-1H-imidazo[4,5-


c]pyridine-7-sulfonamide 850850-39-4P,
4-[7-[[4-(Aminomethyl)-1-piperidinyl]sulfonyl]-1-ethyl-1H-imidazo[4,5-
c]pyridin-2-yl]furazan-3-amine 850850-40-7P,
4-[1-Ethyl-7-(1-piperazinylsulfonyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-
3-amine 850850-41-8P, 2-(4-Aminofurazan-3-yl)-1-ethyl-N-4-
piperidinyl-1H-imidazo[4,5-c]pyridine-7-sulfonamide 850850-42-9P
, 2-(4-Aminofurazan-3-yl)-1-ethyl-N-(3-pyrrolidinyl)-1H-imidazo[4,5-
c]pyridine-7-sulfonamide 850850-43-0P,
N-(trans-4-Aminocyclohexyl)-2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-
c]pyridine-7-sulfonamide 850850-44-1P,
4-[7-(((3R)-3-Amino-1-pyrrolidinyl)sulfonyl)-1-ethyl-1H-imidazo[4,5-
c]pyridin-2-yl]furazan-3-amine 850850-45-2P,
2-(4-Aminofurazan-3-yl)-1-ethyl-N-(phenylmethyl)-1H-imidazo[4,5-c]pyridine-
7-sulfonamide 850850-46-3P,
N-[[4-(Aminomethyl)cyclohexyl]methyl]-2-(4-aminofurazan-3-yl)-1-ethyl-1H-
imidazo[4,5-c]pyridine-7-sulfonamide 850850-47-4P,
2-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-
yl]sulfonyl]-1-piperazinyl]ethanol 850850-48-5P,
N-(2-Aminoethyl)-2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-
7-sulfonamide 850850-49-6P,
4-[1-Ethyl-7-[(4-methyl-1-piperazinyl)sulfonyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-amine 850850-50-9P,
4-[[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-
yl]sulfonyl]amino]methyl]benzoic acid 850850-51-0P,
2-(4-Aminofurazan-3-yl)-1-ethyl-N-[3-(methylamino)propyl]-1H-imidazo[4,5-
c]pyridine-7-sulfonamide 850850-52-1P,
2-(4-Aminofurazan-3-yl)-N-(3-aminopropyl)-1-ethyl-1H-imidazo[4,5-
c]pyridine-7-sulfonamide 850850-53-2P,
N-(4-Aminobutyl)-2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-
7-sulfonamide 850850-54-3P,
4-[1-(1-Methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-
c]pyridin-2-yl]furazan-3-amine 850850-55-4P,
4-[1-Ethyl-7-(2-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
amine 850850-57-6P, N-[2-[[4-[2-(4-Aminofurazan-3-yl)-1H-
imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]ethyl]-N-methylglycine
850850-58-7P, 1,1-Dimethylethyl
(3S)-3-[[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-
yl]carbonyl]amino]methyl]-1-pyrrolidinecarboxylate 850850-59-8P,
4-[1-[4-[(1-Methyl-3-pyrrolidinyl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-amine 850850-60-1P,
4-[1-Ethyl-7-(4-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
amine 850850-62-3P, 4-[1-Ethyl-7-[[4-(methyloxy)phenyl]sulfinyl]-
1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-63-4P,
2-(4-Aminofurazan-3-yl)-N-[2-(2-chlorophenyl)-2-(dimethylamino)ethyl]-1-
ethyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 850850-64-5P,
2-(4-Aminofurazan-3-yl)-N-[4-(dimethylamino)butyl]-1-ethyl-1H-imidazo[4,5-
c]pyridine-7-carboxamide 850850-65-6P,
4-[1-Ethyl-7-(1-pyrrolidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
amine 850850-66-7P, [[4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-
c]pyridin-1-yl]phenyl]oxy]acetic acid 850850-67-8P,
1,1-Dimethylethyl [[4-[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-
yl]phenyl]oxy]acetate 850850-69-0P,
4-[7-[3-(1-Aminoethyl)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-amine 850850-70-3P,
2-(4-Aminofurazan-3-yl)-1-ethyl-N-((3S)-3-pyrrolidinylmethyl)-1H-
imidazo[4,5-c]pyridine-7-carboxamide 850850-71-4P,
2-(4-Aminofurazan-3-yl)-1-ethyl-N-((3R)-3-pyrrolidinylmethyl)-1H-
imidazo[4,5-c]pyridine-7-carboxamide 850850-72-5P,
2-(4-Aminofurazan-3-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-
imidazo[4,5-c]pyridine-7-carboxamide 850850-73-6P,
N-[[3-(Aminomethyl)cyclohexyl]methyl]-2-(4-aminofurazan-3-yl)-1-ethyl-1H-
imidazo[4,5-c]pyridine-7-carboxamide 850850-74-7P,

4-[[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]amino]methyl]benzoic acid 850850-75-8P,
2-(4-Aminofurazan-3-yl)-N-[4-(diethylamino)-1-methylbutyl]-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 850850-76-9P,
2-(4-Aminofurazan-3-yl)-1-ethyl-N-[2-[4-(methyloxy)phenyl]-2-phenylethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide 850850-77-0P,
N-[2-[[4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]ethyl]-N-methylacetamide 850850-78-1P,
N-[2-[[4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]ethyl]-N-methylmethanesulfonamide 850850-79-2P,
N-[2-[[4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]ethyl]-N'-phenylurea 850850-80-5P,
N-[2-[[4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]ethyl]-N'-ethylurea 850850-82-7P,
4-[1-[4-[[2-(Phenylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-83-8P,
[4-[[4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]oxy]-1-piperidinyl]acetic acid 850850-84-9P,
1-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-4-piperidinamine 850850-85-0P,
2-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]ethanol 850850-86-1P,
N-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]thio]phenyl]acetamide 850850-87-2P,
N-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]sulfinyl]phenyl]acetamide 850850-88-3P,
4-[7-[(3S)-3-Amino-1-pyrrolidinyl]carbonyl]-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-89-4P, 1-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-4-piperidinecarboxamide 850850-90-7P, 4-[1-[4-[[2-(Dimethylamino)ethyl]oxy]phenyl]-7-(1-pyrrolidinylcarbonyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-91-8P, 4-[7-[(3S)-3-Amino-1-pyrrolidinyl]carbonyl]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-92-9P, 4-[1-Phenyl-7-(1-pyrrolidinylcarbonyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-93-0P,
4-[1-[4-[(3,3-Dimethylbutyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-94-1P,
4-[1-[4-[(2-Methylpropyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-95-2P,
4-[1-[4-[(1-Methylethyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-96-3P,
4-[1-[4-[(3-Methylbutyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-97-4P,
4-[1-[4-[(Phenylmethyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850850-98-5P, 4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]-N-methylbenzamide 850850-99-6P,
4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]-N-(1-methylethyl)benzamide 850851-00-2P,
4-[1-[4-(1-Pyrrolidinylcarbonyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850851-01-3P,
4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1,7-disubstituted azabenzimidazoles as Rho-kinase inhibitors)



RN 850850-30-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(3-methoxyphenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 850850-31-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-, phenylmethyl ester (CA INDEX NAME)





RN 850850-32-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(2-methyl-4-thiazolyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 850850-33-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[[2-(4-chlorophenyl)-4-thiazolyl]methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 850850-34-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(5-phenyl-1,2,4-oxadiazol-3-yl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-35-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850850-36-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(methylsulfonyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-37-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-7-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 850850-38-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,

2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 850850-39-4 CAPLUS

CN 4-Piperidinemethanamine, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]sulfonyl]- (CA INDEX NAME)




RN 850850-40-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1-piperazinylsulfonyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-41-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-4-piperidinyl- (CA INDEX NAME)




RN 850850-42-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-pyrrolidinyl- (CA INDEX NAME)




RN 850850-43-0 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,
 N-(trans-4-aminocyclohexyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA
 INDEX NAME)

Relative stereochemistry.




RN 850850-44-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-[(3R)-3-amino-1-pyrrolidinyl]sulfonyl]-1-
 ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 850850-45-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(phenylmethyl)- (CA INDEX
 NAME)




RN 850850-46-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,
 N-[[4-(aminomethyl)cyclohexyl]methyl]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA INDEX NAME)




RN 850850-47-4 CAPLUS
 CN 1-Piperazineethanol, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]sulfonyl]- (CA INDEX NAME)




RN 850850-48-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,
 N-(2-aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA INDEX
 NAME)




RN 850850-49-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-methyl-1-piperazinyl)sulfonyl]-
 1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-50-9 CAPLUS
 CN Benzoic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]sulfonyl]amino]methyl]- (CA INDEX NAME)




RN 850850-51-0 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(methylamino)propyl]- (CA INDEX NAME)





RN 850850-52-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(3-aminopropyl)-1-ethyl- (CA INDEX NAME)




RN 850850-53-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide,
 N-(4-aminobutyl)-2-(4-aminobutyl)-1-ethyl- (CA INDEX
 NAME)



RN 850850-54-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1,2,3,4-tetrahydro-1-methyl-7-
 isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-55-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(2-pyridinylthio)-1H-imidazo[4,5-
 c]pyridin-2-yl]- (CA INDEX NAME)



RN 850850-57-6 CAPLUS


CN Glycine, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 850850-58-7 CAPLUS



CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 850850-59-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-60-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850850-62-3 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-methoxyphenyl)sulfinyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-63-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,


2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[2-(2-chlorophenyl)-2-(dimethylamino)ethyl]-1-ethyl- (CA INDEX NAME)



RN 850850-64-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[4-(dimethylamino)butyl]-1-ethyl- (CA
INDEX NAME)




RN 850850-65-6 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1-pyrrolidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-66-7 CAPLUS

CN Acetic acid, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]- (CA INDEX NAME)




RN 850850-67-8 CAPLUS

CN Acetic acid, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 850850-69-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-(1-aminoethyl)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850850-70-3 CAPLUS


RN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 CN 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[(3S)-3-pyrrolidinylmethyl]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 850850-71-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[(3R)-3-pyrrolidinylmethyl]-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 850850-72-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-
 (CA INDEX NAME)




RN 850850-73-6 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 N-[[3-(aminomethyl)cyclohexyl]methyl]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-
 (CA INDEX NAME)




RN 850850-74-7 CAPLUS

CN Benzoic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 850850-75-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[4-(diethylamino)-1-methylbutyl]-1-ethyl- (CA INDEX NAME)




RN 850850-76-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(4-methoxyphenyl)-2-phenylethyl]- (CA INDEX NAME)




RN 850850-77-0 CAPLUS

CN Acetamide, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 850850-78-1 CAPLUS

CN Methanesulfonamide, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 850850-79-2 CAPLUS

CN Urea, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-N'-phenyl- (CA INDEX NAME)




RN 850850-80-5 CAPLUS

CN Urea, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-N'-ethyl- (CA INDEX NAME)





RN 850850-82-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(phenylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850850-83-8 CAPLUS

CN 1-Piperidineacetic acid, 4-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]- (CA INDEX NAME)




RN 850850-84-9 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](4-amino-1-piperidiny)- (CA INDEX NAME)




RN 850850-85-0 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][4-(2-hydroxyethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 850850-86-1 CAPLUS

CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]thio]phenyl]- (CA INDEX NAME)



RN 850850-87-2 CAPLUS


CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]sulfinyl]phenyl]- (CA INDEX NAME)



RN 850850-88-3 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-7-yl][(3S)-3-amino-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 850850-89-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]- (CA INDEX NAME)



RN 850850-90-7 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-7-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 850850-91-8 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][(3S)-3-amino-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 850850-92-9 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 850850-93-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(3,3-dimethylbutyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Me₃C-CH₂-CH₂-NH

RN 850850-94-1 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(2-methylpropyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



i-BuNH

RN 850850-95-2 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(1-methylethyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



i-PrNH

RN 850850-96-3 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(3-methylbutyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Me₂CH-CH₂-CH₂-NH

RN 850850-97-4 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(phenylmethyl)amino]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Ph-CH₂-NH


RN 850850-98-5 CAPLUS

CN Benzamide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]-N-methyl- (CA INDEX NAME)





RN 850850-99-6 CAPLUS

CN Benzamide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 850851-00-2 CAPLUS

CN Methanone, [4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 850851-01-3 CAPLUS

CN Benzamide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)




IT 607369-40-4P, 4-[1-[4-(Methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 607369-43-7P,

4-[1-(4-Aminophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-amine
 607369-54-0P, 4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-
 1-yl]phenol 607369-76-6P,
 1,1-Dimethylethyl[2-[[4-[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-
 1-yl]phenyl]oxy]ethyl]carbamate 607370-99-0P,
 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-ylamine
 607372-25-8P, 4-[1-Ethyl-7-[[4-(methyloxy)phenyl]thio]-1H-
 imidazo[4,5-c]pyridin-2-yl]furan-3-amine 607372-41-8P,
 4-[7-Bromo-1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-
 ylamine 607372-42-9P, 4-[2-(4-Aminofurazan-3-yl)-7-
 bromoimidazo[4,5-c]pyridin-1-yl]phenol 607372-44-1P,
 4-[7-Bromo-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-
 c]pyridin-2-yl]furan-3-amine 607373-26-2P,
 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic
 acid 607373-60-4P, [4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-
 2-yl)furan-3-yl]carbamic acid tert-butyl ester 607373-62-6P,
 (R)-[4-[7-[3-[(tert-Butoxycarbonyl)amino]pyrrolidin-1-yl]sulfonyl]-1-
 ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]carbamic acid tert-butyl
 ester 775577-11-2P, 4-[1-[4-[1-(2-Aminoethyl)oxy]phenyl]-1H-
 imidazo[4,5-c]pyridin-2-yl]furan-3-amine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of 1,7-disubstituted azabenzimidazoles as
 Rho-kinase inhibitors)


RN 607369-40-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-
 yl]- (CA INDEX NAME)




RN 607369-43-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-2-
 yl]- (CA INDEX NAME)




RN 607369-54-0 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]-
(CA INDEX NAME)




RN 607369-76-6 CAPLUS

CN Carbamic acid, [2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607370-99-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
(CA INDEX NAME)




RN 607372-25-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-methoxyphenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-41-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-42-9 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)



RN 607372-44-1 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Me₂N-CH₂-CH₂-O


RN 607373-26-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA INDEX NAME)



RN 607373-60-4 CAPLUS


CN Carbamic acid, [4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 607373-62-6 CAPLUS


CN Carbamic acid, [(3R)-1-[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]sulfonyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 775577-11-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(2-aminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:369222 CAPLUS
 DOCUMENT NUMBER: 142:430279
 TITLE: Preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors
 INVENTOR(S): Lee, Dennis; Stavenger, Robert A.; Goodman, Krista B.; Hilfiker, Mark A.; Cui, Haifeng; Viet, Andrew Q.
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037197	A2	20050428	WO 2004-US32824	20041006
WO 2005037197	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1675552	A2	20060705	EP 2004-794238	20041006
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007507546	T	20070329	JP 2006-534264	20041006
US 20080234261	A1	20080925	US 2006-574676	20060404
PRIORITY APPLN. INFO.:			US 2003-508894P	P 20031006
			US 2003-531949P	P 20031223
			WO 2004-US32824	W 20041006
OTHER SOURCE(S):		CASREACT 142:430279; MARPAT 142:430279		
GI				




AB Title compds. I [wherein X = (un)substituted NH, O, S, SO or SO₂; R₁, R₂ = (un)substituted alkyl, Ph, heteroaryl, etc.; and physiol. acceptable salts thereof] were prepared as Rho-kinase inhibitors. For example, 2,4-dichloro-5-nitropyridine (preparation given) underwent substitution with aniline (71% yield) and 3-acetylaminophenol (97% yield) subsequently followed by nitro reduction with H₂ in the presence of Pd/C to give II (100% yield). Conversion of this compound into III was realized via EDCI-mediated coupling with cyanoacetic acid, thermal intramol. cyclization to an 2-imidazoeacetonitrile (65% yield for the two steps), reaction with NaNO₂-HCl in methanol to an oxime (95% yield), and cyclization with NH₂OH in the presence of Et₃N (40% yield). The invented compds. are useful for the treatment of diseases, such as hypertension, heart failure and ischemic angina.

IT 850663-65-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-66-0P, 4-[6-[(3-Aminophenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850663-83-1P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850663-84-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoic acid 850663-90-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]acetamide 850664-06-1P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)-1-butanone 850664-09-4P, 4-[1-Ethyl-6-[[3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-18-5P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]benzoate
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)


RN 850663-65-9 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850663-66-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(3-aminophenoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850663-83-1 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 850663-84-2 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850663-90-0 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]- (CA INDEX NAME)




RN 850664-06-1 CAPLUS

CN 1-Butanone, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)- (CA INDEX NAME)




RN 850664-09-4 CAPLUS

CN 1-Propanone, 3-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 850664-18-5 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]-, methyl ester (CA INDEX NAME)



IT 850663-53-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-59-1P, N-[3-[[1-[4-[(2-Aminoethyl)oxy]phenyl]-2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-69-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzamide 850663-70-6P 850663-71-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-pyridinecarboxamide 850663-72-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850663-77-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850663-85-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenol 850663-87-5P, 2-(4-Aminofurazan-3-yl)-1-ethyl-N-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-amine 850663-88-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenol 850663-89-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]ethanethioamide 850663-91-1P,

1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanone 850663-92-2P,
4-[2-(4-Aminofurazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenyl 2-methylpropanoate 850663-97-7P, Methyl
3-[[2-(4-aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850664-03-8P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)-1-butanol 850664-07-2P, 4-[1-Ethyl-6-[[3-[(1E)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-11-8P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl-4-(4-morpholinyl)-1-butanone 850664-14-1P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone 850664-17-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]-N-[2-(4-morpholinyl)ethyl]benzamide 850664-21-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide 850664-22-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide 850664-28-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-[[2-(4-morpholinyl)ethyl]oxy]-3-pyridinecarboxamide 850664-30-1P, 4-[6-[[3,4-Bis(methyloxy)phenyl]thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-31-2P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoate 850664-32-3P, 4-[1-Ethyl-6-[[3-(methyloxy)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-33-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoic acid 850664-35-6P, 4-[1-Ethyl-6-[[2-(methyloxy)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-38-9P, 4-[1-Ethyl-6-(1H-imidazol-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-39-0P, 4-[6-(Cyclopentylthio)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-40-3P, 4-[1-Ethyl-6-(1,3-thiazol-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-41-4P, 4-[1-Ethyl-6-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-42-5P, 4-[1-Ethyl-6-(phenylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-43-6P, Methyl 2-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoate 850664-44-7P, N-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]acetamide 850664-45-8P, 4-[6-[(3-Chloro-4-fluorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-47-0P, 4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]benzoic acid 850664-48-1P, N-[2-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]ethyl]acetamide 850664-49-2P, 4-[6-[(2,5-Dimethyl-3-furanyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-50-5P, 4-[1-Ethyl-6-(phenylsulfinyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-51-6P, 4-[6-[(3,4-Dichlorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-52-7P, 4-[1-Ethyl-6-(2-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-53-8P, 4-[1-Ethyl-6-[(4-fluorophenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-54-9P, 7-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-3-methyl-2H-chromen-2-one 850664-55-0P, 4-[1-Ethyl-6-[[4-(trifluoromethyl)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-56-1P 850664-57-2P, 4-[1-Ethyl-6-[[4-(methylthio)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-

yl]furazan-3-amine 850664-58-3P,
4-[1-Ethyl-6-(4-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-59-4P, 4-[1-Ethyl-6-([1,3]thiazolo[4,5-b]pyridin-2-yl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-60-7P, 4-[1-Ethyl-6-[5-(methyloxy)-1,3-benzothiazol-2-yl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-61-8P, Methyl (2E)-3-[4-[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]-2-propenoate 850664-62-9P, 4-[1-Ethyl-6-[4-(methylsulfonyl)phenyl]sulfinyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-63-0P, 4-[1-Ethyl-6-[4-(methylsulfinyl)phenyl]sulfinyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-64-1P, 4-[6-[(4-Fluorophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-65-2P, 4-[1-Ethyl-6-[3-(methyloxy)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-66-3P, 4-[6-[(3,4-Dimethylphenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-67-4P, 4-[6-[(3-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-68-5P, 4-[6-[(4-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-69-6P, 3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzonitrile 850664-70-9P, N-[4-[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-71-0P, 4-[1-Ethyl-6-[3-(1-methylethyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-72-1P, 4-[6-[3-(Dimethylamino)phenyl]oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-73-2P, 4-[1-Ethyl-6-[3-(4-morpholinyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-74-3P, N-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methylbenzenesulfonamide 850664-75-4P, 4-[1-Ethyl-7-[3-(methyloxy)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-76-5P, 1,1-Dimethylethyl [3-[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]carbamate 850664-77-6P, 4-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850664-78-7P, N-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]methanesulfonamide 850664-79-8P, N-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-methylurea 850664-80-1P, N-[3-[2-(4-Aminofurazan-3-yl)-1-[4-[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-81-2P, N-[4-[2-(4-Aminofurazan-3-yl)-1-[4-[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-82-3P, Methyl 4-[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850664-83-4P, Methyl 3-[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850664-84-5P, 4-[6-[(4-Fluorophenyl)oxy]-1-(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850664-85-6P, 1-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanol 850664-86-7P, 2-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-butanol 850664-87-8P, 6-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-3,4-dihydro-1(2H)-naphthalenone 850664-88-9P, N-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-(phenylmethyl)urea 850664-89-0P, Methyl 2-[3-[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetate 850664-90-3P,

[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetic acid 850664-91-4P,
4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzonitrile 850664-92-5P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoic acid 850664-93-6P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(methylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850664-94-7P
850664-95-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-fluorobenzamide
850664-96-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-furancarboxamide
850664-97-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methylpropanamide
850664-98-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]butanamide 850664-99-2P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-(methyloxy)acetamide 850665-00-8P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-morpholinecarboxamide 850665-01-9P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]benzamide 850665-02-0P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-fluorobenzenesulfonamide 850665-03-1P,
N-[4-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850665-04-2P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N,N-dimethylbenzamide 850665-05-3P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-methylbenzamide 850665-06-4P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850665-07-5P,
4-[1-Phenyl-6-[[3-(1-piperidinylcarbonyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-08-6P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-ethylbenzamide 850665-09-7P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N-methylacetamide 850665-10-0P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(methyloxy)ethyl]benzamide 850665-11-1P,
1-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanone 850665-12-2P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-phenylurea 850665-13-3P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzenesulfonamide 850665-14-4P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-butanethanesulfonamide 850665-15-5P,
4-[1-Ethyl-6-[(phenylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-16-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]methanesulfonamide 850665-17-7P,
4-[6-[(3-Nitrophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-18-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-cyanobenzamide
850665-19-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]cyclohexanecarboxamide
850665-20-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(methyloxy)benzamide
850665-21-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)benzamide
850665-22-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-

imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]urea 850665-23-5P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(cyclopropylmethyl)benzamide 850665-24-6P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(4-methyl-1,3-thiazol-2-yl)methyl]benzamide 850665-25-7P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]benzamide 850665-26-8P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-morpholinyl)propyl]benzamide 850665-27-9P,
4-[6-[(4-Fluorophenyl)oxy]-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-28-0P,
4-[2-(4-Aminofurazan-3-yl)-6-bromo-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850665-29-1P, N-[5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-2-(methyloxy)phenyl]acetamide 850665-30-4P, 1-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-propanone 850665-31-5P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(ethyloxy)propyl]benzamide 850665-32-6P,
N-[4-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]methanesulfonamide 850665-33-7P,
4-[1-[2-(Aminoacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-34-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(ethyloxy)benzamide 850665-35-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-methylbutanamide 850665-36-0P, 4-[[[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]amino]carbonyl]amino]benzoic acid 850665-37-1P, 4-[6-Bromo-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-38-2P,
2-[7-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]-3,4-dihydro-2(1H)-isoquinolinyl]acetamide 850665-39-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]amino]benzenethiol 850665-40-6P,
4-[6-[(4-Fluorophenyl)oxy]-1-[4-[[2-(methylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-41-7P,
4-[2-(4-Aminofurazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]-2-chlorophenol 850665-42-8P,
4-[1-[3-Chloro-4-[[2-(dimethylamino)ethyl]oxy]phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-43-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850665-44-0P, N-[2-(Acetylamino)ethyl]-3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850665-45-1P,
, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(tetrahydro-2-furanyl)methyl]benzamide 850665-46-2P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(dimethylamino)ethyl]benzamide 850665-47-3P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]benzamide 850665-48-4P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(2-pyridinyl)ethyl]benzamide 850665-49-5P,
3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)propyl]benzamide 850665-50-8P,
4-[6-(1H-Benzimidazol-4-yloxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-51-9P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-methyl-3-pyridinecarboxamide 850665-52-0P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl-3-pyridinecarboxamide 850665-53-1P,
4-[1-[4-(Aminomethyl)phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850665-54-2P,

3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [3-(1H-imidazol-1-yl)propyl]benzamide 850665-55-3P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [2-(1-pyrrolidinyl)ethyl]benzamide 850665-56-4P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [2-(4-hydroxyphenyl)ethyl]benzamide 850665-57-5P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [2-(3-pyridinyl)ethyl]benzamide 850665-58-6P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [2-(phenyloxy)ethyl]benzamide 850665-59-7P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [2-[3,5-bis(methyloxy)phenyl]ethyl]benzamide 850665-60-0P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850665-61-1P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [(1,3-benzodioxol-5-yl)methyl]benzamide 850665-62-2P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [(1,4-dioxan-2-yl)methyl]benzamide 850665-63-3P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [(4-pyridinyl)methyl]benzamide 850665-64-4P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [3-(1-pyrrolidinyl)propyl]benzamide 850665-65-5P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [3-(4-methyl-1-piperazinyl)propyl]benzamide 850665-66-6P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 [2-(4-pyridinyl)ethyl]benzamide 850665-67-7P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 (2-cyanoethyl)benzamide 850665-68-8P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-
 2-methylphenyl]acetamide 850665-69-9P,
 7-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-4-
 methyl-2(1H)-quinolinone 850665-70-2P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
 yl]oxy]phenyl]-2-(dimethylamino)-5-pyrimidinecarboxamide
 850665-71-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-
 imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-(methyloxy)-3-pyridinecarboxamide
 850665-72-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-
 imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(1-piperidinyl)benzamide
 850665-73-5P
 , N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
 yl]oxy]phenyl]-4-(methyloxy)-3-(trifluoromethyl)benzamide
 850665-74-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-
 imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-fluoro-4-(methyloxy)benzamide
 850665-75-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-
 imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-chloro-4-(methyloxy)benzamide
 850665-76-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-
 imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)benzamide
 850665-77-9P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-
 imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl-1,3-thiazole-5-carboxamide
 850665-78-0P 850665-79-1P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
 yl]oxy]phenyl]-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-carboxamide
 850665-80-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydro-
 7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-
 (methyloxy)benzamide 850665-81-5P 850665-82-6P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-
 (3-amino-3-oxopropyl)benzamide 850665-83-7P,
 N-[4-(Aminomethyl)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-
 imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850665-84-8P,
 4-[6-(1H-Benzimidazol-5-yloxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
 yl]furazan-3-amine 850665-85-9P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-


yl]oxy]phenyl]pyrazolo[1,5-a]pyridine-3-carboxamide 850665-86-0P
, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-methyl-1H-imidazole-2-carboxamide 850665-87-1P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-[(2,2,2-trifluoroethyl)oxy]-3-pyridinecarboxamide
850665-88-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)benzamide 850665-89-3P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(trifluoromethyl)-3-pyridinecarboxamide
850665-90-6P, 4-[2-(4-Aminofurazan-3-yl)-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850665-91-7P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(1H-imidazol-1-yl)benzamide 850665-92-8P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-(1H-pyrazol-1-yl)-3-pyridinecarboxamide
850665-93-9P, 4-[1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine
850665-94-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(dimethylamino)ethyl]oxy]benzamide 850665-95-1P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-methyl-4-piperidinecarboxamide 850665-96-2P,
4-[2-(4-Aminofurazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenyl 4-(methyloxy)benzoate 850665-97-3P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)butanamide
850665-98-4P 850665-99-5P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzamide
850666-00-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]methanesulfonamide
850666-01-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3,4-bis(methyloxy)benzamide
850666-02-3P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2,3-dihydro-1-benzofuran-5-carboxamide 850666-03-4P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-chloro-2-pyridinecarboxamide 850666-04-5P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-methyl-3-pyridinecarboxamide
850666-05-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)butanamide
850666-06-7P, 5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1,3-dimethyl-1,3-dihydro-2H-benzimidazol-2-one
850666-07-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide
850666-08-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-09-0P,
3-[[2-(4-Aminofurazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide
850666-10-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-11-4P 850666-12-5P
, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methylpropanamide
850666-13-6P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850666-14-7P,
3-[[2-(4-Aminofurazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoic acid 850666-15-8P,
3-[[2-(4-Aminofurazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-

yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-16-9P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-methylurea
 850666-17-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-18-1P,
 3-[[2-(4-Aminofurazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide
 850666-19-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[[4-(methyloxy)phenyl]methyl]benzamide
 850666-20-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-21-6P
 , 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide 850666-22-7P,
 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)phenyl]benzamide 850666-23-8P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)benzamide 850666-24-9P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methyloxy)benzamide 850666-25-0P,
 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-26-1P,
 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)


RN 850663-53-5 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850663-59-1 CAPLUS


CN Acetamide, N-[3-[[1-[4-(2-aminoethoxy)phenyl]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850663-69-3 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methoxy- (CA INDEX NAME)





RN 850663-70-6 CAPLUS
 CN Sulfamide, N'-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 850663-71-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850663-72-8 CAPLUS
 CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850663-77-3 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850663-85-3 CAPLUS
 CN Phenol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850663-87-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-6-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 850663-88-6 CAPLUS
CN Phenol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]- (CA INDEX NAME)





RN 850663-89-7 CAPLUS
CN Ethanethioamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]- (CA INDEX NAME)



RN 850663-91-1 CAPLUS
CN Ethanone, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850663-92-2 CAPLUS
CN Propanoic acid, 2-methyl-, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl ester (CA INDEX NAME)




RN 850663-97-7 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-3H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 850664-03-8 CAPLUS


CN 4-Morpholinebutanol, α -[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)



RN 850664-07-2 CAPLUS


CN 2-Propen-1-one, 3-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-(4-methyl-1-piperazinyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 850664-11-8 CAPLUS

CN 1-Butanone, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl-4-(4-morpholinyl)- (CA INDEX NAME)




RN 850664-14-1 CAPLUS

CN 1,4-Butanedione, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 850664-17-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850664-21-0 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 850664-22-1 CAPLUS

CN Benzenesulfonamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850664-28-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 850664-30-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[(3,4-dimethoxyphenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-31-2 CAPLUS


CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-, methyl ester (CA INDEX NAME)




RN 850664-32-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[(3-methoxyphenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-33-4 CAPLUS
 CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]- (CA INDEX NAME)



RN 850664-35-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[(2-methoxyphenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-38-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(1H-imidazol-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-39-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(cyclopentylthio)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-40-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(2-thiazolylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-41-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-42-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(phenylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-43-6 CAPLUS

CN Benzoic acid, 2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-, methyl ester (CA INDEX NAME)




RN 850664-44-7 CAPLUS

CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]- (CA INDEX NAME)



RN 850664-45-8 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[6-[(3-chloro-4-fluorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850664-47-0 CAPLUS


CN Benzoic acid, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]- (CA INDEX NAME)

c]pyridin-6-yl]thio]- (CA INDEX NAME)




RN 850664-48-1 CAPLUS

CN Acetamide, N-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]ethyl]- (CA INDEX NAME)




RN 850664-49-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[(2,5-dimethyl-3-furanyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-50-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(phenylsulfinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-51-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[(3,4-dichlorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-52-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(2-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-53-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[(4-fluorophenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-54-9 CAPLUS

CN 2H-1-Benzopyran-2-one, 7-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-3-methyl- (CA INDEX NAME)



RN 850664-55-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[[4-(trifluoromethyl)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850664-56-1 CAPLUS


CN L-Proline, 1-[(2S)-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]-2-methyl-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 850664-57-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[[4-(methylthio)phenyl]thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-58-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(4-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-59-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(thiazolo[4,5-b]pyridin-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850664-60-7 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[(5-methoxy-2-benzothiazolyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850664-61-8 CAPLUS


CN 2-Propenoic acid, 3-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenyl]-, methyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 850664-62-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[[4-(methanesulfonyl)phenyl]sulfinyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-63-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[[4-(methanesulfinyl)phenyl]sulfinyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-64-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[6-(4-fluorophenoxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-65-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(3-methoxyphenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850664-66-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[6-(3,4-dimethylphenoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-67-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[6-(3-aminophenoxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-68-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(4-aminophenoxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-69-6 CAPLUS

CN Benzonitrile, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850664-70-9 CAPLUS

CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-71-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-(1-methylethyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-72-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-(dimethylamino)phenoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-73-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-(4-morpholinyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-74-3 CAPLUS

CN Benzenesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methyl- (CA INDEX NAME)




RN 850664-75-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(3-methoxyphenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 850664-76-5 CAPLUS

CN Carbamic acid, [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 850664-77-6 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)




RN 850664-78-7 CAPLUS

CN Methanesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-79-8 CAPLUS

CN Urea, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-methyl- (CA INDEX NAME)




RN 850664-80-1 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-81-2 CAPLUS

CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-82-3 CAPLUS

CN Benzoic acid, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)





RN 850664-83-4 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 850664-84-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[6-(4-fluorophenoxy)-1-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850664-85-6 CAPLUS
 CN Benzenemethanol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- α -methyl- (CA INDEX NAME)




RN 850664-86-7 CAPLUS
 CN Benzenemethanol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- α -ethyl- α -methyl- (CA INDEX NAME)




RN 850664-87-8 CAPLUS
 CN 1(2H)-Naphthalenone, 6-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-3,4-dihydro- (CA INDEX NAME)




RN 850664-88-9 CAPLUS
 CN Urea, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-(phenylmethyl)- (CA INDEX NAME)




RN 850664-89-0 CAPLUS
 CN Benzeneacetic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 850664-90-3 CAPLUS
 CN Benzeneacetic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850664-91-4 CAPLUS
 CN Benzonitrile, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850664-92-5 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)





RN 850664-93-6 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(methylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-94-7 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[(1-methyl-2-pyrrolidinyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-95-8 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-fluoro- (CA INDEX NAME)




RN 850664-96-9 CAPLUS

CN 2-Furancarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-97-0 CAPLUS

CN Propanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl- (CA INDEX NAME)




RN 850664-98-1 CAPLUS

CN Butanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850664-99-2 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methoxy- (CA INDEX NAME)




RN 850665-00-8 CAPLUS

CN 4-Morpholinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-01-9 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)





RN 850665-02-0 CAPLUS

CN Benzenesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-fluoro- (CA INDEX NAME)




RN 850665-03-1 CAPLUS


CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-04-2 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N,N-dimethyl- (CA INDEX NAME)




RN 850665-05-3 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-methyl- (CA INDEX NAME)




RN 850665-06-4 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850665-07-5 CAPLUS
 CN Methanone, [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-piperidiny- (CA INDEX NAME)




RN 850665-08-6 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-ethyl- (CA INDEX NAME)



RN 850665-09-7 CAPLUS
 CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N-methyl- (CA INDEX NAME)




RN 850665-10-0 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 850665-11-1 CAPLUS
 CN Ethanone, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-

c[pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-12-2 CAPLUS

CN Urea, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-phenyl]- (CA INDEX NAME)




RN 850665-13-3 CAPLUS

CN Benzenesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methoxy]- (CA INDEX NAME)




RN 850665-14-4 CAPLUS

CN 1-Butanesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)





RN 850665-15-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(phenylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850665-16-6 CAPLUS

CN Methanesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-17-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(3-nitrophenoxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850665-18-8 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-cyano- (CA INDEX NAME)




RN 850665-19-9 CAPLUS

CN Cyclohexanecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-20-2 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-methoxy- (CA INDEX NAME)




RN 850665-21-3 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- (CA INDEX NAME)




RN 850665-22-4 CAPLUS

CN Urea, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-23-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 850665-24-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(4-methyl-2-thiazolyl)methyl]- (CA INDEX NAME)







RN 850665-25-7 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)



RN 850665-26-8 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)






RN 850665-30-4 CAPLUS

CN 1-Propanone, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-31-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(3-ethoxypropyl)- (CA INDEX NAME)





RN 850665-32-6 CAPLUS

CN Methanesulfonamide, N-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]- (CA INDEX NAME)




RN 850665-33-7 CAPLUS

CN Ethanone, 2-amino-1-[7-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]-3,4-dihydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)




RN 850665-34-8 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-ethoxy- (CA INDEX NAME)




RN 850665-35-9 CAPLUS

CN Butanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-methyl- (CA INDEX NAME)




RN 850665-36-0 CAPLUS

CN Benzoic acid, 4-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]amino]carbonyl]amino]- (CA INDEX NAME)



RN 850665-37-1 CAPLUS



CN 1,2,5-Oxadiazol-3-amine, 4-[6-bromo-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Me₂N-CH₂-CH₂-O


RN 850665-38-2 CAPLUS

CN 2(1H)-Isoquinolineacetamide, 7-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]-3,4-dihydro- (CA INDEX NAME)




RN 850665-39-3 CAPLUS

CN Benzenethiol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]amino]- (CA INDEX NAME)





RN 850665-40-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(4-fluorophenoxy)-1-[4-[2-(methylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 850665-41-7 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]-2-chloro- (CA INDEX NAME)




RN 850665-42-8 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-chloro-4-[2-(dimethylamino)ethoxy]phenyl]-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850665-43-9 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 850665-44-0 CAPLUS
 CN Benzamide, N-[2-(acetylamino)ethyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850665-45-1 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 850665-46-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 850665-47-3 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]- (CA INDEX NAME)




RN 850665-48-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 850665-49-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 850665-50-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(1H-benzimidazol-7-yloxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850665-51-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-methyl- (CA INDEX NAME)





RN 850665-52-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl- (CA INDEX NAME)




RN 850665-53-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(aminomethyl)phenyl]-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850665-54-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 850665-55-3 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 850665-56-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)




RN 850665-57-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 850665-58-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(2-phenoxyethyl)- (CA INDEX NAME)




RN 850665-59-7 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(3,5-dimethoxyphenyl)ethyl]- (CA INDEX NAME)




RN 850665-60-0 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 850665-61-1 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(1,3-benzodioxol-5-ylmethyl)- (CA INDEX NAME)




RN 850665-62-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(1,4-dioxan-2-ylmethyl)- (CA INDEX NAME)




RN 850665-63-3 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 850665-64-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 850665-65-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 850665-66-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-pyridinyl)ethyl]- (CA INDEX NAME)




RN 850665-67-7 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(2-cyanoethyl)- (CA INDEX NAME)




RN 850665-68-8 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-methylphenyl]- (CA INDEX NAME)




RN 850665-69-9 CAPLUS

CN 2(1H)-Quinolinone, 7-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-4-methyl- (CA INDEX NAME)




RN 850665-70-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 850665-71-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methoxy- (CA INDEX NAME)




RN 850665-72-4 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(1-piperidinyl)- (CA INDEX NAME)




RN 850665-73-5 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methoxy-3-(trifluoromethyl)- (CA INDEX NAME)




RN 850665-74-6 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-fluoro-4-methoxy- (CA INDEX NAME)




RN 850665-75-7 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-chloro-4-methoxy- (CA INDEX NAME)




RN 850665-76-8 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)- (CA INDEX NAME)




RN 850665-77-9 CAPLUS

CN 5-Thiazolecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl- (CA INDEX NAME)




RN 850665-78-0 CAPLUS

CN 1H-Benzotriazole-5-carboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-methyl- (CA INDEX NAME)



RN 850665-79-1 CAPLUS


CN 2H-1,4-Benzoxazine-7-carboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3,4-dihydro-4-methyl- (CA INDEX NAME)



RN 850665-80-4 CAPLUS


CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methoxy- (CA

INDEX NAME)




RN 850665-81-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(3-oxopropyl)- (CA INDEX NAME)




RN 850665-82-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(3-amino-3-oxopropyl)- (CA INDEX NAME)




RN 850665-83-7 CAPLUS

CN Benzamide, N-[4-(aminomethyl)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850665-84-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-(1H-benzimidazol-6-yloxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850665-85-9 CAPLUS

CN Pyrazolo[1,5-a]pyridine-3-carboxamide,
N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850665-86-0 CAPLUS

CN 1H-Imidazole-2-carboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-methyl- (CA INDEX NAME)



RN 850665-87-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-(2,2,2-trifluoroethoxy)- (CA INDEX NAME)



RN 850665-88-2 CAPLUS


CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)- (CA INDEX NAME)

NAME)




RN 850665-89-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 850665-90-6 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-methoxy-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)




RN 850665-91-7 CAPLUS


CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(1H-imidazol-1-yl)- (CA INDEX NAME)




RN 850665-92-8 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-(1H-pyrazol-1-yl)- (CA INDEX NAME)




RN 850665-93-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850665-94-0 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)





RN 850665-95-1 CAPLUS
 CN 4-Piperidinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1-methyl- (CA INDEX NAME)




RN 850665-96-2 CAPLUS

CN Benzoic acid, 4-methoxy-, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl ester (CA INDEX NAME)




RN 850665-97-3 CAPLUS

CN Butanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- (CA INDEX NAME)




RN 850665-98-4 CAPLUS

CN Sulfamide, N'-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 850665-99-5 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methoxy- (CA INDEX NAME)




RN 850666-00-1 CAPLUS

CN Methanesulfonamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850666-01-2 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3,4-dimethoxy- (CA INDEX NAME)




RN 850666-02-3 CAPLUS

CN 5-Benzofurancarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2,3-dihydro- (CA INDEX NAME)




RN 850666-03-4 CAPLUS

CN 2-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-chloro- (CA INDEX NAME)




RN 850666-04-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-methyl- (CA INDEX NAME)




RN 850666-05-6 CAPLUS

CN Butanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- (CA INDEX NAME)




RN 850666-06-7 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-1,3-dihydro-1,3-dimethyl- (CA INDEX NAME)




RN 850666-07-8 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-08-9 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 850666-09-0 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-10-3 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 850666-11-4 CAPLUS

CN Sulfamide, N'-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 850666-12-5 CAPLUS

CN Propanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-methyl- (CA INDEX NAME)




RN 850666-13-6 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 850666-14-7 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)





RN 850666-15-8 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-16-9 CAPLUS

CN Urea, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-N'-methyl- (CA INDEX NAME)




RN 850666-17-0 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 850666-18-1 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 850666-19-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 850666-20-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 850666-21-6 CAPLUS

CN Benzamide, 3-[[2-[[4-amino-1,2,5-oxadiazol-3-yl]-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 850666-22-7 CAPLUS

CN Benzamide, 3-[[2-[[4-amino-1,2,5-oxadiazol-3-yl]-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 850666-23-8 CAPLUS

CN Benzamide, N-[3-[[2-[[4-amino-1,2,5-oxadiazol-3-yl]-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(dimethylamino)- (CA INDEX NAME)




RN 850666-24-9 CAPLUS

CN Benzamide, N-[3-[[2-[[4-amino-1,2,5-oxadiazol-3-yl]-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-methoxy- (CA INDEX NAME)




RN 850666-25-0 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 850666-26-1 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



IT 850666-27-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide

850666-29-4P, 4-(Aminomethyl)-N-[3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]benzamide

850666-31-8P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(3-pyridinyl)propanamide

850666-33-0P, 4-(Aminomethyl)-N-[3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]benzamide

850666-35-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide

850666-37-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(4-morpholinyl)phenyl]benzamide

850666-39-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-41-0P

, N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(4-morpholinyl)propanamide 850666-43-2P,

3-[[2-(4-Aminofurazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoic acid 850666-45-4P,

3-[[2-(4-Aminofurazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide

850666-47-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(4-

morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-49-8P,
4-[1-Ethyl-6-[[3-[[3-(4-morpholinyl)propyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850666-51-2P,
1-[3-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]oxy]propyl]-2-pyrrolidinone 850666-53-4P,
4-[6-[[3-[[3-(4-Acetyl-1-piperazinyl)propyl]oxy]phenyl]oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850666-54-5P,
3-[[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-55-6P,
3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-56-7P,
3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide 850666-57-8P,
3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-58-9P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(4-morpholinyl)ethyl]oxy]phenyl]benzamide 850666-59-0P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(3-hydroxyphenyl)propanamide 850666-60-3P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(4-hydroxyphenyl)propanamide 850666-61-4P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(2-oxo-1-pyrrolidinyl)butanamide 850666-62-5P,
3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850666-63-6P,
3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-64-7P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-[4-hydroxy-3-(methyloxy)phenyl]ethyl]benzamide 850666-65-8P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(2-oxo-1-pyrrolidinyl)propanamide 850666-66-9P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(2-oxo-1-pyrrolidinyl)butanamide 850666-67-0P,
3-[[2-(4-Aminofurazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide 850666-68-1P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[(4-piperidinyl)methyl]benzamide 850666-69-2P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-piperidinyl)ethyl]benzamide 850666-70-5P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide 850666-71-6P,
N-[2-(4-Acetyl-1-piperazinyl)ethyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-72-7P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850666-73-8P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]benzamide 850666-74-9P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide 850666-75-0P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[3-(dimethylamino)propyl]oxy]phenyl]benzamide 850666-76-1P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[3-(1-piperidinyl)propyl]oxy]benzamide 850666-77-2P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(diethylamino)ethyl]oxy]benzamide 850666-78-3P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(1-

pyrrolidinyl)ethyl]oxy]benzamide 850666-79-4P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-[bis(1-methylethyl)amino]ethyl]oxy]benzamide
850666-80-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(1-piperidinyl)ethyl]oxy]benzamide 850666-81-8P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-hydroxybenzamide 850666-82-9P,
N-[4-(Acetylamino)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-83-0P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(2-oxo-2-phenylethyl)benzamide 850666-84-1P,
N-[4-(Aminocarbonyl)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-86-3P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide 850666-88-5P,
3-[[2-(4-Aminofurazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide
850666-90-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide
850666-92-1P, 4-[1-Ethyl-6-[[3-[[2-(4-morpholinyl)ethyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850666-94-3P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-thiomorpholinyl)ethyl]benzamide
850666-96-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzamide
850666-98-7P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[3-(1-piperazinyl)propyl]oxy]benzamide 850667-00-4P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]benzamide 850667-02-6P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-oxido-4-thiomorpholinyl)ethyl]benzamide 850667-04-8P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-piperidinyl)propyl]benzamide 850667-06-0P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[1-methyl-4-piperidinyl]oxy]benzamide
850667-08-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(4-piperidinyl)propanamide
850667-10-6P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(1-piperazinyl)ethyl]oxy]benzamide 850667-12-8P,
3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide
850667-14-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850667-16-2P,
3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]benzamide
850667-17-3P, 4-[1-(1,2,3,4-Tetrahydro-7-isoquinolinyl)-6-[[4-(trifluoromethyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine
850667-18-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(4-morpholinyl)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-19-5P,
3-[[2-(4-Aminofurazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide
850667-20-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide
850667-21-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(2-methyl-4-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]benzamide
850667-22-0P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate


850667-23-1P, 3-[[2-(4-Aminofurazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-24-2P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-25-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-26-4P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(1-pyrrolidinyl)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-27-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-[2-(dimethylamino)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-28-6P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-29-7P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-30-0P, Methyl 3-[[2-(4-aminofurazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-31-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(4-morpholinyl)methyl]benzamide 850667-32-2P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-5-(trifluoromethyl)phenyl]acetamide 850667-33-3P, 4-[6-[[3-Amino-5-(trifluoromethyl)phenyl]oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-34-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)propyl]-N-methylbenzamide 850667-35-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(diethylamino)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-36-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(dimethylamino)methyl]phenyl]benzamide 850667-37-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethyl]phenyl]benzamide 850667-38-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]benzamide 850667-39-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide 850667-40-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-methyl-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide 850667-41-3P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-42-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-43-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-44-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850667-45-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide 850667-46-8P, 4-[1-[4-[[2-(Dimethylamino)ethyl]oxy]phenyl]-6-[[3-(methylsulfonyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-47-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide 850667-48-0P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(dimethylamino)methyl]benzamide 850667-49-1P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-50-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]benzamide 850667-51-5P, N-[3-[[2-(4-Aminofurazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-52-6P,

4-[1-Ethyl-6-[[3-[[3-(1-methyl-4-piperidinyl)propyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-53-7P,
3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide 850667-54-8P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[[2-(1-piperidinyl)ethyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-55-9P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-[4-[(cyanomethyl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850667-56-0P,
4-[1-Ethyl-6-[[3-(1H-imidazol-1-yl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-57-1P,
4-[1-Ethyl-6-[[3-(1,3-thiazol-5-yl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-58-2P,
4-[1-Ethyl-6-[[3-(1,3-oxazol-5-yl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-59-3P,
4-[1-Ethyl-6-[[3-(methylsulfonyl)phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-60-6P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(dimethylamino)propanamide 850667-61-7P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinyl)butanamide 850667-62-8P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(diethylamino)butanamide 850667-63-9P,
N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methylamino)butanamide 850667-64-0P,
N-[5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-methylphenyl]acetamide 850667-65-1P,
N-[5-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-chlorophenyl]acetamide 850667-66-2P,
4-[1-Ethyl-6-[[3-[[2-(1-methyl-4-piperidinyl)ethyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-67-3P,
4-[1-Ethyl-6-[[3-[[4-(1-methyl-4-piperidinyl)butyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-68-4P,
4-[1-(2,3-Dihydro-1H-isoindol-5-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-69-5P,
4-[1-Ethyl-6-[[3-[[1-(1-methyl-4-piperidinyl)methyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-70-8P,
4-[1-Ethyl-6-[[3-[[1-(1-methyl-3-piperidinyl)methyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-71-9P,
4-[1-Ethyl-6-[[3-[[2-(1-methyl-3-piperidinyl)ethyl]oxy]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-72-0P, Methyl
3-[[2-(4-aminofurazan-3-yl)-1-(2-methyl-1,3-benzoxazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzoate 850667-73-1P,
4-[1-Ethyl-6-[[3-[4-(1-methyl-4-piperidinyl)butyl]phenyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850667-74-2P,
1-[3-[[2-(4-Aminofurazan-3-yl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]ethanone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)


RN 850666-27-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 850666-29-4 CAPLUS

CN Benzamide, 4-(aminomethyl)-N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850666-31-8 CAPLUS

CN 3-Pyridinepropanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850666-33-0 CAPLUS

CN Benzamide, 4-(aminomethyl)-N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850666-35-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)




RN 850666-37-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 850666-39-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 850666-41-0 CAPLUS

CN 4-Morpholinepropanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850666-43-2 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850666-45-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-
(CA INDEX NAME)




RN 850666-47-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]-
(CA INDEX NAME)




RN 850666-49-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[3-(4-morpholinyl)propoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850666-51-2 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenoxy]propyl]- (CA INDEX NAME)




RN 850666-53-4 CAPLUS

CN Ethanone, 1-[4-[3-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenoxy]propyl]-1-piperazinyl]- (CA INDEX NAME)




RN 850666-54-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-3H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-55-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 850666-56-7 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 850666-57-8 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-58-9 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 850666-59-0 CAPLUS

CN Benzenepropanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-hydroxy- (CA INDEX NAME)




RN 850666-60-3 CAPLUS


CN Benzenepropanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-hydroxy- (CA INDEX NAME)




RN 850666-61-4 CAPLUS
 CN 1-Pyrrolidinebutanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-oxo- (CA INDEX NAME)




RN 850666-62-5 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 850666-63-6 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-64-7 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-hydroxy-3-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 850666-65-8 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-oxo- (CA INDEX NAME)




RN 850666-66-9 CAPLUS

CN 1-Pyrrolidinebutanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-2-oxo- (CA INDEX NAME)



RN 850666-67-0 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 850666-68-1 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-

c[pyridin-6-yl]oxy]-N-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 850666-69-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-piperidinyl)ethyl]- (CA INDEX NAME)




RN 850666-70-5 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 850666-71-6 CAPLUS


CN Benzamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)



RN 850666-72-7 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]- (CA INDEX NAME)

NAME)




RN 850666-73-8 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)




RN 850666-74-9 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 850666-75-0 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)




RN 850666-76-1 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[3-(1-piperidinyloxypropoxy]- (CA INDEX NAME)




RN 850666-77-2 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(diethylamino)ethoxy]- (CA INDEX NAME)




RN 850666-78-3 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 850666-79-4 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-[bis(1-methylethyl)amino]ethoxy]- (CA INDEX NAME)






RN 850666-80-7 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(1-piperidinyloxy)- (CA INDEX NAME)




RN 850666-81-8 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-hydroxy- (CA INDEX NAME)




RN 850666-82-9 CAPLUS

CN Benzamide, N-[4-(acetamido)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850666-83-0 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(2-oxo-2-phenylethyl)- (CA INDEX NAME)




RN 850666-84-1 CAPLUS

CN Benzamide, N-[4-(aminocarbonyl)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)




RN 850666-86-3 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)



RN 850666-88-5 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 850666-90-9 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(6-methyl-2-pyridinyl)-

1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-92-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[2-(4-morpholinyl)ethoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850666-94-3 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-thiomorpholinyl)ethyl]- (CA INDEX NAME)




RN 850666-96-5 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]- (CA INDEX NAME)




RN 850666-98-7 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[3-(1-piperazinyl)propoxy]- (CA INDEX NAME)




RN 850667-00-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]- (CA INDEX NAME)




RN 850667-02-6 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(1-oxido-4-thiomorpholinyl)ethyl]- (CA INDEX NAME)




RN 850667-04-8 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-piperidinyl)propyl]- (CA INDEX NAME)




RN 850667-06-0 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(1-methyl-4-piperidinyl)oxy]- (CA INDEX NAME)




RN 850667-08-2 CAPLUS

CN 4-Piperidinepropanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850667-10-6 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)




PAGE 1-A

PAGE 1-B





RN 850667-12-8 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]- (CA INDEX NAME)




RN 850667-14-0 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]-
(CA INDEX NAME)





RN 850667-16-2 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]-
(CA INDEX NAME)





RN 850667-17-3 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-6-[4-(trifluoromethyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-18-4 CAPLUS
 CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)



RN 850667-19-5 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3-methoxypropyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 850667-20-8 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3-methoxypropyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 850667-21-9 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methyl-4-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)





RN 850667-22-0 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)





RN 850667-23-1 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)





RN 850667-24-2 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)





RN 850667-25-3 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 850667-26-4 CAPLUS
 CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-
 (CA INDEX NAME)





RN 850667-27-5 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[2-(dimethylamino)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidiny)propyl]-
 (CA INDEX NAME)





RN 850667-28-6 CAPLUS
 CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 850667-29-7 CAPLUS
 CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 850667-30-0 CAPLUS
 CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1H-benzimidazol-6-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 850667-31-1 CAPLUS
 CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 850667-32-2 CAPLUS
 CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 850667-33-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[6-[3-amino-5-(trifluoromethyl)phenoxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-34-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)propyl]-N-methyl- (CA INDEX NAME)




RN 850667-35-5 CAPLUS


CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(diethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850667-36-6 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(dimethylamino)methyl]phenyl]- (CA INDEX NAME)




RN 850667-37-7 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethyl]phenyl]- (CA INDEX NAME)




RN 850667-38-8 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]- (CA INDEX NAME)




RN 850667-39-9 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-methyl-4-piperidiny)propyl]- (CA INDEX NAME)




RN 850667-40-2 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-methyl-N-[3-(1-methyl-4-piperidiny)propyl]- (CA INDEX NAME)





RN 850667-41-3 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-piperidiny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)





RN 850667-42-4 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)





RN 850667-43-5 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1H-benzimidazol-6-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 850667-44-6 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]-
 (CA INDEX NAME)





RN 850667-45-7 CAPLUS
 CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]-
 (CA INDEX NAME)




RN 850667-46-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-6-[3-(methylsulfonyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-47-9 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(1-methyl-4-piperidiny)propyl]- (CA INDEX NAME)




RN 850667-48-0 CAPLUS

CN Benzamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[(dimethylamino)methyl]- (CA INDEX NAME)




RN 850667-49-1 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850667-50-4 CAPLUS

CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 850667-51-5 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3-methoxypropyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)





RN 850667-52-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[3-(1-methyl-4-piperidinyl)propoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 850667-53-7 CAPLUS


CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 850667-54-8 CAPLUS
 CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-[2-(1-piperidinyl)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850667-55-9 CAPLUS
 CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-[4-(cyanomethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850667-56-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-(1H-imidazol-1-yl)phenoxy]-1H-

imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-57-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-(5-thiazolyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-58-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-(5-oxazolyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-59-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-(methanesulfonyl)phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-60-6 CAPLUS

CN Propanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 850667-61-7 CAPLUS

CN 4-Morpholinebutanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850667-62-8 CAPLUS

CN Butanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(diethylamino)- (CA INDEX NAME)




RN 850667-63-9 CAPLUS

CN Butanamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-(methylamino)- (CA INDEX NAME)




RN 850667-64-0 CAPLUS

CN Acetamide, N-[5-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-methylphenyl]- (CA INDEX NAME)




RN 850667-65-1 CAPLUS

CN Acetamide, N-[5-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-2-chlorophenyl]- (CA INDEX NAME)




RN 850667-66-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[2-(1-methyl-4-piperidinyl)ethoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850667-67-3 CAPLUS



CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[4-(1-methyl-4-piperidinyl)butoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-68-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(2,3-dihydro-1H-isoindol-5-yl)-6-(4-


fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-69-5 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[(1-methyl-4-piperidinyl)methoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850667-70-8 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[(1-methyl-3-piperidinyl)methoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 850667-71-9 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[2-(1-methyl-3-piperidinyl)ethoxy]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-72-0 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methyl-5-benzoxazolyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-, methyl ester (CA INDEX NAME)





RN 850667-73-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-[3-[4-(1-methyl-4-piperidinyl)butyl]phenoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 850667-74-2 CAPLUS


CN Ethanone, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)





IT 850663-82-0P, 4-(6-Bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-amine 850663-86-4P,
 4-(6-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-amine
 850663-96-6P, 4-[2-(4-Aminofurazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl]phenol 850664-19-6P,
 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]benzoic acid 850664-29-8P,
 N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-6-oxo-1,6-dihydro-3-pyridinecarboxamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)
 RN 850663-82-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(6-bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 850663-86-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(6-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 850663-96-6 CAPLUS
 CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-6-(3-aminophenoxy)-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)




RN 850664-19-6 CAPLUS

CN Benzoic acid, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl]- (CA INDEX NAME)



RN 850664-29-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-1,6-dihydro-6-oxo- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:346805 CAPLUS
 DOCUMENT NUMBER: 142:392411
 TITLE: Preparation of 1,6,7-trisubstituted azabenzimidazoles
 as Rho-kinase inhibitors
 INVENTOR(S): Lee, Dennis; Stavenger, Robert A.
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034866	A2	20050421	WO 2004-US32909	20041006
WO 2005034866	A3	20050728		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1670466	A2	20060621	EP 2004-794310	20041006
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007507549	T	20070329	JP 2006-534285	20041006
US 20070004771	A1	20070104	US 2006-574652	20060404
PRIORITY APPLN. INFO.:			US 2003-509123P	P 20031006
			WO 2004-US32909	W 20041006
OTHER SOURCE(S):	CASREACT 142:392411; MARPAT 142:392411			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of novel azabenzimidazoles I, which are inhibitors of Rho-kinases. In compds. I, R1 is H or C1-6 alkyl; R2 is halo or optionally substituted Ph, heteroaryl, or carboxamide; R3 is halo, (un)substituted C1-6 alkoxy, (un)substituted phenoxy, heteroaryloxy, or heterocyclyloxy. The invention also relates to the preparation of I, pharmaceutical compns. containing I as active ingredients, as well as to the use of the compns. for the treatment of disorders involving Rho-kinases. II, prepared by bromination of 3-nitro-4-pyridone followed by chlorination, was oxidized to the corresponding 2-pyridone, which was chlorinated and substituted with ethylamine to give III, which underwent substitution with 4-fluorophenol, reduction, and cyclization with cyanoacetic acid to form IV. Nitrous acid resulted in the transformation of IV into an oxime, which, upon heterocyclization with hydroxylamine, gave the aminofurazan-containing structure V. The compds. of the invention were tested for their inhibition of Rho-kinases (no data).


IT 850180-79-9P, 4-[1-Ethyl-6-[(4-fluorophenyl)oxy]-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850180-89-1P, 4-[1-Ethyl-7-(4-fluorophenyl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-

c]pyridin-2-yl]furazan-3-amine 850180-91-5P,
 (S)-4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine
 850180-93-7P, 1,1-Dimethylethyl
 [3-[[2-(4-aminofurazan-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]carbamate 850180-94-8P,
 N-[3-[[2-(4-Aminofurazan-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide 850180-95-9P,
 4-[1-Ethyl-7-[3-[(ethylamino)methyl]phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of trisubstituted azabenzimidazoles as Rho-kinase inhibitors)


RN 850180-79-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(4-fluorophenoxy)-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850180-89-1 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(4-fluorophenoxy)-7-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850180-91-5 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-7-yl][(3S)-3-amino-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 850180-93-7 CAPLUS

CN Carbamic acid, [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 850180-94-8 CAPLUS

CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]- (CA INDEX NAME)




RN 850180-95-9 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-[(ethylamino)methyl]phenyl]-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




IT 850180-88-0P, 4-[7-Bromo-1-ethyl-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-amine 850180-90-4P, 3-[2-(4-Aminofurazan-3-yl)-1-ethyl-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-7-yl]benzaldehyde 850180-92-6P, 2-(4-Aminofurazan-3-yl)-1-ethyl-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridine-7-carboxylic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of trisubstituted azabenzimidazoles as Rho-kinase inhibitors)
 RN 850180-88-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-1-ethyl-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 850180-90-4 CAPLUS
 CN Benzaldehyde, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)



RN 850180-92-6 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-6-(4-fluorophenoxy)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:120747 CAPLUS

DOCUMENT NUMBER: 142:219283

TITLE: Preparation of 1H-imidazo[4,5-c]pyridin-2-yl derivatives as inhibitors of Akt activity

INVENTOR(S): Heerding, Dirk A.; Clark, Tammy J.; Drewry, David H.; Leber, Jack Dale; Safonov, Igor; Yamashita, Dennis S.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 212 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011700	A1	20050210	WO 2004-US24340	20040728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004261214	A1	20050210	AU 2004-261214	20040728
CA 2534038	A1	20050210	CA 2004-2534038	20040728
EP 1653961	A1	20060510	EP 2004-779406	20040728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004012993	A	20061003	BR 2004-12993	20040728
CN 1859912	A	20061108	CN 2004-80028355	20040728
JP 2007500709	T	20070118	JP 2006-522030	20040728
IN 2006DN00264	A	20070810	IN 2006-DN264	20060116
MX 2006001134	A	20060411	MX 2006-1134	20060127
KR 2006066714	A	20060616	KR 2006-702022	20060127
NO 2006000985	A	20060419	NO 2006-985	20060228
US 20080255143	A1	20081016	US 2007-565329	20071026
PRIORITY APPLN. INFO.:			US 2003-490851P	P 20030729
			US 2003-491055P	P 20030730
			US 2003-493101P	P 20030806
			US 2003-494752P	P 20030813
			US 2003-507014P	P 20030929
			US 2003-530847P	P 20031218
			WO 2004-US24340	W 20040728
OTHER SOURCE(S):			CASREACT 142:219283; MARPAT 142:219283	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein Het = 4-furazan-3-yl, 4-pyridinyl, 2-aminopyridin-4-yl, 2-amino-pyrimidin-5-yl, etc.; R1 = H, (un)substituted alkyl, cycloalkyl containing 1-4 heteroatoms; R4 = H, halo, (un)substituted alkyl, cycloalkyl, poly/cyclic aromatic ring; R7 = H, CONR9R10 and derivs., SO2NR9R10 and derivs., N(CH2)mNR9R10etc.; m = 6, where the carbon chain

formed by m is optionally substituted; R9, R10 = independently H, (un)substituted alkyl, cycloalkyl etc.; with the exception of one compound; and their pharmaceutically acceptable salts, hydrates, solvates, and prodrugs] were prepared as inhibitors of protein kinase B activity. For example, II•xTFA was prepared via cyclocondensation of N-(1-Benzylpiperidin-4-yl)-2-chloropyridin-3,4-diamine (preparation given) with Et cyanoacetate, followed by Pd-coupling with Ph boronic acid, reaction with NaNO₂ and NH₂OH of acetonitrile intermediate, and Bn-deprotection. In an Akt inhibitory activity assay, III displayed IC₅₀ values of 0.069, 0.038, and 0.032, against delta-PH domain of Akt1, Akt2, and Akt3, resp. Thus, I are useful in the treatment of cancer and arthritis (no data).


IT 842143-88-8P, 4-[4-Chloro-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-07-4P, 4-(7-Bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine 842145-69-1P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid 842146-08-1P, 4-[7-[(4-Aminobutyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-17-2P, 4-[7-[(3-Aminopropyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842147-98-2P, Methyl 4-[[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]methyl]benzoate trifluoroacetate
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Akt inhibitor; preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as inhibitors of Akt activity for treating cancer and arthritis)
 RN 842143-88-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[4-chloro-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842144-07-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 842145-69-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl- (CA INDEX NAME)




RN 842146-08-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-aminobutoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-07-0


CMF C20 H23 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842146-17-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842147-98-2 CAPLUS
 CN Benzoic acid, 4-[[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]methyl]-, methyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842147-97-1
 CMF C29 H31 N7 O4


PAGE 1-A



PAGE 2-A



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



IT 607373-68-2P, [4-[1-Ethyl-7-(piperidin-4-yloxy)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 842143-50-4P,
 [4-[4-Phenyl-1-(piperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 842143-51-5P, [4-[4-Phenyl-1-(piperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate 842143-57-1P, [4-[4-(3-Chlorophenyl)-1-(piperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine hydrochloride 842143-58-2P, [4-[1-(3-Amino-2,2-dimethylpropyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate 842143-72-0P,
 [4-[1-(3-Amino-2,2-dimethylpropyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 842143-73-1P,
 [4-[1-(3-Amino-2,2-dimethylpropyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate 842143-74-2P,
 4-[1-(5-Aminopentyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-75-3P,
 4-[1-(5-Aminopentyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842143-76-4P,
 4-[1-(6-Aminohexyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-77-5P,
 4-[1-(6-Aminohexyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842143-78-6P,
 4-[1-(5-Aminopentyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-79-7P,
 4-[1-(5-Aminopentyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842143-80-0P,
 4-[1-(6-Aminohexyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-81-1P,
 4-[1-(6-Aminohexyl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842143-82-2P,
 [4-[1-(3-Amino-2,2-dimethylpropyl)-4-(3-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 842143-83-3P,
 [4-[1-(3-Amino-2,2-dimethylpropyl)-4-(3-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate 842143-84-4P,
 4-[1-(5-Aminopentyl)-4-(3-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-85-5P,
 4-[1-(5-Aminopentyl)-4-(3-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842143-86-6P,
 4-[1-(6-Aminohexyl)-4-(3-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-87-7P,
 4-[1-(6-Aminohexyl)-4-(3-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842143-93-5P,
 4-[4-(3-Chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-94-6P,
 4-[1-(Cyclopropylmethyl)-4-(2-methylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-95-7P,
 4-[4-(2-Chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842143-96-8P,
 4-[1-(Cyclopropylmethyl)-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-01-8P,
 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone 842144-02-9P
 , 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(3-chlorophenyl)-1H-imidazo[4,5-

c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone trifluoroacetate
 842144-12-1P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-phenyl-1H-
 imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 hydrochloride 842144-13-2P,
 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(thiophen-3-yl)-1H-imidazo[4,5-
 c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone hydrochloride
 842144-14-3P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(pyridin-4-yl)-
 1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 842144-15-4P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(pyridin-3-yl)-
 1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 842144-16-5P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(furan-3-yl)-1H-
 imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 842144-17-6P, 1-[2-(4-Aminofurazan-3-yl)-4-chloro-1-ethyl-1H-
 imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 842144-18-7P, 1-[2-(4-Aminofurazan-3-yl)-4-chloro-1-ethyl-1H-
 imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 trifluoroacetate 842144-19-8P,
 1-[2-(4-Aminofurazan-3-yl)-4-(1H-pyrrol-2-yl)-1-ethyl-1H-imidazo[4,5-
 c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone 842144-20-1P
 , 1-[2-(4-Aminofurazan-3-yl)-4-(1H-pyrrol-2-yl)-1-ethyl-1H-imidazo[4,5-
 c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone trifluoroacetate
 842144-21-2P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2-
 methoxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-
 yl)methanone 842144-22-3P,
 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2-methoxyphenyl)-1H-imidazo[4,5-
 c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone trifluoroacetate
 842144-23-4P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(furan-2-yl)-1H-
 imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 842144-24-5P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(furan-2-yl)-1H-
 imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone
 trifluoroacetate 842144-25-6P,
 2-(4-Aminofurazan-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-
 carboxylic acid [1-(4-chlorobenzyl)-2-hydroxyethyl]amide
 842144-26-7P, 2-(4-Aminofurazan-3-yl)-1-ethyl-4-(3-chlorophenyl)-
 1H-imidazo[4,5-c]pyridine-7-carboxylic acid
 [1-(4-chlorobenzyl)-2-hydroxyethyl]amide 842144-27-8P,
 2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2,3-dichlorophenyl)-1H-imidazo[4,5-
 c]pyridine-7-carboxylic acid [1-(4-chlorobenzyl)-2-hydroxyethyl]amide
 842144-28-9P, 2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2,3-
 dichlorophenyl)-1H-imidazo[4,5-c]pyridine-7-carboxylic acid
 N-[1-(4-chlorobenzyl)-2-hydroxyethyl]amide trifluoroacetate
 842144-29-0P, 2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2-chlorophenyl)-
 1H-imidazo[4,5-c]pyridine-7-carboxylic acid
 [1-(4-chlorobenzyl)-2-hydroxyethyl]amide 842144-30-3P,
 2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2-chlorophenyl)-1H-imidazo[4,5-
 c]pyridine-7-carboxylic acid N-[1-(4-chlorobenzyl)-2-hydroxyethyl]amide
 trifluoroacetate 842144-31-4P,
 2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2-hydroxyphenyl)-1H-imidazo[4,5-
 c]pyridine-7-carboxylic acid [1-(4-chlorobenzyl)-2-hydroxyethyl]amide
 842144-32-5P, 2-(4-Aminofurazan-3-yl)-1-ethyl-4-(2-hydroxyphenyl)-
 1H-imidazo[4,5-c]pyridine-7-carboxylic acid
 N-[1-(4-chlorobenzyl)-2-hydroxyethyl]amide trifluoroacetate
 842144-33-6P, 2-(4-Aminofurazan-3-yl)-4-(3-chlorophenyl)-1-ethyl-
 1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide
 842144-34-7P, 2-(4-Aminofurazan-3-yl)-4-(3-chlorophenyl)-1-ethyl-
 1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide
 trifluoroacetate 842144-35-8P,
 2-(4-Aminofurazan-3-yl)-4-phenyl-1-ethyl-1H-imidazo[4,5-c]pyridine-7-
 carboxylic acid N-(pyrrolidin-3-yl)amide 842144-36-9P,
 2-(4-Aminofurazan-3-yl)-4-phenyl-1-ethyl-1H-imidazo[4,5-c]pyridine-7-
 carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate
 842144-37-0P, 2-(4-Aminofurazan-3-yl)-4-(5-chlorothiophen-2-yl)-1-

ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-38-1P, 2-(4-Aminofurazan-3-yl)-4-(5-chlorothiophen-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-39-2P, 2-(4-Aminofurazan-3-yl)-4-(2-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-40-5P, 2-(4-Aminofurazan-3-yl)-4-(2-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-41-6P, 2-(4-Aminofurazan-3-yl)-4-(3-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-42-7P, 2-(4-Aminofurazan-3-yl)-4-(3-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-43-8P, 2-(4-Aminofurazan-3-yl)-4-(3-bromophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-44-9P, 2-(4-Aminofurazan-3-yl)-4-(3-bromophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-45-0P, 2-(4-Aminofurazan-3-yl)-4-(1-naphthalenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-46-1P, 2-(4-Aminofurazan-3-yl)-4-(1-naphthalenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-47-2P, 2-(4-Aminofurazan-3-yl)-4-(thiophen-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-48-3P, 2-(4-Aminofurazan-3-yl)-4-(thiophen-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-49-4P, 2-(4-Aminofurazan-3-yl)-4-(3,4-methylenedioxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-50-7P, 2-(4-Aminofurazan-3-yl)-4-(3,4-methylenedioxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-51-8P, 2-(4-Aminofurazan-3-yl)-4-(3,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide 842144-52-9P, 2-(4-Aminofurazan-3-yl)-4-(3,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(pyrrolidin-3-yl)amide trifluoroacetate 842144-53-0P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(biphenyl-4-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-54-1P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(biphenyl-4-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-55-2P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-56-3P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-58-5P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-59-6P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-60-9P, 2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenol 842144-61-0P, 2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenol trifluoroacetate 842144-62-1P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-63-2P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-64-3P, [2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]methanol 842144-65-4P,

[2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]methanol trifluoroacetate 842144-66-5P, 4-[1-Ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-67-6P, 4-[1-Ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-68-7P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-(4-methylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-69-8P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-(4-methylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-70-1P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(2,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-71-2P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(2,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-72-3P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(benzo[b]thien-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-73-4P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(benzo[b]thien-2-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-74-5P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-[4-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-75-6P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-[4-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-76-7P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-77-8P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-78-9P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-N-[2-[(phenylmethyl)amino]ethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide 842144-79-0P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-N-[2-[(phenylmethyl)amino]ethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842144-80-3P, 3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenol 842144-81-4P, 3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenol trifluoroacetate 842144-82-5P, 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]benzonitrile 842144-83-6P, 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]benzonitrile trifluoroacetate 842144-85-8P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-87-0P, 4-[4-(3-Chlorophenyl)-1-ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-88-1P, 4-[4-(3-Chlorophenyl)-1-ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-89-2P, 4-[4-(2,5-Dichlorophenyl)-1-ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-90-5P, 4-[4-(2,5-Dichlorophenyl)-1-ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-91-6P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-N-[3-(dimethylamino)propyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide 842144-92-7P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-N-[3-(dimethylamino)propyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842144-93-8P,

4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(4-bromophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842144-94-9P
 , 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-(4-bromophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842144-95-0P,
 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenol 842144-96-1P,
 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenol trifluoroacetate 842144-97-2P,
 2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-4-chlorophenol 842144-98-3P
 , 2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-4-chlorophenol trifluoroacetate 842145-01-1P,
 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-11-3P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-(1-methyl-4-piperidinyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-12-4P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-(1-methyl-4-piperidinyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-13-5P,
 4-[1-(4-Aminobutyl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-14-6P
 , 4-[1-(4-Aminobutyl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-15-7P,
 4-[1-(4-Aminobutyl)-7-[(3-(methylamino)-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-16-8P,
 4-[1-(4-Aminobutyl)-7-[(3-(methylamino)-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-17-9P,
 1-(4-Aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-N-[2-[(phenylmethyl)amino]ethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-18-0P,
 1-(4-Aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-N-[2-[(phenylmethyl)amino]ethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-21-5P,
 4-[7-[(3-(Methylamino)-1-pyrrolidinyl)carbonyl]-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-22-6P,
 4-[7-[(3-(Methylamino)-1-pyrrolidinyl)carbonyl]-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-23-7P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-N-(3-aminopropyl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-24-8P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-N-(3-aminopropyl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-25-9P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-N-(2-propen-1-yl)-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-26-0P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-morpholinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide hydrochloride 842145-27-1P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1H-imidazol-4-yl)ethyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide hydrochloride 842145-28-2P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-29-3P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-methyl-1-piperazinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-31-7P,
 N-[1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]-N-methylacetamide trifluoroacetate 842145-32-8P
 , 2-(4-Amino-1,2,5-oxadiazol-3-yl)-N-[3-(dimethylamino)propyl]-1-ethyl-4-phenyl-

1H-imidazo[4,5-c]pyridine-7-carboxamide hydrochloride 842145-35-1P
 , 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-36-2P
 , 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-37-3P,
 4-[1-Cyclopentyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-38-4P,
 4-[1-Cyclopentyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-39-5P, (3R)-1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinol hydrochloride 842145-40-8P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-N-[3-(diethylamino)propyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-41-9P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-N-[3-(diethylamino)propyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-42-0P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(2-methyl-1-piperidinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide hydrochloride 842145-43-1P,
 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-(4-fluorophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-44-2P
 , 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-(4-fluorophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-45-3P, N-(2-Aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-46-4P, N-(2-Aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-47-5P,
 4-[1-(4-Aminophenyl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-48-6P
 , 4-[1-(4-Aminophenyl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-49-7P, 4-[7-[[3-(Dimethylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-50-0P,
 4-[7-[[3-(Dimethylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-51-1P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-52-2P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-53-3P,
 1-[1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one 842145-54-4P, 1-[1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one trifluoroacetate 842145-55-5P,
 1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-piperidinecarboxamide hydrochloride 842145-56-6P, N-(3-Amino-2-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842145-57-7P, N-(3-Amino-2-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide trifluoroacetate 842145-59-9P,
 N-(2-Amino-3-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide hydrochloride 842145-61-3P, [4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-2-piperazinyl]methanol hydrochloride 842145-62-4P,
 4-[1-Ethyl-7-[[3-[(methyloxy)methyl]-1-piperazinyl]carbonyl]-4-phenyl-1H-


imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine hydrochloride 842145-63-5P, 4-[1-Methyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine hydrochloride 842145-71-5P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine hydrochloride 842145-72-6P, 4-[1-Butyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine hydrochloride 842145-73-7P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-butyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine hydrochloride 842145-74-8P, N-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-4-piperidinecarboxamide 842145-75-9P, N-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-4-piperidinecarboxamide trifluoroacetate 842145-82-8P, 1-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-3-(3-pyrrolidinyl)urea trifluoroacetate 842145-85-1P, 3-Amino-N-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-pyrrolidinecarboxamide trifluoroacetate 842145-86-2P, 4-[1-Ethyl-7-[(4-methyl-1-piperazinyl)methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-87-3P, 4-[1-Ethyl-7-[(4-methyl-1-piperazinyl)methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-90-8P, N-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl-N-methyl-1-methyl-4-piperidinamine 842145-91-9P, 4-[1-Ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-92-0P, 4-[1-Ethyl-7-[[3-(methylamino)-1-pyrrolidinyl]methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-93-1P, (3-Amino-2,2-dimethylpropyl)[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amine 842145-94-2P, (3-Amino-2,2-dimethylpropyl)[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amine trifluoroacetate 842145-95-3P, 4-[7-[[3-(Dimethylamino)-1-pyrrolidinyl]methyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-96-4P, 4-[7-[[3-(Dimethylamino)-1-pyrrolidinyl]methyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842145-97-5P, 4-[7-[(3S)-3-Amino-1-pyrrolidinyl]methyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-98-6P, 4-[1-Ethyl-7-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842145-99-7P, 4-[1-Ethyl-4-phenyl-7-(1-piperazinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-00-3P, [2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanol hydrochloride 842146-01-4P, 4-[1-Ethyl-4-phenyl-7-[(3-piperidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-02-5P, 4-[1-Ethyl-4-phenyl-7-[(3-piperidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-07-0P, 4-[7-[(4-Aminobutyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-09-2P, 4-[4-(3-Chlorophenyl)-1-ethyl-7-[(4-piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Akt inhibitor; preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as inhibitors of Akt activity for treating cancer and arthritis)


RN 607373-68-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842143-50-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-phenyl-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842143-51-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-phenyl-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842143-50-4


CMF C19 H19 N7 O



CM 2



CRN 76-05-1

CMF C2 H F3 O2




RN 842143-57-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-, hydrochloride (1:?) (CA INDEX NAME)



RN 842143-58-2 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-1-propanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-β,β-dimethyl- (CA INDEX NAME)



RN 842143-72-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-propanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-β,β-dimethyl-4-phenyl- (CA INDEX NAME)

INDEX NAME)




RN 842143-73-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-propanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-β,β-dimethyl-4-phenyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842143-72-0


CMF C19 H21 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842143-74-2 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-1-pentanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl- (CA INDEX NAME)



RN 842143-75-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-pentanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-, 2,2,2-trifluoroacetate (1:?)
 (CA INDEX NAME)


CM 1

CRN 842143-74-2
 CMF C19 H21 N7 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 842143-76-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-hexanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl- (CA INDEX NAME)




RN 842143-77-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-hexanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-, 2,2,2-trifluoroacetate (1:?)
(CA INDEX NAME)


CM 1

CRN 842143-76-4
CMF C20 H23 N7 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842143-78-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-1-pentanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)- (CA INDEX NAME)



RN 842143-79-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-1-pentanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842143-78-6
CMF C19 H20 Cl N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842143-80-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-hexanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)- (CA INDEX NAME)




RN 842143-81-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-hexanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842143-80-0

CMF C20 H22 Cl N7 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842143-82-2 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-1-propanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-methoxyphenyl)-β,β-
dimethyl- (CA INDEX NAME)



RN 842143-83-3 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-1-propanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-methoxyphenyl)-β,β-
dimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842143-82-2
CMF C20 H23 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842143-84-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-pentanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-thienyl)- (CA INDEX NAME)




RN 842143-85-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-pentanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-thienyl)-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)

CM 1


CRN 842143-84-4

CMF C17 H19 N7 O S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842143-86-6 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-1-hexanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-thienyl)- (CA INDEX NAME)



RN 842143-87-7 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-1-hexanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-thienyl)-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)

CM 1


CRN 842143-86-6
CMF C18 H21 N7 O S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842143-93-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842143-94-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(cyclopropylmethyl)-4-(2-methylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842143-95-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(2-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842143-96-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(cyclopropylmethyl)-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842144-01-8 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842144-02-9 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842144-01-8
 CMF C21 H21 Cl N8 O2




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 842144-12-1 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, hydrochloride (1:?)
(CA INDEX NAME)



●x HCl

RN 842144-13-2 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-thienyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, hydrochloride (1:?)
(CA INDEX NAME)



●x HCl


RN 842144-14-3 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-pyridinyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-15-4 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-pyridinyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-16-5 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-furanyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842144-17-6 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-18-7 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-17-6


CMF C15 H17 Cl N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-19-8 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-20-1 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-19-8


CMF C19 H21 N9 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-21-2 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidiny)- (CA INDEX NAME)




RN 842144-22-3 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidiny)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842144-21-2
CMF C22 H24 N8 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842144-23-4 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-furanyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-24-5 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-furanyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-,

2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-23-4


CMF C19 H20 N8 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842144-25-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[2-(4-chlorophenyl)-1-(hydroxymethyl)ethyl]-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 842144-26-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-N-[2-(4-chlorophenyl)-
 1-(hydroxymethyl)ethyl]-1-ethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 842144-27-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[2-(4-chlorophenyl)-1-(
(hydroxymethyl)ethyl)-4-(2,3-dichlorophenyl)-1-ethyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 842144-28-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[2-(4-chlorophenyl)-1-(
(hydroxymethyl)ethyl)-4-(2,3-dichlorophenyl)-1-ethyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-27-8
CMF C26 H22 Cl3 N7 O3

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-29-0 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-chlorophenyl)-N-[2-(4-chlorophenyl)-
1-(hydroxymethyl)ethyl]-1-ethyl- (CA INDEX NAME)



RN 842144-30-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-chlorophenyl)-N-[2-(4-chlorophenyl)-
 1-(hydroxymethyl)ethyl]-1-ethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX
 NAME)

CM 1


CRN 842144-29-0
 CMF C26 H23 Cl2 N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-31-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[2-(4-chlorophenyl)-1-(hydroxymethyl)ethyl]-1-ethyl-4-(2-hydroxyphenyl)- (CA INDEX NAME)




RN 842144-32-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[2-(4-chlorophenyl)-1-(hydroxymethyl)ethyl]-1-ethyl-4-(2-hydroxyphenyl)-, 2,2,2-trifluoroacetate
(1:?) (CA INDEX NAME)

CM 1

CRN 842144-31-4


CMF C26 H24 Cl N7 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-33-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-N-3-
pyrrolidinyl- (CA INDEX NAME)



RN 842144-34-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-N-3-
 pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842144-33-6
 CMF C21 H21 Cl N8 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 842144-35-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-N-3-pyrrolidinyl- (CA
INDEX NAME)




RN 842144-36-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-N-3-pyrrolidinyl-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-35-8


CMF C21 H22 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-37-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(5-chloro-2-thienyl)-1-ethyl-N-3-
pyrrolidinyl- (CA INDEX NAME)




RN 842144-38-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(5-chloro-2-thienyl)-1-ethyl-N-3-
pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842144-37-0

CMF C19 H19 Cl N8 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842144-39-2 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-aminophenyl)-1-ethyl-N-3-
pyrrolidinyl- (CA INDEX NAME)




RN 842144-40-5 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,

2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-aminophenyl)-1-ethyl-N-3-pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-39-2


CMF C21 H23 N9 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-41-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-aminophenyl)-1-ethyl-N-3-pyrrolidinyl- (CA INDEX NAME)



RN 842144-42-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-aminophenyl)-1-ethyl-N-3-
 pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842144-41-6
 CMF C21 H23 N9 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 842144-43-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-bromophenyl)-1-ethyl-N-3-
pyrrolidinyl- (CA INDEX NAME)




RN 842144-44-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-bromophenyl)-1-ethyl-N-3-
pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-43-8


CMF C21 H21 Br N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-45-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1-naphthalenyl)-N-3-
pyrrolidinyl- (CA INDEX NAME)




RN 842144-46-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1-naphthalenyl)-N-3-
pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-45-0


CMF C25 H24 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-47-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-pyrrolidinyl-4-(2-thienyl)-
(CA INDEX NAME)




RN 842144-48-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-pyrrolidinyl-4-(2-thienyl)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-47-2


CMF C19 H20 N8 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-49-4 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(1,3-benzodioxol-5-yl)-1-ethyl-N-3-
pyrrolidinyl- (CA INDEX NAME)



RN 842144-50-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(1,3-benzodioxol-5-yl)-1-ethyl-N-3-
 pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842144-49-4
 CMF C22 H22 N8 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 842144-51-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3,5-dichlorophenyl)-1-ethyl-N-3-
pyrrolidinyl- (CA INDEX NAME)




RN 842144-52-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3,5-dichlorophenyl)-1-ethyl-N-3-
pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-51-8


CMF C21 H20 Cl2 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-53-0 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-[1,1'-biphenyl]-4-yl-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-54-1 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-[1,1'-biphenyl]-4-yl-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842144-53-0

CMF C27 H26 N8 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842144-55-2 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-(CA INDEX NAME)



RN 842144-56-3 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-

(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-
 , 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-55-2


CMF C23 H23 Cl N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842144-58-5 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842144-59-6 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842144-58-5
 CMF C21 H20 Cl2 N8 O2




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 842144-60-9 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-61-0 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842144-60-9

CMF C21 H22 N8 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842144-62-1 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842144-63-2 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842144-62-1
CMF C21 H21 Cl N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-64-3 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-[2-(hydroxymethyl)phenyl]-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-65-4 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-[2-(hydroxymethyl)phenyl]-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842144-64-3
CMF C22 H24 N8 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842144-66-5 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 842144-67-6 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-

imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-66-5


CMF C22 H24 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-68-7 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-methylphenyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-69-8 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-methylphenyl)-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-68-7


CMF C22 H24 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-70-1 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-71-2 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-70-1


CMF C21 H20 Cl2 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-72-3 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-benzo[b]thien-2-yl-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-73-4 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-benzo[b]thien-2-yl-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842144-72-3

CMF C23 H22 N8 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842144-74-5 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-75-6 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-methoxyphenyl)-

1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-74-5


CMF C22 H24 N8 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-76-7 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-77-8 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-76-7


CMF C21 H21 Cl N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-78-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-
N-[2-[(phenylmethyl)amino]ethyl]- (CA INDEX NAME)




RN 842144-79-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-
N-[2-[(phenylmethyl)amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 842144-78-9


CMF C28 H27 Cl N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-80-3 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-81-4 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-80-3


CMF C21 H22 N8 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-82-5 CAPLUS

CN Benzonitrile, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]- (CA INDEX NAME)




RN 842144-83-6 CAPLUS

CN Benzonitrile, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-amino-1-pyrrolidinyl)carbonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842144-82-5

CMF C22 H21 N9 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842144-85-8 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842144-87-0 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl] [3-(methylanino)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 842144-88-1 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylanino)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-87-0


CMF C22 H23 Cl N8 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842144-89-2 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 842144-90-5 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2,5-dichlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842144-89-2
 CMF C22 H22 Cl2 N8 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 842144-91-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-
N-[3-(dimethylamino)propyl]- (CA INDEX NAME)




RN 842144-92-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-
N-[3-(dimethylamino)propyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX
NAME)

CM 1

CRN 842144-91-6


CMF C24 H27 Cl N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842144-93-8 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(4-bromophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-94-9 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(4-bromophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842144-93-8

CMF C21 H21 Br N8 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842144-95-0 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842144-96-1 CAPLUS
CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(4-hydroxyphenyl)-

1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842144-95-0


CMF C21 H22 N8 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842144-97-2 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(5-chloro-2-hydroxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842144-98-3 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(5-chloro-2-hydroxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842144-97-2
 CMF C21 H21 Cl N8 O3



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 842145-01-1 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-00-0


CMF C22 H24 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842145-11-3 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-(1-methyl-4-piperidinyl)-4-phenyl- (CA INDEX NAME)



RN 842145-12-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-(1-methyl-4-
 piperidiny)-4-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842145-11-3
 CMF C24 H28 N8 O2




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 842145-13-5 CAPLUS

CN Methanone, [1-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842145-14-6 CAPLUS

CN Methanone, [1-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-13-5


CMF C23 H27 N9 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-15-7 CAPLUS

CN Methanone, [1-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 842145-16-8 CAPLUS

CN Methanone, [1-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-15-7


CMF C24 H29 N9 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-17-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
1-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-N-[2-
[(phenylmethyl)amino]ethyl]- (CA INDEX NAME)




RN 842145-18-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
1-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-N-[2-
[(phenylmethyl)amino]ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 842145-17-9


CMF C28 H31 N9 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-21-5 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 842145-22-6 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-21-5


CMF C23 H26 N8 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842145-23-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(3-aminopropyl)-1-(1-methylethyl)-4-
 phenyl- (CA INDEX NAME)



RN 842145-24-8 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(3-aminopropyl)-1-(1-methylethyl)-4-
 phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842145-23-7
 CMF C21 H24 N8 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842145-25-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-N-2-propen-1-yl- (CA INDEX NAME)




RN 842145-26-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-morpholinyl)propyl]-4-phenyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 842145-27-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1H-imidazol-5-yl)ethyl]-4-phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 842145-28-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-methyl-1-
 piperazinyl)propyl]-4-phenyl- (CA INDEX NAME)




RN 842145-29-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-methyl-1-
 piperazinyl)propyl]-4-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX
 NAME)

CM 1

CRN 842145-28-2


CMF C25 H31 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842145-31-7 CAPLUS

CN Acetamide, N-[[1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-30-6


CMF C24 H26 N8 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-32-8 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[3-(dimethylamino)propyl]-1-ethyl-4-
phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 842145-35-1 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-
imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842145-36-2 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842145-35-1
 CMF C24 H26 N8 O2




CM 2


CRN 76-05-1
 CMF C2 H F3 O2




RN 842145-37-3 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl] [3-(methyamino)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 842145-38-4 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylanino)-1-pyrrolidinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842145-37-3
 CMF C25 H28 N8 O2




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 842145-39-5 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][(3R)-3-hydroxy-1-pyrrolidinyl]-, hydrochloride


(1:?) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 842145-40-8 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[3-(diethylamino)propyl]-1-ethyl-4-
phenyl- (CA INDEX NAME)



RN 842145-41-9 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[3-(diethylamino)propyl]-1-ethyl-4-
phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842145-40-8
CMF C24 H30 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842145-42-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(2-methyl-1-
piperidiny)propyl]-4-phenyl-, hydrochloride (1:?) (CA INDEX NAME)



RN 842145-43-1 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-4-phenyl-
1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidiny)- (CA INDEX NAME)



RN 842145-44-2 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl] (3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842145-43-1
 CMF C25 H21 F N8 O2





CM 2

CRN 76-05-1
 CMF C2 H F3 O2





RN 842145-45-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, N-(2-aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-4-phenyl- (CA INDEX NAME)



RN 842145-46-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 N-(2-aminoethyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-fluorophenyl)-4-
 phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842145-45-3
 CMF C23 H19 F N8 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 842145-47-5 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-aminophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842145-48-6 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(4-aminophenyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-47-5


CMF C25 H23 N9 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-49-7 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-7-yl][3-(dimethylamino)-1-pyrrolidiny]- (CA INDEX NAME)




RN 842145-50-0 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1-(2,2,2-trifluoroethyl)-1H-imidazo[4,5-c]pyridin-7-yl][3-(dimethylamino)-1-pyrrolidiny]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-49-7


CMF C23 H23 F3 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-51-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-methyl-2-
pyrrolidiny)ethyl]-4-phenyl- (CA INDEX NAME)




RN 842145-52-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-methyl-2-
pyrrolidiny)ethyl]-4-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX
NAME)

CM 1

CRN 842145-51-1


CMF C24 H28 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-53-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-4-piperidinyll]-1,3-dihydro- (CA INDEX NAME)




RN 842145-54-4 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-4-piperidinyll]-1,3-dihydro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842145-53-3
 CMF C29 H27 N9 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842145-55-5 CAPLUS
 CN 3-Piperidinecarboxamide, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 842145-56-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
N-(3-amino-2-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-
phenyl- (CA INDEX NAME)




RN 842145-57-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
N-(3-amino-2-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-
phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-56-6


CMF C20 H22 N8 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-59-9 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
N-(2-amino-3-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-
phenyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 842145-61-3 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(hydroxymethyl)-1-piperazinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 842145-62-4 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methoxymethyl)-1-piperazinyl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 842145-63-5 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 842145-71-5 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 842145-72-6 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-butyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 842145-73-7 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-butyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 842145-74-8 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 842145-75-9 CAPLUS

CN 4-Piperidinecarboxamide, N-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842145-74-8

CMF C22 H24 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842145-82-8 CAPLUS
CN Urea, N-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-3H-imidazo[4,5-c]pyridin-7-yl]-N'-3-pyrrolidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842145-81-7
CMF C19 H19 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842145-85-1 CAPLUS

CN 1-Pyrrolidinecarboxamide, 3-amino-N-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-3H-imidazo[4,5-c]pyridin-7-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-84-0


CMF C19 H19 N9 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-86-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-methyl-1-piperazinyl)methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842145-87-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-methyl-1-piperazinyl)methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-86-2


CMF C22 H26 N8 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842145-90-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-(1-methyl-4-
piperidiny)-4-phenyl- (CA INDEX NAME)




RN 842145-91-9 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[3-(methylamino)-1-
pyrrolidiny]methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX
NAME)



RN 842145-92-0 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[3-(methylamino)-1-
pyrrolidiny]methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 842145-91-9
CMF C22 H26 N8 O




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842145-93-1 CAPLUS

CN 1,3-Propanediamine, N1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl)methyl]-2,2-dimethyl- (CA INDEX NAME)




RN 842145-94-2 CAPLUS

CN 1,3-Propanediamine, N1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl)methyl]-2,2-dimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842145-93-1
CMF C22 H28 N8 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842145-95-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842145-96-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842145-95-3


CMF C23 H28 N8 O


$$\begin{array}{c} \text{F} \\ | \\ \text{F}-\text{C}-\text{CO}_2\text{H} \\ | \\ \text{F} \end{array}$$

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[(3S)-3-amino-1-pyrrolidinyl]methyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


CC1=NC(=C2C(=N1)C(=CN2)C3=CC=CC=C3)C4=CC=CC=C4C5=CC=CC=C5C6=CC=CC=C6C7=CC=CC=C7C8=CC=CC=C8C9=CC=CC=C9C10=CC=CC=C10C11=CC=CC=C11C12=CC=CC=C12C13=CC=CC=C13C14=CC=CC=C14C15=CC=CC=C15C16=CC=CC=C16C17=CC=CC=C17C18=CC=CC=C18C19=CC=CC=C19C20=CC=CC=C20C21=CC=CC=C21C22=CC=CC=C22C23=CC=CC=C23C24=CC=CC=C24C25=CC=CC=C25C26=CC=CC=C26C27=CC=CC=C27C28=CC=CC=C28C29=CC=CC=C29C30=CC=CC=C30C31=CC=CC=C31C32=CC=CC=C32C33=CC=CC=C33C34=CC=CC=C34C35=CC=CC=C35C36=CC=CC=C36C37=CC=CC=C37C38=CC=CC=C38C39=CC=CC=C39C40=CC=CC=C40C41=CC=CC=C41C42=CC=CC=C42C43=CC=CC=C43C44=CC=CC=C44C45=CC=CC=C45C46=CC=CC=C46C47=CC=CC=C47C48=CC=CC=C48C49=CC=CC=C49C50=CC=CC=C50C51=CC=CC=C51C52=CC=CC=C52C53=CC=CC=C53C54=CC=CC=C54C55=CC=CC=C55C56=CC=CC=C56C57=CC=CC=C57C58=CC=CC=C58C59=CC=CC=C59C60=CC=CC=C60C61=CC=CC=C61C62=CC=CC=C62C63=CC=CC=C63C64=CC=CC=C64C65=CC=CC=C65C66=CC=CC=C66C67=CC=CC=C67C68=CC=CC=C68C69=CC=CC=C69C70=CC=CC=C70C71=CC=CC=C71C72=CC=CC=C72C73=CC=CC=C73C74=CC=CC=C74C75=CC=CC=C75C76=CC=CC=C76C77=CC=CC=C77C78=CC=CC=C78C79=CC=CC=C79C80=CC=CC=C80C81=CC=CC=C81C82=CC=CC=C82C83=CC=CC=C83C84=CC=CC=C84C85=CC=CC=C85C86=CC=CC=C86C87=CC=CC=C87C88=CC=CC=C88C89=CC=CC=C89C90=CC=CC=C90C91=CC=CC=C91C92=CC=CC=C92C93=CC=CC=C93C94=CC=CC=C94C95=CC=CC=C95C96=CC=CC=C96C97=CC=CC=C97C98=CC=CC=C98C99=CC=CC=C99C100=CC=CC=C100C101=CC=CC=C101C102=CC=CC=C102C103=CC=CC=C103C104=CC=CC=C104C105=CC=CC=C105C106=CC=CC=C106C107=CC=CC=C107C108=CC=CC=C108C109=CC=CC=C109C110=CC=CC=C110C111=CC=CC=C111C112=CC=CC=C112C113=CC=CC=C113C114=CC=CC=C114C115=CC=CC=C115C116=CC=CC=C116C117=CC=CC=C117C118=CC=CC=C118C119=CC=CC=C119C120=CC=CC=C120C121=CC=CC=C121C122=CC=CC=C122C123=CC=CC=C123C124=CC=CC=C124C125=CC=CC=C125C126=CC=CC=C126C127=CC=CC=C127C128=CC=CC=C128C129=CC=CC=C129C130=CC=CC=C130C131=CC=CC=C131C132=CC=CC=C132C133=CC=CC=C133C134=CC=CC=C134C135=CC=CC=C135C136=CC=CC=C136C137=CC=CC=C137C138=CC=CC=C138C139=CC=CC=C139C140=CC=CC=C140C141=CC=CC=C141C142=CC=CC=C142C143=CC=CC=C143C144=CC=CC=C144C145=CC=CC=C145C146=CC=CC=C146C147=CC=CC=C147C148=CC=CC=C148C149=CC=CC=C149C150=CC=CC=C150C151=CC=CC=C151C152=CC=CC=C152C153=CC=CC=C153C154=CC=CC=C154C155=CC=CC=C155C156=CC=CC=C156C157=CC=CC=C157C158=CC=CC=C158C159=CC=CC=C159C160=CC=CC=C160C161=CC=CC=C161C162=CC=CC=C162C163=CC=CC=C163C164=CC=CC=C164C165=CC=CC=C165C166=CC=CC=C166C167=CC=CC=C167C168=CC=CC=C168C169=CC=CC=C169C170=CC=CC=C170C171=CC=CC=C171C172=CC=CC=C172C173=CC=CC=C173C174=CC=CC=C174C175=CC=CC=C175C176=CC=CC=C176C177=CC=CC=C177C178=CC=CC=C178C179=CC=CC=C179C180=CC=CC=C180C181=CC=CC=C181C182=CC=CC=C182C183=CC=CC=C183C184=CC=CC=C184C185=CC=CC=C185C186=CC=CC=C186C187=CC=CC=C187C188=CC=CC=C188C189=CC=CC=C189C190=CC=CC=C190C191=CC=CC=C191C192=CC=CC=C192C193=CC=CC=C193C194=CC=CC=C194C195=CC=CC=C195C196=CC=CC=C196C197=CC=CC=C197C198=CC=CC=C198C199=CC=CC=C199C200=CC=CC=C200C201=CC=CC=C201C202=CC=CC=C202C203=CC=CC=C203C204=CC=CC=C204C205=CC=CC=C205C206=CC=CC=C206C207=CC=CC=C207C208=CC=CC=C208C209=CC=CC=C209C210=CC=CC=C210C211=CC=CC=C211C212=CC=CC=C212C213=CC=CC=C213C214=CC=CC=C214C215=CC=CC=C215C216=CC=CC=C216C217=CC=CC=C217C218=CC=CC=C218C219=CC=CC=C219C220=CC=CC=C220C221=CC=CC=C221C222=CC=CC=C222C223=CC=CC=C223C224=CC=CC=C224C225=CC=CC=C225C226=CC=CC=C226C227=CC=CC=C227C228=CC=CC=C228C229=CC=CC=C229C230=CC=CC=C230C231=CC=CC=C231C232=CC=CC=C232C233=CC=CC=C233C234=CC=CC=C234C235=CC=CC=C235C236=CC=CC=C236C237=CC=CC=C237C238=CC=CC=C238C239=CC=CC=C239C240=CC=CC=C240C241=CC=CC=C241C242=CC=CC=C242C243=CC=CC=C243C244=CC=CC=C244C245=CC=CC=C245C246=CC=CC=C246C247=CC=CC=C247C248=CC=CC=C248C249=CC=CC=C249C250=CC=CC=C250C251=CC=CC=C251C252=CC=CC=C252C253=CC=CC=C253C254=CC=CC=C254C255=CC=CC=C255C256=CC=CC=C256C257=CC=CC=C257C258=CC=CC=C258C259=CC=CC=C259C260=CC=CC=C260C261=CC=CC=C261C262=CC=CC=C262C263=CC=CC=C263C264=CC=CC=C264C265=CC=CC=C265C266=CC=CC=C266C267=CC=CC=C267C268=CC=CC=C268C269=CC=CC=C269C270=CC=CC=C270C271=CC=CC=C271C272=CC=CC=C272C273=CC=CC=C273C274=CC=CC=C274C275=CC=CC=C275C276=CC=CC=C276C277=CC=CC=C277C278=CC=CC=C278C279=CC=CC=C279C280=CC=CC=C280C281=CC=CC=C281C282=CC=CC=C282C283=CC=CC=C283C284=CC=CC=C284C285=CC=CC=C285C286=CC=CC=C286C287=CC=CC=C287C288=CC=CC=C288C289=CC=CC=C289C290=CC=CC=C290C291=CC=CC=C291C292=CC=CC=C292C293=CC=CC=C293C294=CC=CC=C294C295=CC=CC=C295C296=CC=CC=C296C297=CC=CC=C297C298=CC=CC=C298C299=CC=CC=C299C300=CC=CC=C300C301=CC=CC=C301C302=CC=CC=C302C303=CC=CC=C303C304=CC=CC=C304C305=CC=CC=C305C306=CC=CC=C306C307=CC=CC=C307C308=CC=CC=C308C309=CC=CC=C309C310=CC=CC=C310C311=CC=CC=C311C312=CC=CC=C312C313=CC=CC=C313C314=CC=CC=C314C315=CC=CC=C315C316=CC=CC=C316C317=CC=CC=C317C318=CC=CC=C318C319=CC=CC=C319C320=CC=CC=C320C321=CC=CC=C321C322=CC=CC=C322C323=CC=CC=C323C324=CC=CC=C324C325=CC=CC=C325C326=CC=CC=C326C327=CC=CC=C327C328=CC=CC=C328C329=CC=CC=C329C330=CC=CC=C330C331=CC=CC=C331C332=CC=CC=C332C333=CC=CC=C333C334=CC=CC=C334C335=CC=CC=C335C336=CC=CC=C336C337=CC=CC=C337C338=CC=CC=C338C339=CC=CC=C339C340=CC=CC=C340C341=CC=CC=C341C342=CC=CC=C342C343=CC=CC=C343C344=CC=CC=C344C345=CC=CC=C345C346=CC=CC=C346C347=CC=CC=C347C348=CC=CC=C348C349=CC=CC=C349C350=CC=CC=C350C351=CC=CC=C351C352=CC=CC=C352C353=CC=CC=C353C354=CC=CC=C354C355=CC=CC=C355C356=CC=CC=C356C357=CC=CC=C357C358=CC=CC=C358C359=CC=CC

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842145-99-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(1-piperazinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-00-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 842146-01-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(3-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-02-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(3-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842146-01-4
 CMF C22 H25 N7 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842146-07-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-aminobutoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-09-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



IT 842146-10-5P, 4-[4-(3-Chlorophenyl)-1-ethyl-7-[[4-(piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-11-6P, 4-[7-[(4-Aminobutyl)oxy]-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-12-7P, 4-[7-[(4-Aminobutyl)oxy]-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-13-8P, 4-[7-[(2-Aminoethyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-14-9P, 4-[7-[(2-Aminoethyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-15-0P, 4-[1-Ethyl-4-phenyl-7-[(3-pyrrolidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-16-1P,

4-[1-Ethyl-4-phenyl-7-[(3-pyrrolidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-18-3P,
4-[7-[(3-Aminopropyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-19-4P,
4-[7-[(2S)-2-Amino-3-phenylpropyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-20-7P,
4-[7-[(2S)-2-Amino-3-phenylpropyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-21-8P,
4-[1-Ethyl-4-phenyl-7-(3-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-22-9P,
, 4-[1-Ethyl-4-phenyl-7-(3-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-23-0P,
4-[1-Ethyl-4-phenyl-7-[[2-(4-piperidinyl)ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-24-1P,
4-[1-Ethyl-4-phenyl-7-[[2-(4-piperidinyl)ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-25-2P,
4-[7-[(2R)-2-Amino-3-phenylpropyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-26-3P,
4-[7-[(2R)-2-Amino-3-phenylpropyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-27-4P,
4-[1-Ethyl-7-[[2-(methylamino)ethyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-28-5P,
4-[1-Ethyl-7-[[2-(methylamino)ethyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-29-6P,
4-[1-Ethyl-4-phenyl-7-[[2-[(phenylmethyl)amino]ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-30-9P,
4-[1-Ethyl-4-phenyl-7-[[2-[(phenylmethyl)amino]ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-31-0P,
4-[7-[(5-Aminopentyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-32-1P,
, 4-[7-[(5-Aminopentyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-33-2P,
4-[7-[[3-(Dimethylamino)-2,2-dimethylpropyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-34-3P,
, 4-[7-[[3-(Dimethylamino)-2,2-dimethylpropyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-35-4P,
4-[7-[[2-(Dimethylamino)ethyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-36-5P,
4-[7-[[2-(Dimethylamino)ethyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-37-6P,
4-[1-Ethyl-4-phenyl-7-[(2S)-pyrrolidin-2-ylmethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-38-7P,
4-[1-Ethyl-4-phenyl-7-[(2S)-pyrrolidin-2-ylmethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-39-8P,
4-[1-Ethyl-4-phenyl-7-[(2R)-pyrrolidin-2-ylmethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-40-1P,
4-[1-Ethyl-4-phenyl-7-[(2R)-pyrrolidin-2-ylmethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-41-2P,
4-[7-[(3-Aminopropyl)oxy]-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-42-3P,
4-[7-[(3-Aminopropyl)oxy]-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-43-4P,
4-[7-[(3-Aminopropyl)oxy]-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-44-5P,
4-[7-[(3-Aminopropyl)oxy]-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-45-6P,
4-[7-[(3-Aminopropyl)oxy]-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-46-7P,
4-[7-[(3-Aminopropyl)oxy]-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate

842146-47-8P, 4-[7-[(3-Aminopropyl)oxy]-4-[5-chloro-2-(methyloxy)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-48-9P, 4-[7-[(3-Aminopropyl)oxy]-4-[5-chloro-2-(methyloxy)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-49-0P, 2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-4-chlorophenol 842146-50-3P, 2-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-4-chlorophenol trifluoroacetate 842146-51-4P, 4-[7-[(3-Aminopropyl)oxy]-1-ethyl-4-(2-pyridinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-52-5P, 4-[7-[(3-Aminopropyl)oxy]-1-ethyl-4-(2-pyridinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-53-6P, 4-[7-[[3-(Dimethylamino)propyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-54-7P, 4-[7-[[3-(Dimethylamino)propyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-55-8P, 4-[1-Ethyl-7-[[3-(4-morpholinyl)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-56-9P, 4-[1-Ethyl-7-[[3-(4-morpholinyl)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-57-0P, 4-[1-Ethyl-7-[[3-(methylamino)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-58-1P, 4-[1-Ethyl-7-[[3-(methylamino)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-59-2P, 4-[1-Ethyl-7-[(3-hydrazinopropyl)oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-60-5P, 4-[1-Ethyl-7-[(3-hydrazinopropyl)oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-61-6P, 2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethanol 842146-62-7P, 2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethanol trifluoroacetate 842146-64-9P, 4-[1-Ethyl-7-[[3-(hydroxyamino)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-65-0P, 4-[1-Ethyl-7-[[3-(hydroxyamino)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-67-2P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-phenylurea 842146-68-3P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-phenylurea trifluoroacetate 842146-69-4P, 3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-propanol 842146-70-7P, 3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-1-propanol trifluoroacetate 842146-72-9P, 4-[7-[(4-Amino-2-methylbutyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-75-2P, 4-[1-Ethyl-4-phenyl-7-[[2-(2-piperidinyl)ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842146-76-3P, N-[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]benzenesulfonamide 842146-78-5P, N-[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]methanesulfonamide 842146-79-6P, 1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-3-(4-morpholinyl)-2-propanol 842146-80-9P, 1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-3-(4-morpholinyl)-2-propanol trifluoroacetate 842146-83-2P, 4-[1-Ethyl-7-[[2-(4-morpholinyl)ethyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-84-3P, 4-[1-Ethyl-7-[[2-(4-morpholinyl)ethyl]oxy]-4-phenyl-1H-imidazo[4,5-

c[pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842146-87-6P, 4-[1-Ethyl-4-phenyl-7-[[3-(1-piperidiny)propyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842146-88-7P, (2-Aminoethyl)[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]amine
842146-89-8P, (2-Aminoethyl)[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]amine
trifluoroacetate 842146-90-1P,
4-[1-Ethyl-4-phenyl-7-[[2-(1-piperazinyl)ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-91-2P,
4-[1-Ethyl-4-phenyl-7-[[2-(1-piperazinyl)ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842146-93-4P, 4-[7-[[2-(4-Acetyl-1-piperazinyl)ethyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine
trifluoroacetate 842146-94-5P,
4-[1-Ethyl-7-[[3-(4-methyl-1-piperazinyl)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842146-95-6P
, 4-[1-Ethyl-7-[[3-(4-methyl-1-piperazinyl)propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842146-96-7P, 4-[1-Ethyl-4-phenyl-7-[[3-(1-piperazinyl)propyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine
842146-97-8P, 4-[1-Ethyl-4-phenyl-7-[[3-(1-piperazinyl)propyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842146-99-0P, 4-[1-Ethyl-4-phenyl-7-[[2-(1-piperidiny)ethyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842147-00-6P, [3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl][2-(dimethylamino)ethyl]methanamine 842147-01-7P,
N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-N-[2-(dimethylamino)ethyl]-N-methanamine
trifluoroacetate 842147-02-8P,
3-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1,2-propanediol 842147-03-9P,
3-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1,2-propanediol trifluoroacetate
842147-04-0P, 4-[7-[[3-[[2,4-Bis(methyloxy)phenyl]methyl]amino]propyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842147-05-1P
, 4-[7-[[3-[[2,4-Bis(methyloxy)phenyl]methyl]amino]propyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine
trifluoroacetate 842147-06-2P,
(2S)-2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-4-methyl-1-pentanol
842147-07-3P, (2S)-2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-4-methyl-1-pentanol trifluoroacetate 842147-09-5P,
[4-[1-Ethyl-4-phenyl-7-[3-[[2-(pyridin-4-yl)ethyl]amino]propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate
842147-11-9P, 4-[2-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]benzenesulfonamide
trifluoroacetate 842147-13-1P,
[4-[1-Ethyl-7-[3-[[2-(1-methyl-1H-pyrrol-2-yl)ethyl]amino]propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate
842147-15-3P, [4-[7-[3-[[2-(4-Aminophenyl)ethyl]amino]propoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine
trifluoroacetate 842147-17-5P,
[4-[1-Ethyl-7-[3-[[2-(1H-imidazol-4-yl)ethyl]amino]propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate
842147-19-7P, [4-[1-Ethyl-7-[3-[[3-(imidazol-1-yl)propyl]amino]propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate 842147-21-1P,
4-[2-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-

c[pyridin-7-yl]oxy]propyl]amino]ethyl]phenol trifluoroacetate
842147-23-3P, 2-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-4-phenyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-phenylethanol
trifluoroacetate 842147-25-5P,
[4-[1-Ethyl-7-[3-[[3-(morpholin-4-yl)propyl]amino]propoxy]-4-phenyl-1H-
imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate
842147-27-7P, [4-[1-Ethyl-7-[3-[[2-(5-methoxy-1H-indol-3-
yl)ethyl]amino]propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
yl]amine trifluoroacetate 842147-29-9P,
4-[2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]benzenesulfonamide
trifluoroacetate 842147-32-4P,
4-[4-(3-Chlorophenyl)-1-ethyl-7-[[3-[[2-(1H-imidazol-4-
yl)ethyl]amino]propyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-
3-amine trifluoroacetate 842147-36-8P,
4-[7-[[3-[[3-(Aminophenyl)methyl]amino]propyl]oxy]-1-ethyl-4-phenyl-1H-
imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842147-38-0P, 4-[1-Ethyl-7-[[3-[[5-methyl-2-
pyrazinyl]methyl]amino]propyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-
1,2,5-oxadiazol-3-amine trifluoroacetate 842147-40-4P,
5-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]methyl]-2-methyl-4-
pyrimidinamine trifluoroacetate 842147-42-6P,
3-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1,2-propanediol
trifluoroacetate 842147-44-8P,
4-[2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]phenol trifluoroacetate
842147-47-1P, 4-[7-[[3-[[2-(4-Aminophenyl)ethyl]amino]propyl]oxy]-
1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-
3-amine trifluoroacetate 842147-49-3P,
4-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]methyl]benzenesulfonamide
trifluoroacetate 842147-51-7P,
1-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-deoxy-D-glucitol
trifluoroacetate 842147-54-0P,
4-[2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]benzenesulfonamide
trifluoroacetate 842147-56-2P,
3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl 4-(aminomethyl)benzoate
trifluoroacetate 842147-58-4P,
1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-
c]pyridin-7-yl]oxy]-3-[[3-(aminophenyl)methyl]amino]-2-propanol
trifluoroacetate 842147-60-8P,
4-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-
c]pyridin-7-yl]oxy]-2-hydroxypropyl]amino]methyl]benzenesulfonamide
trifluoroacetate 842147-62-0P,
4-[(1R)-2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-hydroxyethyl]-1,2-
benzenediol trifluoroacetate 842147-64-2P,
4-[(1R)-2-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]-2-hydroxypropyl]amino]-1-hydroxyethyl]-1,2-
benzenediol trifluoroacetate 842147-66-4P,
N-[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-
7-yl]oxy]butyl]-1,4-benzenediamine trifluoroacetate 842147-68-6P
, 3-[[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-
c]pyridin-7-yl]oxy]butyl]amino]-1,2-propanediol trifluoroacetate
842147-70-0P, 4-[1-Ethyl-4-phenyl-7-[[4-[[3-
pyridinylmethyl]amino]butyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-
oxadiazol-3-amine trifluoroacetate 842147-72-2P,

4-[2-[[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]ethyl]benzenesulfonamide trifluoroacetate 842147-74-4P,
 4-[1-Ethyl-4-phenyl-7-[[4-[[2-(4-pyridinyl)ethyl]amino]butyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842147-76-6P, 4-[1-Ethyl-4-phenyl-7-[[4-[[4-pyridinylmethyl]amino]butyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842147-78-8P,
 4-[1-Ethyl-4-phenyl-7-[[4-[[2-(2-pyridinyl)ethyl]amino]butyl]oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842147-80-2P, 4-[1-Ethyl-7-[[4-[[5-methyl-2-pyrazinyl)methyl]amino]butyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842147-82-4P,
 4-[1-Ethyl-7-[[4-[[2-(1H-imidazol-2-yl)ethyl]amino]butyl]oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842147-84-6P, 4-[[[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]methyl]benzenesulfonamide trifluoroacetate 842147-86-8P, N-[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-N'-(2-pyrimidinyl)-1,2-ethanediamine trifluoroacetate 842147-88-0P,
 4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl 4-(aminomethyl)benzoate trifluoroacetate 842147-90-4P, 4-[2-[[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]ethyl]-1,2-benzenediol trifluoroacetate 842147-92-6P,
 4-[7-[[4-[[2-(4-Chlorophenyl)ethyl]amino]butyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842147-94-8P, 4-[2-[[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]ethyl]-2-fluorophenol trifluoroacetate 842147-96-0P,
 4-[7-[[4-[[2-(4-Fluorophenyl)ethyl]amino]butyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-00-9P, 4-[7-[[4-[[4-(Dimethylamino)phenyl]methyl]amino]butyl]oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-02-1P, N-[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]guanidine trifluoroacetate 842148-04-3P,
 , 4-[1-Ethyl-7-[(1-methyl-4-piperidinyl)oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-06-5P,
 4-[[[4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]methyl]benzoic acid trifluoroacetate 842148-08-7P, 4-[7-[(3-Aminopropyl)oxy]-1-ethyl-4-(2-pyrimidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-11-2P, 4-[1-Ethyl-4-phenyl-7-(1-piperazinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-15-6P, 4-[7-[(4-Aminobutyl)oxy]-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-20-3P, 4-[7-[(4-Aminobutyl)oxy]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol trifluoroacetate 842148-22-5P,
 4-[7-[(4-Aminobutyl)oxy]-4-(cyclopropylethynyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-23-6P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-24-7P, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate 842148-26-9P 842148-28-1P,
 3-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]propane-1,2-diol trifluoroacetate 842148-30-5P, 2-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(1H-pyrrol-

2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-phenylethanol
trifluoroacetate 842148-32-7P,
4-[7-[3-[(5-Aminomethyltetrazol-1-yl)propyl]oxy]-1-ethyl-4-(1H-pyrrol-2-
yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 842148-34-9P
, 4-[(R)-2-[[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-hydroxyethyl]benzene-1,2-
diol trifluoroacetate 842148-36-1P,
4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-
imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol trifluoroacetate
842148-39-4P, 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[4-
piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-
ol trifluoroacetate 842148-41-8P,
3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-
imidazo[4,5-c]pyridin-4-yl]-2-propyn-1-ol trifluoroacetate
842148-43-0P, 4-[7-[(3-Aminopropyl)oxy]-4-(3-amino-1-propyn-1-yl)-
1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine
trifluoroacetate 842148-45-2P,
4-[7-[(3-Aminopropyl)oxy]-4-(cyclopropylethynyl)-1-ethyl-1H-imidazo[4,5-
c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842148-47-4P, 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-
aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-3-butyn-1-ol
trifluoroacetate 842148-49-6P,
4-[7-[(3-Aminopropyl)oxy]-1-ethyl-4-[3-(methyloxy)-1-propyn-1-yl]-1H-
imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine trifluoroacetate
842148-52-1P, 4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-
aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-3-butyn-2-ol
trifluoroacetate 842148-54-3P,
(2S)-3-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-
phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]propyl]amino]-1,2-propanediol
trifluoroacetate 842148-67-8P,
N-[2-(4-Aminofurazan-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-
7-yl]propane-1,3-diamine trifluoroacetate 842148-69-0P,
N-(3-Aminobenzyl)-N'-[2-(4-aminofurazan-3-yl)-1-cyclopentyl-4-phenyl-1H-
imidazo[4,5-c]pyridin-7-yl]propane-1,3-diamine trifluoroacetate
842148-71-4P, (S)-3-[[3-[[2-(4-Aminofurazan-3-yl)-1-cyclopentyl-4-
phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]propyl]amino]propane-1,2-diol
trifluoroacetate 842148-73-6P,
N-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]-1,3-propanediamine trifluoroacetate
842148-84-9P, N-(3-Aminobenzyl)-N'-[2-(4-aminofurazan-3-yl)-4-(3-
chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]propane-1,3-diamine
trifluoroacetate 842148-85-0P,
(S)-3-[[3-[[2-(4-Aminofurazan-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]amino]propyl]amino]propane-1,2-diol
trifluoroacetate 842148-87-2P,
1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-
c]pyridin-7-yl]amino]-3-[[[(3-aminophenyl)methyl]amino]-2-propanol
trifluoroacetate 842148-89-4P,
4-[[[E)-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-
imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino](imino)methyl]amino]benzenesul
fonamide trifluoroacetate 842148-93-0P,
4-[[[E)-[[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-
1H-imidazo[4,5-c]pyridin-7-
yl]oxy]propyl]amino](imino)methyl]amino]benzenesulfonamide
trifluoroacetate 842148-95-2P,
N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-
c]pyridin-7-yl]oxy]propyl]-N'-(4-nitrophenyl)guanidine trifluoroacetate
842148-97-4P, N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-
phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-N'-(4-
hydroxyphenyl)guanidine trifluoroacetate 842148-99-6P,
1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-
imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(4-chlorophenyl)urea trifluoroacetate

842149-03-5P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-methylurea trifluoroacetate 842149-05-7P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(phenylmethyl)urea trifluoroacetate 842149-06-8P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[4-(piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-ethylurea 842149-09-1P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-ethylurea trifluoroacetate 842149-11-5P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(1-methylethyl)urea trifluoroacetate 842149-13-7P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-[3-(trifluoromethyl)phenyl]urea trifluoroacetate 842149-15-9P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-[4-(trifluoromethyl)phenyl]urea trifluoroacetate 842149-17-1P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-[3-(methyloxy)phenyl]urea trifluoroacetate 842149-18-2P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-[4-(methyloxy)phenyl]urea 842149-20-6P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[4-(piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(phenylmethyl)urea trifluoroacetate 842149-22-8P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[4-(piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(3-chlorophenyl)urea trifluoroacetate 842149-24-0P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[4-(piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-[3-(methyloxy)phenyl]urea trifluoroacetate 842149-26-2P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-[2-(methyloxy)phenyl]urea trifluoroacetate 842149-28-4P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(2,3-dihydro-1H-inden-5-yl)urea trifluoroacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Akt inhibitor; preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as inhibitors of Akt activity for treating cancer and arthritis)


RN 842146-10-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-09-2

CMF C22 H24 Cl N7 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842146-11-6 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-aminobutoxy)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-12-7 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-aminobutoxy)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-11-6
CMF C20 H22 Cl N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-13-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(2-aminoethoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-14-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(2-aminoethoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-13-8


CMF C18 H19 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-15-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(3-pyrrolidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-16-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(3-pyrrolidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-15-0


CMF C21 H23 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842146-18-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-17-2


CMF C19 H21 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 842146-19-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[(2S)-2-amino-3-phenylpropoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 842146-20-7 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[(2S)-2-amino-3-phenylpropoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-19-4

CMF C25 H25 N7 O2


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-21-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(3-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-22-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(3-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-21-8


CMF C21 H23 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-23-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-(4-piperidinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-24-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-(4-piperidinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842146-23-0

CMF C23 H27 N7 O2

CMF C25 H25 N7 O2


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-27-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[2-(methylanino)ethoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-28-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[2-(methylanino)ethoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-27-4


CMF C19 H21 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-29-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-
[(phenylmethyl)amino]ethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX
NAME)





RN 842146-30-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-
[(phenylmethyl)amino]ethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-29-6


CMF C25 H25 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-31-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[(5-aminopentyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-32-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[(5-aminopentyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-31-0


CMF C21 H25 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-33-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-(dimethylamino)-2,2-dimethylpropoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-34-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-(dimethylamino)-2,2-dimethylpropoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-33-2


CMF C23 H29 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-35-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[2-(dimethylamino)ethoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-36-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[2-(dimethylamino)ethoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-35-4


CMF C20 H23 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 842146-37-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[(2S)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 842146-38-7 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[(2S)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-37-6


CMF C21 H23 N7 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842146-39-8 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[(2R)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 842146-40-1 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[(2R)-2-pyrrolidinylmethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-39-8
CMF C21 H23 N7 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842146-41-2 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-42-3 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(2-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842146-41-2
 CMF C19 H20 Cl N7 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842146-43-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-44-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-43-4
 CMF C19 H20 Cl N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-45-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-46-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(4-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-45-6


CMF C19 H20 Cl N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-47-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(5-chloro-2-methoxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-48-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(5-chloro-2-methoxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-47-8


CMF C20 H22 Cl N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-49-0 CAPLUS

CN Phenol, 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-4-chloro- (CA INDEX NAME)




RN 842146-50-3 CAPLUS

CN Phenol, 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-4-chloro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-49-0


CMF C19 H20 Cl N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-51-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(2-pyridinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-52-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(2-pyridinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-51-4


CMF C18 H20 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-53-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-(dimethylamino)propoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-54-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-(dimethylamino)propoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-53-6


CMF C21 H25 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-55-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(4-morpholinyl)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-56-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(4-morpholinyl)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-55-8

CMF C23 H27 N7 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842146-57-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(methoxymethyl)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-58-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(methoxymethyl)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-57-0
CMF C20 H23 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-59-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(3-hydrazinylpropoxy)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-60-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(3-hydrazinylpropoxy)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-59-2

CMF C19 H22 N8 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842146-61-6 CAPLUS
CN Ethanol, 2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]- (CA INDEX NAME)



RN 842146-62-7 CAPLUS
CN Ethanol, 2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-61-6
CMF C21 H25 N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-64-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(hydroxyamino)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-65-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(hydroxyamino)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-64-9


CMF C19 H21 N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-67-2 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 842146-68-3 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-phenyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-67-2


CMF C26 H27 N9 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-69-4 CAPLUS

CN 1-Propanol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]- (CA INDEX NAME)




RN 842146-70-7 CAPLUS

CN 1-Propanol, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-69-4


CMF C19 H20 N6 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842146-72-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-amino-2-methylbutoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-71-8


CMF C21 H25 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 842146-75-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-(2-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842146-74-1
 CMF C23 H27 N7 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842146-76-3 CAPLUS
 CN Benzenesulfonamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]- (CA INDEX NAME)




RN 842146-78-5 CAPLUS

CN Methanesulfonamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]- (CA INDEX NAME)



RN 842146-79-6 CAPLUS

CN 4-Morpholineethanol, α -[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]- (CA INDEX NAME)




RN 842146-80-9 CAPLUS

CN 4-Morpholineethanol, α -[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-79-6

CMF C23 H27 N7 O4




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842146-83-2 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[2-(4-morpholinyl)ethoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-84-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[2-(4-morpholinyl)ethoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842146-83-2
 CMF C22 H25 N7 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 842146-87-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[3-(1-piperidiny)propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-86-5
 CMF C24 H29 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842146-88-7 CAPLUS

CN 1,2-Ethanediamine, N1-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]- (CA INDEX NAME)



H₂N-CH₂-CH₂-NH-CH₂-CH₂-O


RN 842146-89-8 CAPLUS

CN 1,2-Ethanediamine, N1-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-88-7

CMF C20 H24 N8 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842146-90-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-(1-piperazinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-91-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-(1-piperazinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-90-1
 CMF C22 H26 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842146-93-4 CAPLUS

CN Ethanone, 1-[4-[2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]ethyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842146-92-3

CMF C24 H28 N8 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842146-94-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 842146-95-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?)
 (CA INDEX NAME)


CM 1

CRN 842146-94-5
 CMF C24 H30 N8 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 842146-96-7 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[3-(1-piperazinyl)propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-97-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[3-(1-piperazinyl)propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-96-7


CMF C23 H28 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842146-99-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-[2-(1-piperidinyl)ethoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842146-98-9


CMF C23 H27 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842147-00-6 CAPLUS

CN 1,2-Ethanediamine, N1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-N1,N2,N2-trimethyl- (CA INDEX NAME)




RN 842147-01-7 CAPLUS

CN 1,2-Ethanediamine, N1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-N1,N2,N2-trimethyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-00-6


CMF C24 H32 N8 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 842147-02-8 CAPLUS


CN 1,2-Propanediol, 3-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]- (CA INDEX NAME)




RN 842147-03-9 CAPLUS
 CN 1,2-Propanediol, 3-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842147-02-8
 CMF C22 H27 N7 O4



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



RN 842147-04-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-[[[(2,4-dimethoxyphenyl)methyl]amino]propoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842147-05-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-[[[(2,4-dimethoxyphenyl)methyl]amino]propoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-04-0


CMF C28 H31 N7 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 842147-06-2 CAPLUS

CN 1-Pentanol, 2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-4-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 842147-07-3 CAPLUS


CN 1-Pentanol, 2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-4-methyl-, (2S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-06-2


CMF C25 H33 N7 O3

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842147-09-5 CAPLUS
CN 4-Pyridineethanamine, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-08-4
CMF C26 H28 N8 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842147-11-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]-,


2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-10-8

CMF C27 H30 N8 O4 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-13-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-[[2-(1-methyl-1H-pyrrol-2-yl)ethyl]amino]propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-12-0


CMF C26 H30 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-15-3 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-[[2-(4-aminophenyl)ethyl]amino]propoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-14-2

CMF C27 H30 N8 O2

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842147-17-5 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-[[2-(1H-imidazol-5-yl)ethyl]amino]propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-16-4
CMF C24 H27 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-19-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-[[3-(1H-imidazol-1-yl)propyl]amino]propoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-18-6


CMF C25 H29 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-21-1 CAPLUS


CN Phenol, 4-[2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-20-0

CMF C27 H29 N7 O3

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-23-3 CAPLUS

CN Benzenemethanol, α -[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-22-2


CMF C27 H29 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-25-5 CAPLUS

CN 4-Morpholinepropanamine, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-24-4

CMF C26 H34 N8 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842147-27-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-5-methoxy-,
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-26-6
CMF C30 H32 N8 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-29-9 CAPLUS
CN Benzenesulfonamide, 4-[2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-28-8

CMF C27 H29 Cl N8 O4 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-32-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-ethyl-7-[3-[[2-(1H-imidazol-5-yl)ethyl]amino]propoxy]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-31-3


CMF C24 H26 Cl N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-36-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-[[[(3-aminophenyl)methyl]amino]propoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-35-7


CMF C26 H28 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-38-0 CAPLUS

CN 2-Pyrazinemethanamine, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-5-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-37-9


CMF C25 H27 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-40-4 CAPLUS


CN 5-Pyrimidinemethanamine, 4-amino-N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-2-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-39-1

CMF C25 H27 Cl N10 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-42-6 CAPLUS

CN 1,2-Propanediol, 3-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-41-5


CMF C22 H26 Cl N7 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-44-8 CAPLUS


CN Phenol, 4-[2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-43-7

CMF C25 H28 N8 O3

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-47-1 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-[[2-(4-aminophenyl)ethyl]amino]propoxy]-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-46-0

CMF C25 H29 N9 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-49-3 CAPLUS
CN Benzenesulfonamide, 4-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-48-2

CMF C26 H27 Cl N8 O4 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-51-7 CAPLUS


CN D-Glucitol, 1-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-deoxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 842147-50-6

CMF C25 H32 Cl N7 O7


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-54-0 CAPLUS


CN Benzenesulfonamide, 4-[2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-53-9

CMF C25 H29 N9 O4 S

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842147-56-2 CAPLUS
CN Benzoic acid, 4-(aminomethyl)-, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-55-1
 CMF C25 H26 N8 O4



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842147-58-4 CAPLUS
 CN 2-Propanol, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-3-[[3-aminophenyl)methyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-57-3
 CMF C26 H28 N8 O3

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-60-8 CAPLUS
CN Benzenesulfonamide, 4-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-2-hydroxypropyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-59-5
CMF C26 H28 N8 O5 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-62-0 CAPLUS
CN 1,2-Benzenediol, 4-[(1R)-2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-hydroxyethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-61-9
 CMF C27 H29 N7 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 842147-64-2 CAPLUS
 CN 1,2-Benzenediol, 4-[(1R)-2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-2-hydroxypropyl]amino]-1-hydroxyethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-63-1
 CMF C27 H29 N7 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-66-4 CAPLUS

CN 1,4-Benzenediamine, N1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-65-3

CMF C24 H24 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842147-68-6 CAPLUS
CN 1,2-Propanediol, 3-[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-67-5
CMF C23 H29 N7 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-70-0 CAPLUS

CN 3-Pyridinemethanamine, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-69-7


CMF C26 H28 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-72-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-71-1
CMF C28 H32 N8 O4 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-74-4 CAPLUS
CN 4-Pyridineethanamine, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-73-3


CMF C27 H30 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-76-6 CAPLUS

CN 4-Pyridinemethanamine, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-75-5

CMF C26 H28 N8 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842147-78-8 CAPLUS
CN 2-Pyridineethanamine, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-77-7
CMF C27 H30 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-80-2 CAPLUS

CN 2-Pyrazinemethanamine, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-5-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-79-9


CMF C26 H29 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-82-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-[[2-(1H-imidazol-2-yl)ethyl]amino]butoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-81-3

CMF C25 H29 N9 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-84-6 CAPLUS

CN Benzenesulfonamide, 4-[[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-83-5
CMF C27 H30 N8 O4 S

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842147-86-8 CAPLUS
CN 1,2-Ethanediamine, N1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-N2-2-pyrimidinyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842147-85-7
CMF C26 H30 N10 O2

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842147-88-0 CAPLUS
CN Benzoic acid, 4-(aminomethyl)-, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-87-9
CMF C28 H29 N7 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-90-4 CAPLUS

CN 1,2-Benzenediol, 4-[2-[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-89-1


CMF C28 H31 N7 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-92-6 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[4-[[2-(4-chlorophenyl)ethyl]amino]butoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-91-5

CMF C28 H30 Cl N7 O2

PAGE 1-A




PAGE 2-A

C1

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842147-94-8 CAPLUS

CN Phenol, 4-[2-[[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]ethyl]-2-fluoro-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-93-7


CMF C28 H30 F N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842147-96-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-[[2-(4-fluorophenyl)ethyl]amino]butoxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842147-95-9

CMF C28 H30 F N7 O2

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-00-9 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-[4-[[[4-(dimethylamino)phenyl]methyl]amino]butoxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842147-99-3
CMF C29 H34 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-02-1 CAPLUS

CN Guanidine, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842148-01-0

CMF C21 H25 N9 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-04-3 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(1-methyl-4-piperidinyloxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-03-2
CMF C22 H25 N7 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-06-5 CAPLUS
CN Benzoic acid, 4-[[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-05-4
CMF C28 H29 N7 O4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-08-7 CAPLUS
CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(2-pyrimidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842148-07-6
CMF C17 H19 N9 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-11-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(1-piperazinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-10-1


CMF C20 H22 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-15-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-aminobutoxy)-1-ethyl-4-(2-phenylethynyl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-14-5


CMF C22 H23 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-20-3 CAPLUS

CN 3-Butyn-2-ol, 4-[7-(4-aminobutoxy)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-19-0


CMF C19 H25 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-22-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(4-aminobutoxy)-4-(2-cyclopropylethynyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-21-4


CMF C19 H23 N7 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842148-23-6 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-phenylethynyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842148-24-7 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-phenylethynyl)-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-23-6


CMF C23 H22 N8 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 842148-26-9 CAPLUS

CN 1,2-Propanediol, 3-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]propyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 842148-28-1 CAPLUS

CN 1,2-Propanediol, 3-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-27-0


CMF C20 H26 N8 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-30-5 CAPLUS

CN Benzenemethanol, α -[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-29-2


CMF C25 H28 N8 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-32-7 CAPLUS

CN 1H-Tetrazole-5-methanamine, 1-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842148-31-6

CMF C19 H22 N12 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842148-34-9 CAPLUS
CN 1,2-Benzenediol, 4-[(1R)-2-[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]-1-hydroxyethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-33-8
CMF C25 H28 N8 O5

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-36-1 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-35-0
CMF C18 H23 N7 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-39-4 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-38-3
CMF C21 H27 N7 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842148-41-8 CAPLUS

CN 2-Propyn-1-ol, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-40-7


CMF C16 H19 N7 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-43-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(3-amino-1-propyn-1-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-42-9


CMF C16 H20 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-45-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-4-(2-cyclopropylethynyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-44-1


CMF C18 H21 N7 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 842148-47-4 CAPLUS
 CN 3-Butyn-1-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-46-3
 CMF C17 H21 N7 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 842148-49-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminopropoxy)-1-ethyl-4-(3-methoxy-1-propyn-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-48-5
 CMF C17 H21 N7 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-52-1 CAPLUS
CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-51-0
CMF C17 H21 N7 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842148-54-3 CAPLUS
CN 1,2-Propanediol, 3-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]propyl]amino]-, (2S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-53-2
CMF C26 H36 N8 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-67-8 CAPLUS

CN 1,3-Propanediamine, N1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-66-7


CMF C22 H26 N8 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-69-0 CAPLUS

CN 1,3-Propanediamine, N1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-N3-[(3-aminophenyl)methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-68-9


CMF C29 H33 N9 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842148-71-4 CAPLUS

CN 1,2-Propanediol, 3-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]propyl]amino]-, (2S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842148-70-3
 CMF C25 H32 N8 O3

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 842148-73-6 CAPLUS
 CN 1,3-Propanediamine, N1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-72-5
 CMF C19 H21 Cl N8 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-84-9 CAPLUS
CN 1,3-Propanediamine, N1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N3-[(3-aminophenyl)methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-83-8
CMF C26 H28 Cl N9 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 842148-85-0 CAPLUS
CN 1,2-Propanediol, 3-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]propyl]amino]-,


(2S)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-26-9

CMF C22 H27 Cl N8 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 842148-87-2 CAPLUS


CN 2-Propanol, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]-3-[[(3-aminophenyl)methyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842148-86-1

CMF C29 H33 N9 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842148-89-4 CAPLUS
CN Benzenesulfonamide, 4-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]iminomethyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-88-3
CMF C26 H28 N10 O4 S

PAGE 1-A




PAGE 2-A



CM 2



CRN 76-05-1
CMF C2 H F3 O2



RN 842148-93-0 CAPLUS
CN Benzenesulfonamide, 4-[[[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]amino]iminomethyl]amino]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842148-92-9
CMF C24 H27 N11 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




```
RN      842148-95-2  CAPLUS
CN      Guanidine, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-
        imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-N'-(4-nitrophenyl)-,
        2,2,2-trifluoroacetate (1:?)  (CA INDEX NAME)
```

CM 1

CRN 842148-94-1
CMF C26 H26 N10 O4

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 842148-97-4 CAPLUS
CN Guanidine, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-N'-(4-hydroxyphenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842148-96-3
CMF C26 H27 N9 O3

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 842148-99-6 CAPLUS
CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(4-chlorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842148-98-5
CMF C26 H26 Cl N9 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-03-5 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-methyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-02-4


CMF C21 H25 N9 O3




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 842149-05-7 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)
 CM 1
 CRN 842149-04-6
 CMF C27 H29 N9 O3



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 842149-06-8 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-ethyl- (CA INDEX NAME)



RN 842149-09-1 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-ethyl-, 2,2,2-trifluoroacetate (1:?)
 (CA INDEX NAME)


CM 1

CRN 842149-08-0
 CMF C22 H27 N9 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 842149-11-5 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842149-10-4
 CMF C23 H29 N9 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 842149-13-7 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842149-12-6
 CMF C27 H26 F3 N9 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-15-9 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-[4-(trifluoromethyl)phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-14-8


CMF C27 H26 F3 N9 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-17-1 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-16-0


CMF C27 H29 N9 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 842149-18-2 CAPLUS


CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(4-methoxyphenyl)- (CA INDEX NAME)



RN 842149-20-6 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(phenylmethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842149-19-3
 CMF C30 H33 N9 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 842149-22-8 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(3-chlorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 842149-21-7
 CMF C29 H30 Cl N9 O3



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 842149-24-0 CAPLUS
 CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(3-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842149-23-9
 CMF C30 H33 N9 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-26-2 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(2-methoxyphenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-25-1


CMF C27 H29 N9 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-28-4 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(2,3-dihydro-1H-inden-5-yl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-27-3


CMF C29 H31 N9 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 842149-30-8P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(2-chlorophenyl)urea trifluoroacetate 842149-32-0P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(3-chlorophenyl)urea trifluoroacetate 842149-34-2P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(4-cyanophenyl)urea trifluoroacetate 842149-36-4P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(3-cyanophenyl)urea trifluoroacetate 842149-38-6P, 1-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(cyclohexyl)urea trifluoroacetate 842149-40-0P,

N-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[4-(piperidinyl)methyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]acetamide trifluoroacetate 842149-42-2P, Ethyl
3-[[[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]amino]carbonyl]amino]benzoate trifluoroacetate 842149-44-4P,
N-[3-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-7-[(3-aminopropyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-(methyloxy)propanamide trifluoroacetate 842149-45-5P,
4-[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[3-[[2-[4-(methyloxy)phenyl]ethyl]amino]propyl]oxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl-3-butyn-2-ol 842149-47-7P,
1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone 842149-48-8P,
[4-[4-(3-Chlorophenyl)-1-(piperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 842149-49-9P,
4-[4-Phenyl-1-(3-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-50-2P,
4-[4-(3-Chlorophenyl)-1-[(3-piperidinyl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-51-3P,
4-[4-(4-Chlorophenyl)-1-[(3-piperidinyl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-52-4P,
4-[1-(3-Aminopropyl)-4-(2-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-53-5P,
4-[1-(3-Aminopropyl)-4-(1-piperidinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-54-6P,
1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-(thiophen-3-yl)-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone 842149-55-7P,
1-[2-(4-Aminofurazan-3-yl)-1-ethyl-4-pyridinyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-(3-aminopyrrolidin-1-yl)methanone 842149-56-8P,
4-[1-Ethyl-4-phenyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-57-9P,
4-[4-(3-Chlorophenyl)-1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-58-0P,
4-[4-(2,5-Dichlorophenyl)-1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-59-1P,
2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-N-(3-pyrrolidinyl)-1H-imidazo[4,5-c]pyridine-7-carboxamide 842149-60-4P,
2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-morpholinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842149-61-5P,
2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1H-imidazol-4-yl)ethyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842149-62-6P,
N-[1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]-N-methylacetamide 842149-63-7P,
2-(4-Amino-1,2,5-oxadiazol-3-yl)-N-[3-(dimethylamino)propyl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842149-64-8P,
2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-N-(3-pyrrolidinyl)-1H-imidazo[4,5-c]pyridine-7-carboxamide 842149-65-9P,
(3R)-1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinol 842149-66-0P,
2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(2-methyl-1-piperidinyl)propyl]-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842149-67-1P,
4-[1-Methyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-68-2P,
4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-69-3P,
4-[1-Butyl-7-[[3-(methylamino)-1-pyrrolidinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-70-6P,
4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-1-butyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-71-7P,

1-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-piperidinecarboxamide 842149-72-8P,
 N-(2-Amino-3-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxamide 842149-73-9P,
 [4-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-2-piperazinyl]methanol 842149-74-0P,
 4-[1-Ethyl-7-[[3-[(methyloxy)methyl]-1-piperazinyl]carbonyl]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842149-75-1P
 , Diethyl 1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-1,2-hydrazinedicarboxylate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Akt inhibitor; preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as inhibitors of Akt activity for treating cancer and arthritis)


RN 842149-30-8 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(2-chlorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-29-5


CMF C26 H26 Cl N9 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-32-0 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(3-chlorophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-31-9


CMF C26 H26 Cl N9 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-34-2 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(4-cyanophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-33-1


CMF C27 H26 N10 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-36-4 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-(3-cyanophenyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-35-3


CMF C27 H26 N10 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-38-6 CAPLUS

CN Urea, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-N'-cyclohexyl-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 842149-37-5


CMF C26 H33 N9 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 842149-40-0 CAPLUS

CN Acetamide, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 842149-39-7

CMF C24 H28 N8 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN	842149-42-2	CAPLUS
CN	Benzoic acid, 3-[[[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]amino]carbonyl]amino]-, ethyl ester, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)	


CM 1

CRN 842149-41-1
CMF C29 H31 N9 O5



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN	842149-44-4	CAPLUS
CN	Propanamide, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-(3-aminopropoxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]phenyl]-3-methoxy-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)	

CM 1


CRN 842149-43-3
CMF C23 H28 N8 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 842149-45-5 CAPLUS


CN 3-Butyn-2-ol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[3-[[2-(4-methoxyphenyl)ethyl]amino]propoxy]-1H-imidazo[4,5-c]pyridin-4-yl]-2-methyl- (CA INDEX NAME)

PAGE 1-A








RN 842149-47-7 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842149-48-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-(4-piperidiny1)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842149-49-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[4-phenyl-1-(3-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842149-50-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-(3-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842149-51-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(4-chlorophenyl)-1-(3-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842149-52-4 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-1-propanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(2-thienyl)- (CA INDEX NAME)




RN 842149-53-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-propanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(1-piperidinyl)- (CA INDEX NAME)



RN 842149-54-6 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(3-thienyl)-1H-
 imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842149-55-7 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-pyridinyl)-1H-
 imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842149-56-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(4-piperidin-1-yl-1-oxo-1H-imidazo[4,5-c]pyridin-2-yl)]- (CA INDEX NAME)




RN 842149-57-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(3-chlorophenyl)-1-ethyl-7-(4-piperidin-1-yl-1-oxo-1H-imidazo[4,5-c]pyridin-2-yl)]- (CA INDEX NAME)




RN 842149-58-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-(2,5-dichlorophenyl)-1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842149-59-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-N-3-pyrrolidinyl- (CA INDEX NAME)




RN 842149-60-4 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-morpholinyl)propyl]-4-phenyl- (CA INDEX NAME)



RN 842149-61-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1H-imidazol-5-yl)ethyl]-4-
 phenyl- (CA INDEX NAME)




RN 842149-62-6 CAPLUS
 CN Acetamide, N-[1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-
 imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX
 NAME)




RN 842149-63-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[3-(dimethylamino)propyl]-1-ethyl-4-
phenyl- (CA INDEX NAME)



RN 842149-64-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopentyl-4-phenyl-N-3-pyrrolidinyl-
(CA INDEX NAME)




RN 842149-65-9 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-


imidazo[4,5-c]pyridin-7-yl] [(3R)-3-hydroxy-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 842149-66-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(2-methyl-1-piperidinyl)propyl]-4-phenyl- (CA INDEX NAME)




RN 842149-67-1 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl] [3-(methylamino)-1-pyrrolidinyl]- (CA INDEX NAME)




RN 842149-68-2 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)



RN 842149-69-3 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-butyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methylamino)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 842149-70-6 CAPLUS


CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-butyl-4-phenyl-1H-

imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842149-71-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]- (CA INDEX NAME)




RN 842149-72-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, N-(2-amino-3-hydroxypropyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl- (CA INDEX NAME)




RN 842149-73-9 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(hydroxymethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 842149-74-0 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl][3-(methoxymethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 842149-75-1 CAPLUS

CN 1,2-Hydrazinedicarboxylic acid, 1-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]-, 1,2-diethyl ester (CA INDEX NAME)



IT 607373-60-4P, [4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]carbamic acid tert-butyl ester 842143-56-0P,
 [4-[1-(1-Benzylpiperidin-4-yl)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 842143-69-5P,
 2-[3-[2-(4-Aminofurazan-3-yl)-4-chloro-1H-imidazo[4,5-c]pyridin-1-yl]-2,2-dimethylpropyl]isoindole-1,3-dione 842143-71-9P,
 N-[3-[2-(4-Aminofurazan-3-yl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-1-yl]-2,2-dimethylpropyl]phthalamic acid 842143-99-1P,
 [4-(1-Ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]carbamic acid tert-butyl ester 842144-00-7P,
 4-[[2-[4-[(tert-Butoxycarbonyl)amino]furazan-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 842144-08-5P, 1,1-Dimethylethyl
 [4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]carbamate 842144-09-6P,
 4-Chloro-2-[4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid 842144-10-9P,
 [4-[7-[1-[3-[(tert-Butoxycarbonyl)amino]pyrrolidin-1-yl]carbonyl]-4-chloro-1-ethyl-1H-imidazo[4,5-a]pyridin-2-yl]furazan-3-yl]carbamic acid tert-butyl ester 842144-11-0P,
 [4-[7-[3-[(tert-Butoxycarbonyl)amino]pyrrolidin-1-yl]methyl]-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]carbamic acid tert-butyl ester 842145-08-8P, Ethyl
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylate 842145-09-9P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid 842145-10-2P, 1,1-Dimethylethyl
 [1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]carbamate 842145-70-4P, 1,1-Dimethylethyl
 [1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]methylcarbamate 842145-76-0P, Ethyl 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylate 842145-77-1P,
 Ethyl 2-[4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylate 842145-78-2P, 2-[4-[[[(1,1-Dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid 842145-79-3P, 1,1-Dimethylethyl
 [4-(7-amino-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]carbamate 842145-80-6P, Phenylmethyl
 4-[[[2-[4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]carbonyl]-1-piperidinecarboxylate 842145-83-9P, 1,1-Dimethylethyl
 3-[[[2-[4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-3-yl]-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]carbonyl]amino]-1-pyrrolidinecarboxylate 842145-88-4P,
 [2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-

c]pyridin-7-yl]methanol 842145-89-5P,
 4-[7-(Chloromethyl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-
 oxadiazol-3-amine 842146-03-6P, 1,1-Dimethylethyl
 [4-(4-chloro-1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-
 oxadiazol-3-yl]carbamate 842146-04-7P, 1,1-Dimethylethyl
 [4-(1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-
 oxadiazol-3-yl]carbamate 842146-05-8P,
 4-[1-Ethyl-4-phenyl-7-[(4-piperidinylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-
 2-yl]-1,2,5-oxadiazol-3-amine 842146-06-9P 842146-81-0P
 , 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-
 c]pyridin-7-ol 842146-82-1P,
 4-[1-Ethyl-7-[(2-oxiranylmethyl)oxy]-4-phenyl-1H-imidazo[4,5-c]pyridin-2-
 yl]-1,2,5-oxadiazol-3-amine 842146-85-4P,
 4-[7-[(2-Bromoethyl)oxy]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-
 1,2,5-oxadiazol-3-amine 842148-12-3P, 1,1-Dimethylethyl
 4-[4-chloro-2-[4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-
 3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-piperazinecarboxylate
 842148-13-4P, 1,1-Dimethylethyl
 4-[2-[4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-
 ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-piperazinecarboxylate
 842148-16-7P, Bis(1,1-dimethylethyl)[4-[7-[[[(1,1-
 dimethylethyl)oxy]carbonyl]oxy]-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-
 c]pyridin-2-yl]-1,2,5-oxadiazol-3-yl]imidodicarbonate 842148-17-8P
 , 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(phenylethynyl)-1H-
 imidazo[4,5-c]pyridin-7-ol 842148-18-9P, 1,1-Dimethylethyl
 [4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(phenylethynyl)-1H-
 imidazo[4,5-c]pyridin-7-yl]oxy]butyl]carbamate 842148-25-8P,
 [4-[7-[1-[3-[(tert-Butoxycarbonyl)amino]pyrrolidin-1-yl]methanoyl]-1-ethyl-
 4-phenylethynyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]carbamic acid
 tert-butyl ester 842148-61-2P, Ethyl
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-phenyl-1H-
 imidazo[4,5-c]pyridine-7-carboxylate 842148-62-3P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-phenyl-1H-
 imidazo[4,5-c]pyridine-7-carboxylic acid 842148-63-4P,
 1,1-Dimethylethyl [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-
 4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbamate 842148-64-5P,
 1,1-Dimethylethyl [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-
 4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-bromopropyl)carbamate
 842148-65-6P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-N-(3-bromopropyl)-1-
 (3,3-dimethylbutyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-amine
 842148-79-2P, Ethyl 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-
 chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylate
 842148-80-5P, 2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-
 1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid 842148-81-6P
 , 1,1-Dimethylethyl [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-
 ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbamate 842148-82-7P,
 1,1-Dimethylethyl [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-
 ethyl-1H-imidazo[4,5-c]pyridin-7-yl][3-[[[(1,1-
 dimethylethyl)oxy]carbonyl]amino]propyl]carbamate 842148-91-8P,
 1,1-Dimethylethyl [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-
 1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]carbamate 842149-01-3P,
 1,1-Dimethylethyl [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-[3-[[[(4-
 chlorophenyl)amino]carbonyl]amino]phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-
 7-yl]oxy]propyl]carbamate 842149-46-6P,
 2-(4-Amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-
 7-ol


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as
 inhibitors of Akt activity for treating cancer and arthritis)

RN 607373-60-4 CAPLUS


CN Carbamic acid, [4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-

oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842143-56-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[4-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 842143-69-5 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1H-imidazo[4,5-c]pyridin-1-yl]-2,2-dimethylpropyl]- (CA INDEX NAME)




RN 842143-71-9 CAPLUS

CN Benzoic acid, 2-[[[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-1-yl]-2,2-dimethylpropyl]amino]carbonyl]- (CA INDEX NAME)




RN 842143-99-1 CAPLUS

CN Carbamic acid, [4-(1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842144-00-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842144-08-5 CAPLUS

CN Carbamic acid, [4-(7-bromo-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842144-09-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 4-chloro-2-[4-[[1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl- (CA INDEX NAME)




RN 842144-10-9 CAPLUS


CN Carbamic acid, [1-[[4-chloro-2-[4-[[1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842144-11-0 CAPLUS
 CN Carbamic acid, [1-[[4-(3-chlorophenyl)-2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842145-08-8 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl-, ethyl ester (CA INDEX NAME)




RN 842145-09-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-phenyl- (CA INDEX
 NAME)



RN 842145-10-2 CAPLUS
 CN Carbamic acid, [1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(1-methylethyl)-4-
 phenyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842145-70-4 CAPLUS
 CN Carbamic acid, [1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-4-phenyl-1H-
 imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]methyl-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842145-76-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-, ethyl ester (CA INDEX
NAME)




RN 842145-77-1 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]]-1-ethyl-4-
phenyl-, ethyl ester (CA INDEX NAME)




RN 842145-78-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]]-1-ethyl-4-
phenyl- (CA INDEX NAME)




RN 842145-79-3 CAPLUS

CN Carbamic acid, [4-(7-amino-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842145-80-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]amino]carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 842145-83-9 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-4-phenyl-3H-imidazo[4,5-c]pyridin-7-yl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester
(CA INDEX NAME)




RN 842145-88-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanol,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl- (CA INDEX NAME)




RN 842145-89-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(chloromethyl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-03-6 CAPLUS

CN Carbamic acid, [4-(4-chloro-1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842146-04-7 CAPLUS

CN Carbamic acid, [4-(1-ethyl-7-hydroxy-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842146-05-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-phenyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-06-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842146-81-0 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-7-yl, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl- (CA INDEX NAME)




RN 842146-82-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(2-oxiranylmethoxy)-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842146-85-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(2-bromoethoxy)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 842148-12-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-chloro-2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842148-13-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842148-16-7 CAPLUS

CN Imidodicarbonic acid, [4-[7-[[[(1,1-dimethylethoxy)carbonyl]oxy]-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-yl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 842148-17-8 CAPLUS


CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(2-phenylethynyl)- (CA INDEX NAME)



RN 842148-18-9 CAPLUS


CN Carbamic acid, [4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-7-yl]oxy]butyl]-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842148-25-8 CAPLUS

CN Carbamic acid, [1-[[2-[4-[[(1,1-dimethylethoxy) carbonyl] amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-4-(phenylethynyl)-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 842148-61-2 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-phenyl-, ethyl ester (CA INDEX NAME)



RN 842148-62-3 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-phenyl- (CA INDEX NAME)

INDEX NAME)




RN 842148-63-4 CAPLUS

CN Carbamic acid, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842148-64-5 CAPLUS

CN Carbamic acid, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(3,3-dimethylbutyl)-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl](3-bromopropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842148-65-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridin-7-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N-(3-bromopropyl)-1-(3,3-dimethylbutyl)-4-phenyl- (CA INDEX NAME)




RN 842148-79-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-, ethyl ester
 (CA INDEX NAME)




RN 842148-80-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl- (CA INDEX
 NAME)




RN 842148-81-6 CAPLUS
 CN Carbamic acid, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842148-82-7 CAPLUS
 CN Carbamic acid, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-chlorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][3-[[1,1-dimethylethoxy)carbonyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 842148-91-8 CAPLUS
 CN Carbamic acid, [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842149-01-3 CAPLUS
 CN Carbamic acid, [3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-[3-[[[(4-chlorophenyl)amino]carbonyl]amino]phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 842149-46-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl- (CA INDEX NAME)



IT 842144-99-4, 4-[7-[(3-Amino-1-pyrrolidinyl)carbonyl]-4-[5-chloro-2-(methoxy)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine 842147-30-2 842147-45-9, 1,1-Dimethylethyl [4-[1-ethyl-7-hydroxy-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-yl]carbamate 842148-09-8, 1,1-Dimethylethyl [3-[[4-chloro-2-[4-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]carbamate 842149-07-9, 1,1-Dimethylethyl 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-1-piperidinecarboxylate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as inhibitors of Akt activity for treating cancer and arthritis)


RN 842144-99-4 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-4-(5-chloro-2-methoxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](3-amino-1-pyrrolidinyl)- (CA INDEX NAME)




RN 842147-30-2 CAPLUS

CN Carbamic acid, N-[4-[4-(3-chlorophenyl)-1-ethyl-7-hydroxy-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 842147-45-9 CAPLUS

CN Carbamic acid, [4-[1-ethyl-7-hydroxy-4-(1H-pyrrol-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 842148-09-8 CAPLUS

CN Carbamic acid, [3-[[4-chloro-2-[4-[[1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 842149-07-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 959928-52-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of 1H-imidazo[4,5-a]pyridin-2-yl derivs. as inhibitors of Akt activity for treating cancer and arthritis)


RN 959928-52-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 607373-68-2


CMF C15 H19 N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT:



3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:777793 CAPLUS
DOCUMENT NUMBER: 139:292251
TITLE: Preparation of imidazopyridines as kinase inhibitors
INVENTOR(S): Bailey, Nicholas; Bamford, Mark James; Garland, Stephen; Goodman, Krista B.; Haifeng, Cui; Hilfiker, Mark A.; Lee, Dennis; Panchal, Terence Aaron; Stavenger, Robert A.; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003080610	A1	20031002	WO 2003-GB1205	20030321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003215753	A1	20031008	AU 2003-215753	20030321
EP 1490367	A1	20041229	EP 2003-744904	20030321
EP 1490367	B1	20080723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005526802	T	20050908	JP 2003-578364	20030321
AT 402174	T	20080815	AT 2003-744904	20030321
ES 2309330	T3	20081216	ES 2003-744904	20030321
US 20050197328	A1	20050908	US 2004-508760	20040922
US 7348339	B2	20080325		
PRIORITY APPLN. INFO.:			GB 2002-6860	A 20020322
			WO 2003-GB1205	W 20030321
OTHER SOURCE(S):	MARPAT 139:292251			
GI				



AB This patent concerns imidazopyridines (shown as I; variables defined below; e.g. 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-ylamine) and physiol. acceptable salts and or N-oxides thereof, processes for their preparation, pharmaceutical compns. containing them and their use in medicine.

For


I, X1 is N or CR3; X2 is N or CR4; X3 is N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X2, X3 and X4 = N; R1 is a 5-, or 6-membered heterocyclic group II, III, IV or V wherein X5 is a N or CR7; and X6 is a O, S or NR8; X7 and X8, which may be the same or different is a N or CR9; X9 is a O, S or NR8 and X10 is N or CR10; X11, X12 and X13 may be the same or different and = N or R11; addnl. details are given in the claims. For Rho-kinase (ROCK) activity the compds. I of the examples have a pIC50 of 9 to 5.2; for mitogen and stress activated protein kinase-1 (Msk-1) activity the compds. I of the examples have a pIC50 value of 9.28-5.15. The compds. I are essentially non-toxic at therapeutically useful doses; thus no adverse effects were observed when compds. of the invention were administered to rats at a dose of 100 mg/kg. Although no specific therapeutic applications are claimed, because of the inhibition by I of Msk-1, I should be useful for the treatment or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events or inflammatory conditions, e.g. cerebral stroke; also, because of the inhibition by I of Rho kinases, I should be useful for the treatment or prophylaxis of cardiovascular and neuroinflammatory diseases. More than 300 example preps. and/or characterization data for I are included. For example, [4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-yl]amine was prepared in 4 steps (88, 94, 37 and 43 % yields, resp.) starting from 4-methoxy-3-nitropyridine hydrochloride and ethylamine and involving intermediates ethyl(3-nitropyridin-4-yl)amine, N'-ethylpyridine-3,4-diamine and (1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile.

IT 607369-14-2P, [4-[1-(2-Dimethylamino-1-methylethyl)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]amine 607369-34-6P, [4-[1-(Piperidin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]amine
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)


(drug candidate, chromatog. resolution; preparation of imidazopyridines as kinase inhibitors)

RN 607369-14-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-1-ethanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-N,N,β-trimethyl- (CA INDEX NAME)




RN 607369-34-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-piperidiny)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




IT 607369-25-5P, [(+)-4-[1-(2-Dimethylamino-1-methylethyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-27-7P, [(-)-4-[1-(2-Dimethylamino-1-methylethyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-37-9P, [(+)-4-[1-(Piperidin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-38-0P, [(-)-4-[1-(Piperidin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of imidazopyridines as kinase inhibitors)
 RN 607369-25-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-ethanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-N,N,β-trimethyl-, (+)- (CA INDEX NAME)

Rotation (+).




RN 607369-27-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-ethanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-N,N, β -trimethyl-, (-)- (CA INDEX
 NAME)

Rotation (-).




RN 607369-37-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-piperidiny1)-1H-imidazo[4,5-c]pyridin-2-
 yl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 607369-38-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-piperidiny1)-1H-imidazo[4,5-c]pyridin-2-
 yl]-, (-)- (CA INDEX NAME)

Rotation (-).



IT 607369-19-7P, [4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
 yl]butyl]carbamic acid tert-butyl ester 607369-40-4P,
 [4-[1-(4-Methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine


607369-43-7P, [4-[1-(4-Aminophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-45-9P, [4-[1-(3-Methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-53-9P, [4-[1-(3-Bromophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-54-0P, 4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenol 607369-73-3P, 4-[1-[4-[(Methylsulfonyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607369-75-5P, 4-[1-[4-[(Phenylsulfonyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607369-77-7P, [2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]carbamic acid tert-butyl ester trifluoroacetate 607369-88-0P, [4-[1-[4-(2-Aminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine hydrochloride 607370-41-2P, N-[4-[2-(4-Aminofurazan-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-N',N'-dimethylethane-1,2-diamine 607370-88-7P, [4-[1-(1,2,3,4-Tetrahydroisoquinolin-7-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-99-0P, [4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607371-24-4P, [4-[1-Ethyl-7-[4-(methylsulfonyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-97-1P, 4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzaldehyde 607372-01-0P, 4-[4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzyl]amino]piperidine-1-carboxylic acid tert-butyl ester 607372-09-8P, 4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzoic acid 607372-10-1P, 3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzoic acid 607372-27-0P, [4-(1-Cyclopropyl-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607372-33-8P, [4-(7-Bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607372-41-8P, [4-[7-Bromo-1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-42-9P, 4-[2-(4-Aminofurazan-3-yl)-7-bromoimidazo[4,5-c]pyridin-1-yl]phenol 607372-46-3P, [[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](piperidin-4-yl)amine 607372-47-4P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxaldehyde 607372-99-6P, [[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amine 607373-25-1P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-(piperazin-1-yl)methanone dihydrochloride 607373-28-4P, [2-[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]ethyl]carbamic acid tert-butyl ester 607373-29-5P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-(piperazin-1-yl)methanone 607373-40-0P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(piperidin-4-yl)amide dihydrochloride 607373-60-4P, [4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]carbamic acid tert-butyl ester 607373-65-9P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-ol 607373-72-8P, [4-(1-Ethyl-5-oxo-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607373-73-9P, [4-(4-Chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607373-76-2P, [4-(7-Bromo-1-ethyl-4-methyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607374-02-7P, [4-(1-Cyclopropyl-6-methyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of imidazopyridines as kinase inhibitors)


RN 607369-19-7 CAPLUS

CN Carbamic acid, [4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607369-40-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-43-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-45-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-53-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-bromophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-54-0 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)



RN 607369-73-3 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(methylthio)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



MeS-CH₂-O

RN 607369-75-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(phenylthio)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



PhS-CH₂-O


RN 607369-77-7 CAPLUS

CN Carbamic acid, [2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 607369-76-6

CMF C21 H23 N7 O4




t-BuO-C(=O)-NH-CH₂-CH₂-O

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 607369-88-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(2-aminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl



RN 607370-41-2 CAPLUS

CN 1,2-Ethanediamine, N2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 607370-88-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-99-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
(CA INDEX NAME)




RN 607371-24-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-(methylthio)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-
(CA INDEX NAME)




RN 607371-97-1 CAPLUS

CN Benzaldehyde, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-
(CA INDEX NAME)




RN 607372-01-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]methyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 607372-09-8 CAPLUS


CN Benzoic acid, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607372-10-1 CAPLUS
 CN Benzoic acid, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607372-27-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607372-33-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607372-41-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-1-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-42-9 CAPLUS
 CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)




RN 607372-46-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-4-piperidinyl- (CA INDEX NAME)




RN 607372-47-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxaldehyde,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA INDEX NAME)



RN 607372-99-6 CAPLUS
 CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-8-methyl- (CA INDEX NAME)




RN 607373-25-1 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-piperazinyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 607373-28-4 CAPLUS
 CN Carbamic acid, [2-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607373-29-5 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-piperazinyl- (CA INDEX NAME)



RN 607373-40-0 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-4-piperidinyl-, hydrochloride
(1:2) (CA INDEX NAME)




● 2 HCl

RN 607373-60-4 CAPLUS


CN Carbamic acid, [4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607373-65-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridin-7-ol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-
 (CA INDEX NAME)




RN 607373-72-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-5-oxido-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)




RN 607373-73-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(4-chloro-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)



RN 607373-76-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-ethyl-4-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)



RN 607374-02-7 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-6-methyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



IT 607368-87-6P, [4-(1-Ethyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607368-93-4P, [4-(1-Cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607368-95-6P, [4-(1-Methyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607368-97-8P, [4-(1-Cyclohexyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607368-99-0P, [4-[1-(Cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-01-7P, [4-[1-(Cyclohexylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-03-9P, [4-(1-Cyclobutyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607369-05-1P, [4-[1-(2-Ethylbutyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-07-3P, [4-(1-Isopropyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607369-09-5P, [4-(1-sec-Butyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607369-11-9P, [4-(1-Cyclopentyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607369-13-1P, [4-(1-Cycloheptyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607369-16-4P, 4-[1-(Piperidin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607369-17-5P, [4-[1-(4-Diethylamino-1-methylbutyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-21-1P, [4-[1-(3-Dimethylaminopropyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-23-3P, [4-[1-[2-(4-Methylpiperazin-1-yl)ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-29-9P, [4-[1-(4-Aminobutyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-31-3P, [4-[1-(Pyrrolidin-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-32-4P, [4-[1-(5-Aminopentyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-33-5P, [4-[1-(3-Aminopropyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-36-8P, [4-[1-[2-(Piperazin-1-yl)ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-39-1P, [4-[1-[(Piperidin-4-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-41-5P, [4-(1-Phenyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607369-46-0P, [4-[1-(2-Methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-47-1P, [4-[1-(2-Ethylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-49-3P, [4-[1-(3-Chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-55-1P, 3-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenol 607369-56-2P, [4-[1-[3-[(Pyrrolidin-1-yl)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607369-59-5P, [4-[1-[4-(2-Dimethylaminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine hydrochloride 607369-62-0P, 2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]acetamide

trifluoroacetate 607369-64-2P,
2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]-N,N-
dimethylacetamide 607369-66-4P,
2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]ethanol
607369-68-6P, 3-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenoxy]propionitrile 607369-70-0P,
3-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]propan-1-
ol 607369-72-2P, 2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-
c]pyridin-1-yl]phenoxy]-N-methylacetamide 607369-80-2P,
[4-[1-[4-(2-Methylaminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607369-82-4P,
[4-[1-[4-[(Benzenesulfinyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607369-84-6P,
[4-[1-[4-[(Benzenesulfonyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607369-86-8P,
[4-[1-[4-[(Methanesulfinyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607369-90-4P 607369-92-6P,
N-[2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenoxy]ethyl]acetamide 607369-94-8P,
N-[2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenoxy]ethyl]isonicotinamide 607369-96-0P,
[2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenoxy]ethyl]urea 607369-97-1P,
2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenoxy]propionamide 607370-01-4P,
2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]-2-
methylpropionamide 607370-07-0P,
N-[2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenoxy]ethyl]methanesulfonamide trifluoroacetate 607370-09-2P
, [4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenoxy]acetonitrile 607370-11-6P,
[4-[1-[4-(2-Dimethylamino-1-methylethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-
2-yl]furazan-3-yl]amine 607370-12-7P,
[4-[1-[4-[[[(S)-1-Methylpyrrolidin-2-yl)methyl]oxy]phenyl]-1H-imidazo[4,5-
c]pyridin-2-yl]furazan-3-yl]amine 607370-16-1P,
4-[1-[4-[2-[(Benzyl)(methyl)amino]ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-
2-yl]furazan-3-yl]amine 607370-18-3P,
[4-[1-[4-(2-Diethylaminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-21-8P,
[4-[1-[4-(3-Dimethylaminopropoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-23-0P,
[4-[1-[4-(2-Diisopropylaminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-25-2P,
[4-[1-[4-[2-(Morpholin-4-yl)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-27-4P,
4-[1-[4-[(1-Methylpiperidin-4-yl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-28-5P,
[4-[1-[4-[2-(Piperidin-1-yl)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-30-9P,
4-[1-[4-[[[(S)-Pyrrolidin-2-yl)methyl]oxy]phenyl]-1H-imidazo[4,5-c]pyridin-
2-yl]furazan-3-yl]amine 607370-33-2P,
[4-[1-[3-(2-Dimethylaminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-35-4P,
[4-[1-[3-(3-Dimethylaminopropoxy)phenyl]1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607370-37-6P,
[4-[1-[4-(3-Methylbutoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
yl]amine 607370-39-8P, 4-[1-[3-[(1-Methylpiperidin-4-
yl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine
607370-44-5P, 1-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-
yl]phenyl]-3-methylurea 607370-46-7P,
N-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenyl]-2-
(dimethylamino)acetamide 607370-48-9P,

[4-[1-(1H-Indazol-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-50-3P, [4-[1-(1H-Indazol-6-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-52-5P, [4-[1-[4-(3-Dimethylaminopropyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-54-7P, [4-[1-(4-Dimethylaminophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-55-8P, [4-[1-(Benzo-[1,3]dioxol-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-57-0P, [4-[1-(2-Methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-59-2P, 1-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenyl]ethanone oxime 607370-61-6P, [4-[1-(2,3,4,5-Tetrahydro-1H-benzo[c]azepin-8-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-62-7P, 7-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]-3,4-dihydro-2H-isoquinolin-1-one 607370-65-0P, 4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]-N-hydroxybenzamidine 607370-67-2P, N-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenyl]-N,N',N'-trimethylethane-1,2-diamine 607370-71-8P, N-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenyl]-N-(2-dimethylaminoethyl)-N',N'-dimethylethane-1,2-diamine 607370-79-6P, N-[2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]benzenesulfonamide trifluoroacetate 607370-81-0P, [4-[1-(4-Aminomethylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-83-2P, [4-[1-(3-Aminomethylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-85-4P, [4-[1-(1,2,3,4-Tetrahydroisoquinolin-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-91-2P, [4-[1-(2,3-Dihydro-1H-isoindol-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607370-94-5P, [4-[1-[3-(Pyrrolidin-2-yl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-05-1P, [4-(1-Ethyl-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-07-3P, [4-[1-Ethyl-7-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-09-5P, [4-[1-Ethyl-7-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-11-9P, [4-[7-(4-Aminomethylphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-14-2P, [4-[7-(3-Ethoxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-16-4P, [4-[1-Ethyl-7-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-18-6P, [4-[1-Ethyl-7-[4-(methanesulfonyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-20-0P, [4-[1-Ethyl-7-(4-trifluoromethylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-22-2P, [4-[7-(2,4-Difluorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-23-3P, [4-[1-Ethyl-7-(2-trifluoromethylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-26-6P, [4-[7-(2,6-Dimethylphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-28-8P, 5-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-2-fluorobenzaldehyde 607371-31-3P, [4-[7-(3-Aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-33-5P, 4-[1-Ethyl-7-(3-trifluoromethoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607371-35-7P, 1-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]ethanone 607371-36-8P, N-[4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]methanesulfonamide 607371-38-0P, [4-[1-[2-[3,5-Bis(trifluoromethyl)phenyl]ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-40-4P, 4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-2-fluorobenzaldehyde 607371-41-5P, [4-[1-Ethyl-7-[4-(methanesulfinyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-

yl]furazan-3-yl]amine 607371-43-7P,
5-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]thiophene-
2-carboxaldehyde 607371-44-8P,
[4-[7-(Benzo[b]thiophen-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607371-47-1P,
[4-[1-Ethyl-7-[4-(methyl)thiophen-2-yl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607371-49-3P,
[4-[1-Ethyl-7-(5-phenyl-thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607371-51-7P,
[4-[7-(Benzo[1,3]dioxol-5-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607371-53-9P,
[4-[1-Ethyl-7-(pyridin-4-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
yl]amine 607371-54-0P, [4-[1-Ethyl-7-(pyridin-3-yl)-1H-
imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-56-2P,
[4-[1-Ethyl-7-(furan-3-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
yl]amine 607371-58-4P, [4-[1-Ethyl-7-(thiophen-3-yl)-1H-
imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-59-5P,
[4-[1-Ethyl-7-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
yl]amine 607371-62-0P, [4-[1-Ethyl-7-(quinolin-8-yl)-1H-
imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607371-64-2P,
[4-[7-(3,5-Dimethylisoxazole-4-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607371-66-4P,
[4-[1-Ethyl-7-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-
yl]amine 607371-68-6P, [4-[1-Ethyl-7-(indol-5-yl)-1H-imidazo[4,5-
c]pyridin-2-yl]furazan-3-yl]amine 607371-70-0P,
3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-
yl]benzonitrile 607371-72-2P,
4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenol
607371-74-4P, N-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-
c]pyridin-7-yl]phenyl]acetamide 607371-75-5P,
4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-
yl]benzonitrile 607371-77-7P,
[4-[1-Ethyl-7-(3-trifluoromethylphenyl)-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607371-78-8P,
[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-
yl]phenyl]methanol 607371-79-9P,
3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N,N-
dimethylbenzamide 607371-82-4P,
[4-[1-Ethyl-7-[4-(5-methyl-[1,2,4]Oxadiazol-3-yl)phenyl]-1H-imidazo[4,5-
c]pyridin-2-yl]furazan-3-yl]amine 607371-86-8P,
4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzamide
607371-88-0P, 3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-
c]pyridin-7-yl]benzamide 607371-90-4P,
[4-[7-[4-(2-Aminoethyl)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607371-93-7P,
[4-[7-(3-Aminomethylphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-
3-yl]amine 607371-95-9P,
[4-(1-Ethyl-7-o-tolyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine
607371-99-3P, [4-[1-Ethyl-7-[4-[(morpholin-4-yl)methyl]phenyl]-1H-
imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-00-9P,
4-[1-Ethyl-7-[4-[(ethylamino)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607372-02-1P,
[4-[1-Ethyl-7-[4-[(pyrrolidin-1-yl)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-
2-yl]furazan-3-yl]amine 607372-03-2P,
4-[1-Ethyl-7-[3-[(ethylamino)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607372-04-3P,
4-[7-[3-[(Dimethylamino)methyl]phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-
yl]furazan-3-yl]amine 607372-05-4P,
[4-[1-Ethyl-7-[3-[(morpholin-4-yl)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-
2-yl]furazan-3-yl]amine 607372-06-5P,
[4-[1-Ethyl-7-[3-[(pyrrolidin-1-yl)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-
2-yl]furazan-3-yl]amine 607372-07-6P,

[4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzyl](piperidin-4-yl)amine 607372-08-7P,
[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzyl](piperidin-4-yl)amine 607372-11-2P,
1-[4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-1-morpholin-4-ylmethanone 607372-12-3P,
4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-phenethylbenzamide 607372-13-4P,
1-[4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-1-(pyrrolidin-1-yl)methanone 607372-14-5P,
4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-benzylbenzamide 607372-15-6P,
(2S)-1-[[4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]methanoyl]pyrrolidine-2-carboxylic acid methyl ester 607372-16-7P,
1-[4-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-1-(4-methylpiperazin-1-yl)methanone 607372-17-8P,
3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-phenethylbenzamide 607372-18-9P,
3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-benzylbenzamide 607372-19-0P,
(2S)-1-[[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]methanoyl]pyrrolidine-2-carboxylic acid methyl ester 607372-20-3P,
1-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-1-(4-methylpiperazin-1-yl)methanone 607372-21-4P,
1-[3-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-1-(morpholin-4-yl)methanone 607372-22-5P,
N-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenylamine 607372-23-6P,
[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl](pyridin-3-yl)amine 607372-24-7P,
[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][4-(morpholin-4-yl)phenyl]amine 607372-25-8P,
[4-[1-Ethyl-7-(4-methoxyphenylsulfanyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-26-9P,
[4-[1-Ethyl-7-(phenylsulfanyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-31-6P,
[4-[7-(4-Aminomethylphenyl)-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-32-7P,
[4-[1-Cyclopropyl-7-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-34-9P,
[4-[1-Phenyl-7-(thiophen-2-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-35-0P,
[4-(1,7-Diphenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-36-1P,
4-[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]phenol 607372-37-2P,
[4-[7-(3,5-Dimethylisoxazol-4-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-38-3P,
4-[7-[4-[(Ethylamino)methyl]phenyl]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-40-7P,
2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid 607372-43-0P,
[4-[1-[4-(2-Dimethylaminoethoxy)phenyl]-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-45-2P,
[4-[1-[4-(2-Dimethylaminoethoxy)phenyl]-7-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-49-6P,
1-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]piperidin-4-ylamine 607372-50-9P,
[4-[1-Ethyl-7-[(piperazin-1-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-51-0P,
N-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-N-piperidin-4-ylacetamide 607372-53-2P,
4-[7-[(4-Bromobenzylamino)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-54-3P,
4-[1-Ethyl-7-[(3-methoxy-benzylamino)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-55-4P,
[4-[1-Ethyl-7-[(morpholin-4-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-

yl]furazan-3-yl]amine 607372-56-5P,
 [4-[1-Ethyl-7-[(piperidin-1-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-57-6P,
 4-[1-Ethyl-7-[(4-ethylpiperazin-1-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-58-7P,
 4-[1-Ethyl-7-[[4-(4-fluorophenyl)piperazin-1-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-59-8P,
 4-[1-Ethyl-7-[[[3-(pyrrolidin-1-yl)propyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-60-1P,
 [[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](methyl)(1-methylpiperidin-4-yl)amine 607372-61-2P,
 4-[1-Ethyl-7-[[[3-(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-62-3P,
 2-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]piperazin-1-yl]-1-(pyrrolidin-1-yl)ethanone 607372-64-5P
 , 4-[1-Ethyl-7-[[[2-(pyrrolidin-1-yl)ethyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-65-6P,
 4-[1-Ethyl-7-[(4-methylpiperazin-1-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-66-7P,
 4-[1-Ethyl-7-[[[3-(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-67-8P,
 4-[7-[[[3-(3-Dimethylaminopyrrolidin-1-yl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-68-9P
 , [[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](1-methylpiperidin-4-yl)amine 607372-69-0P,
 4-[1-Ethyl-7-[[[3-(morpholin-4-yl)methyl]pyrrolidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-70-3P,
 4-[1-Ethyl-7-[[[3-(piperidin-1-yl)propyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-71-4P,
 4-[1-Ethyl-7-[[[3-(morpholin-4-yl)propyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-72-5P,
 4-[1-Ethyl-7-[[[3-(4-methylpiperazin-1-yl)propyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-73-6P,
 4-[1-Ethyl-7-[[[3-(piperidin-1-yl)methyl]pyrrolidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-74-7P,
 4-[7-[[[3-(3R*,5S*)-3,5-Dimethylpiperazin-1-yl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-75-8P,
 4-[1-Ethyl-7-[[[4-(pyrrolidin-1-yl)piperidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-76-9P,
 1-[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]piperazin-1-yl]ethanone 607372-77-0P,
 4-[7-[[[3-(3-Dimethylaminopyrrolidin-1-yl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-78-1P,
 [[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](1-isopropylpiperidin-4-yl)amine 607372-79-2P,
 [(S)-1-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]pyrrolidin-2-yl]methanol 607372-80-5P,
 3-[[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]propan-1-ol 607372-81-6P,
 4-[1-Ethyl-7-[[[3-(pyrrolidin-3-yl)amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-82-7P,
 [4-[1-Ethyl-7-[[[3-(pyrrolidin-2-yl)methyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-83-8P,
 [4-[7-[[[4-(4-Aminomethylcyclohexyl)methyl]amino]methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-84-9P,
 4-[1-Ethyl-7-[[[2-(piperazin-1-yl)ethyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-85-0P,
 4-[7-[[[3-(3-Aminopyrrolidin-1-yl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-86-1P,
 4-[7-[[[3-(3-Aminopyrrolidin-1-yl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-87-2P,
 4-[1-Ethyl-7-[[[3-(pyrrolidin-2-yl)methyl]amino]methyl]-1H-imidazo[4,5-

c]pyridin-2-yl]furazan-3-ylamine 607372-88-3P,
[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](methyl)(piperidin-4-yl)amine 607372-89-4P,
[1-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]piperidin-4-yl]methylaniline 607372-90-7P,
[4-[7-([1,4]Diazepan-1-yl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-91-8P,
4-[1-Ethyl-7-[[[(piperidin-4-yl)methyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-92-9P,
N-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-trans-cyclohexane-1,4-diamine 607372-94-1P,
[4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]piperidin-1-yl]methylaniline 607372-97-4P,
[1-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]piperidin-4-yl](cyclopropyl)amine 607372-98-5P,
[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amine dihydrochloride 607373-00-2P,
4-[1-Ethyl-7-[[[3-(piperazin-1-yl)propyl]amino]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-04-6P,
[4-[1-Ethyl-7-[(R)-2-[(morpholin-4-yl)methyl]pyrrolidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607373-06-8P,
4-[1-Ethyl-7-[(R)-2-[(piperidin-1-yl)methyl]pyrrolidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-08-0P,
[4-[1-Ethyl-7-[(R)-2-[(piperazin-1-yl)methyl]pyrrolidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607373-11-5P,
4-[1-Ethyl-7-[4-[(phenylamino)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-12-6P,
[4-[1-Ethyl-7-[4-fluoro-3-[(pyrrolidin-1-yl)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607373-13-7P,
[4-[1-Ethyl-7-[3-fluoro-4-[(pyrrolidin-1-yl)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607373-14-8P,
4-[1-Ethyl-7-[4-[(ethylamino)methyl]-3-fluorophenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-15-9P,
[[2-(4-Aminofurazan-3-yl)-1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-7-yl]methyl](piperidin-4-yl)amine 607373-21-7P,
[[2-(4-Aminofurazan-3-yl)-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](piperidin-4-yl)amine dihydrochloride 607373-22-8P,
[4-[1-Cyclopropyl-7-[(piperazin-1-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607373-23-9P,
[[2-(4-Aminofurazan-3-yl)-1-methyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl](piperidin-4-yl)amine 607373-30-8P,
1-[4-(2-Aminoethyl)piperazin-1-yl]-1-[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanone Dihydrochloride 607373-31-9P,
1-[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]-2-methylaminoethanone 607373-33-1P,
1-[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]-2-aminoethanone 607373-34-2P,
1-[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]-3-amino-1-propanone 607373-35-3P,
(2S)-1-[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]-2-amino-1-propanone 607373-36-4P,
(2R)-1-[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]-2-amino-1-propanone 607373-37-5P,
[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]((2S)-pyrrolidin-2-yl)methanone 607373-38-6P,
2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-[(piperidin-4-yl)methyl]amide dihydrochloride 607373-39-7P,
2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(piperidin-3-yl)amide dihydrochloride 607373-41-1P,
2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(3-methylaminopropyl)amide dihydrochloride 607373-42-2P,


2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(4-aminobutyl)amide dihydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyridines as kinase inhibitors)


RN 607368-87-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607368-93-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607368-95-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607368-97-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclohexyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)





RN 607368-99-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-01-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(cyclohexylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-03-9 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclobutyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607369-05-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(2-ethylbutyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-07-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-09-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1-methylpropyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-11-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopentyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607369-13-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-cycloheptyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 (CA INDEX NAME)




RN 607369-16-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-piperidiny1)-1H-imidazo[4,5-c]pyridin-2-yl]-
 (CA INDEX NAME)




RN 607369-17-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-butanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-N,N-diethyl-δ-methyl- (CA INDEX
 NAME)




RN 607369-21-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-propanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 607369-23-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[2-(4-methyl-1-piperazinyl)ethyl]-1H-
 imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-29-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-butanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-
 (CA INDEX NAME)




RN 607369-31-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-pyrrolidinyl)-1H-imidazo[4,5-c]pyridin-2-
 yl]- (CA INDEX NAME)




RN 607369-32-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-pentanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-
 (CA INDEX NAME)



RN 607369-33-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-1-propanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-
 (CA INDEX NAME)





RN 607369-36-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[2-(1-piperazinyl)ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-39-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(4-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-41-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607369-46-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-47-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(2-ethylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-49-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(3-chlorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607369-55-1 CAPLUS

CN Phenol, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)




RN 607369-56-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-(1-pyrrolidinylmethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607369-59-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 607369-62-0 CAPLUS
 CN Acetamide, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 607369-61-9
 CMF C16 H13 N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2





RN 607369-64-2 CAPLUS

CN Acetamide, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-N,N-dimethyl- (CA INDEX NAME)





RN 607369-66-4 CAPLUS

CN Ethanol, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]- (CA INDEX NAME)





RN 607369-68-6 CAPLUS

CN Propanenitrile, 3-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]- (CA INDEX NAME)




RN 607369-70-0 CAPLUS

CN 1-Propanol, 3-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]- (CA INDEX NAME)




RN 607369-72-2 CAPLUS


CN Acetamide, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-N-methyl- (CA INDEX NAME)




RN 607369-80-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(methylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607369-82-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(phenylsulfinyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607369-84-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(phenylsulfonyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607369-86-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(methylsulfinyl)methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607369-90-4 CAPLUS
 CN 5-Isoxazolecarboxamide, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


CRN 607369-89-1
 CMF C20 H16 N8 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2





RN 607369-92-6 CAPLUS

CN Acetamide, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 607369-94-8 CAPLUS

CN 4-Pyridinecarboxamide, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 607369-96-0 CAPLUS

CN Urea, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 607369-97-1 CAPLUS


CN Propanamide, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]- (CA INDEX NAME)



RN 607370-01-4 CAPLUS

CN Propanamide, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-

c[pyridin-1-yl]phenoxy]-2-methyl- (CA INDEX NAME)




RN 607370-07-0 CAPLUS

CN Methanesulfonamide, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 607370-06-9


CMF C17 H17 N7 O4 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 607370-09-2 CAPLUS


CN Acetonitrile, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-

c[pyridin-1-yl]phenoxy]- (CA INDEX NAME)



RN 607370-11-6 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(dimethylamino)-1-methylethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607370-12-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607370-16-1 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-

[methyl(phenylmethyl)amino]ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-
(CA INDEX NAME)




RN 607370-18-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(diethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607370-21-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[3-(dimethylamino)propoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607370-23-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607370-25-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607370-27-4 CAPLUS



CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607370-28-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(1-piperidinyl)ethoxy]phenyl]-1H-


imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607370-30-9 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[(2S)-2-pyrrolidinylmethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607370-33-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-35-4 CAPLUS



CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-[3-(dimethylamino)propoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-37-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(3-methylbutoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-39-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-[(1-methyl-4-piperidinyl)oxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607370-44-5 CAPLUS
 CN Urea, N-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-N'-methyl- (CA INDEX NAME)



RN 607370-46-7 CAPLUS
 CN Acetamide, N-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-2-(dimethylamino)- (CA INDEX NAME)




RN 607370-48-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-50-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1H-indazol-6-yl)-1H-imidazo[4,5-c]pyridin-2-

yl]- (CA INDEX NAME)



RN 607370-52-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[3-(dimethylamino)propyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Me2N- (CH2)3



RN 607370-54-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607370-55-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-57-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-59-2 CAPLUS

CN Ethanone, 1-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-, oxime (CA INDEX NAME)





RN 607370-61-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-62-7 CAPLUS

CN 1(2H)-Isoquinolinone, 7-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]-3,4-dihydro- (CA INDEX NAME)




RN 607370-65-0 CAPLUS

CN Benzenecarboximidamide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]-N-hydroxy- (CA INDEX NAME)




RN 607370-67-2 CAPLUS

CN 1,2-Ethanediamine, N1-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-N1,N2,N2-trimethyl- (CA INDEX NAME)



RN 607370-71-8 CAPLUS

CN 1,2-Ethanediamine, N1-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-N1-[2-(dimethylamino)ethyl]-N2,N2-dimethyl- (CA INDEX NAME)




RN 607370-79-6 CAPLUS

CN Benzenesulfonamide, N-[2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]ethyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 607370-78-5


CMF C22 H19 N7 O4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 607370-81-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(aminomethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-83-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-(aminomethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607370-85-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(1,2,3,4-tetrahydro-5-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)





RN 607370-91-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-(2,3-dihydro-1H-isoindol-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607370-94-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-[3-(2-pyrrolidinyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-05-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 607371-07-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-09-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(2-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-11-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[4-(aminomethyl)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-14-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-ethoxyphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-16-4 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(2-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-18-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-(methanesulfonyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607371-20-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-22-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-(2,4-difluorophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-23-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[2-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-26-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(2,6-dimethylphenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-28-8 CAPLUS

CN Benzaldehyde, 5-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-2-fluoro- (CA INDEX NAME)




RN 607371-31-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3-aminophenyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-33-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(trifluoromethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-35-7 CAPLUS


CN Ethanone, 1-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]- (CA INDEX NAME)




RN 607371-36-8 CAPLUS
 CN Methanesulfonamide, N-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]- (CA INDEX NAME)



RN 607371-38-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-40-4 CAPLUS
 CN Benzaldehyde, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-2-fluoro- (CA INDEX NAME)




RN 607371-41-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-(methanesulfinyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-43-7 CAPLUS

CN 2-Thiophenecarboxaldehyde, 5-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607371-44-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-benzo[b]thien-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607371-47-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-methyl-2-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-49-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(5-phenyl-2-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-51-7 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-(1,3-benzodioxol-5-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-53-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-pyridinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-54-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(3-pyridinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-56-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(3-furanyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-58-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(3-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607371-59-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-62-0 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(8-quinolinyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-64-2 CAPLUS

1,2,5-Oxadiazol-3-amine, 4-[7-(3,5-dimethyl-4-isoxazolyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-66-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-68-6 CAPLUS

1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1H-indol-5-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-70-0 CAPLUS

CN Benzonitrile, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607371-72-2 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607371-74-4 CAPLUS


CN Acetamide, N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]- (CA INDEX NAME)




RN 607371-75-5 CAPLUS
 CN Benzonitrile, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)



RN 607371-77-7 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-78-8 CAPLUS
 CN Benzenemethanol, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607371-79-9 CAPLUS

CN Benzamide, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 607371-82-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-86-8 CAPLUS


CN Benzamide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607371-88-0 CAPLUS
 CN Benzamide, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)



RN 607371-90-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-[4-(2-aminoethyl)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-93-7 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-(aminomethyl)phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-95-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(2-methylphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607371-99-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-(4-morpholinylmethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-00-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-[(ethylamino)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-02-1 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-(1-pyrrolidinylmethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-03-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-[(ethylamino)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-04-3 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[3-[(dimethylamino)methyl]phenyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-05-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(4-morpholinylmethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607372-06-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-(1-pyrrolidinylmethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-07-6 CAPLUS
 CN 4-Piperidinamine, N-[[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]methyl]- (CA INDEX NAME)




RN 607372-08-7 CAPLUS

CN 4-Piperidinamine, N-[[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]methyl]- (CA INDEX NAME)




RN 607372-11-2 CAPLUS

CN Methanone, [4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 607372-12-3 CAPLUS

CN Benzamide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-(2-phenylethyl)- (CA INDEX NAME)




RN 607372-13-4 CAPLUS

CN Methanone, [4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 607372-14-5 CAPLUS


CN Benzamide, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 607372-15-6 CAPLUS


CN L-Proline, 1-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 607372-16-7 CAPLUS

CN Methanone, [4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 607372-17-8 CAPLUS

CN Benzamide, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-(2-phenylethyl)- (CA INDEX NAME)



RN 607372-18-9 CAPLUS


CN Benzamide, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 607372-19-0 CAPLUS


CN L-Proline, 1-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 607372-20-3 CAPLUS

CN Methanone, [3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 607372-21-4 CAPLUS

CN Methanone, [3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 607372-22-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-7-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-phenyl- (CA INDEX NAME)




RN 607372-23-6 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-7-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-pyridinyl- (CA INDEX NAME)




RN 607372-24-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-7-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 607372-25-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-methoxyphenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-26-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(phenylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-31-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[4-(aminomethyl)phenyl]-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-32-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-cyclopropyl-7-(2-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-34-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-phenyl-7-(2-thienyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-35-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(1,7-diphenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607372-36-1 CAPLUS

CN Phenol, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607372-37-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(3,5-dimethyl-4-isoxazolyl)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-38-3 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[4-[(ethylamino)methyl]phenyl]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-40-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl- (CA INDEX NAME)



RN 607372-43-0 CAPLUS



CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-7-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



Me₂N-CH₂-CH₂-O


RN 607372-45-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-7-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-49-6 CAPLUS

CN 4-Piperidinamine, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]- (CA INDEX NAME)




RN 607372-50-9 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1-piperazinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-51-0 CAPLUS

CN Acetamide, N-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-N-4-piperidinyl- (CA INDEX NAME)




RN 607372-53-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[(4-bromophenyl)methyl]-1-ethyl- (CA
INDEX NAME)




RN 607372-54-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[(3-methoxyphenyl)methyl]- (CA
INDEX NAME)




RN 607372-55-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-morpholinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-56-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(1-piperidinylmethyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-57-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-ethyl-1-piperazinyl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607372-58-7 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[4-(4-fluorophenyl)-1-piperazinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-59-8 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(1-pyrrolidinyl)propyl]-
 (CA INDEX NAME)



RN 607372-60-1 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-(1-methyl-4-
piperidinyl)- (CA INDEX NAME)



RN 607372-61-2 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[(2S)-2-(1-pyrrolidinylmethyl)-1-
pyrrolidinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607372-62-3 CAPLUS

CN Ethanone, 2-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-1-piperazinyl]-1-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 607372-64-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 607372-65-6 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(4-methyl-1-piperazinyl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607372-66-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[(2R)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607372-67-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[(3S)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607372-68-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,


2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(1-methyl-4-piperidiny)- (CA INDEX NAME)



RN 607372-69-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[(2S)-2-(4-morpholinylmethyl)-1-pyrrolidinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607372-70-3 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(1-piperidiny)propyl]- (CA INDEX NAME)



RN 607372-71-4 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-morpholinyl)propyl]- (CA
 INDEX NAME)




RN 607372-72-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(4-methyl-1-
 piperazinyl)propyl]- (CA INDEX NAME)



RN 607372-73-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[1-(2,5-dimethyl-1H-imidazo[4,5-c]pyridin-2-yl)methyl]piperidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607372-74-7 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[1-(2,5-dimethyl-1H-imidazo[4,5-c]pyridin-2-yl)methyl]piperidin-1-yl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 607372-75-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607372-76-9 CAPLUS


CN Ethanone, 1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-1-piperazinyl]- (CA INDEX NAME)



RN 607372-77-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[(3R)-3-(dimethylamino)-1-pyrrolidinyl]methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 607372-78-1 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[1-(1-methylethyl)-4-
piperidinyl]- (CA INDEX NAME)



RN 607372-79-2 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 607372-80-5 CAPLUS

CN 1-Propanol, 3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]- (CA INDEX NAME)



RN 607372-81-6 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-pyrrolidinyl- (CA INDEX NAME)



RN 607372-82-7 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[(2S)-2-pyrrolidinylmethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




RN 607372-83-8 CAPLUS

CN 1,4-Cyclohexanedimethanamine, N1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]- (CA INDEX NAME)



RN 607372-84-9 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 607372-85-0 CAPLUS

1,2,5-Oxadiazol-3-amine, 4-[7-[(3R)-3-amino-1-pyrrolidinyl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607372-86-1 CAPLUS


1,2,5-Oxadiazol-3-amine, 4-[7-[[(3S)-3-amino-1-pyrrolidinyl]methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607372-87-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(2-pyrrolidinylmethyl)- (CA
INDEX NAME)




RN 607372-88-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl-N-4-piperidinyl- (CA
INDEX NAME)




RN 607372-89-4 CAPLUS

CN 4-Piperidinamine, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-N-methyl- (CA INDEX NAME)




RN 607372-90-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607372-91-8 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(4-piperidinylmethyl)- (CA
INDEX NAME)



RN 607372-92-9 CAPLUS


CN 1,4-Cyclohexanediamine, N1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-
imidazo[4,5-c]pyridin-7-yl]methyl]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 607372-94-1 CAPLUS

CN 1-Piperidinamine, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-N-methyl- (CA INDEX NAME)




RN 607372-97-4 CAPLUS

CN 4-Piperidinamine, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-N-cyclopropyl- (CA INDEX NAME)



RN 607372-98-5 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-amine, N-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]-8-methyl-, hydrochloride (1:2)
(CA INDEX NAME)



● 2 HCl

RN 607373-00-2 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(1-piperazinyl)propyl]- (CA
INDEX NAME)



RN 607373-04-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[[(2R)-2-(4-morpholinylmethyl)-1-pyrrolidinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607373-06-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[[(2R)-2-(1-piperidinylmethyl)-1-pyrrolidinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 607373-08-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[[[(2R)-2-(1-piperazinylmethyl)-1-pyrrolidinyl]methyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607373-11-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-[(phenylamino)methyl]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-12-6 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-fluoro-3-(1-pyrrolidinylmethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-13-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[3-fluoro-4-(1-pyrrolidinylmethyl)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-14-8 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[4-[(ethylamino)methyl]-3-fluorophenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-15-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyphenyl)-N-4-piperidinyl- (CA
INDEX NAME)




RN 607373-21-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-cyclopropyl-N-4-piperidinyl-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 607373-22-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-cyclopropyl-7-(1-piperazinylmethyl)-1H-
 imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-23-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-methyl-N-4-piperidinyl- (CA INDEX
NAME)



RN 607373-30-8 CAPLUS


CN Methanone, [4-(2-aminoethyl)-1-piperazinyl][2-(4-amino-1,2,5-oxadiazol-3-
yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-, hydrochloride (1:2) (CA
INDEX NAME)



● 2 HCl


RN 607373-31-9 CAPLUS

CN Ethanone, 1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]-2-(methylamino)- (CA INDEX NAME)




RN 607373-33-1 CAPLUS

CN Ethanone, 2-amino-1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 607373-34-2 CAPLUS


CN 1-Propanone, 3-amino-1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 607373-35-3 CAPLUS

CN 1-Propanone, 2-amino-1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 607373-36-4 CAPLUS

CN 1-Propanone, 2-amino-1-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 607373-37-5 CAPLUS

CN Piperazine, 1-[[2-[[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-4-[(2S)-2-pyrrolidinylcarbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 607373-38-6 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(4-piperidinylmethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




RN 607373-39-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-3-piperidinyl-, hydrochloride
 (1:2) (CA INDEX NAME)




●2 HCl

RN 607373-41-1 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[3-(methylamino)propyl]-,
 hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 607373-42-2 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 N-(4-aminobutyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-, hydrochloride
 (1:2) (CA INDEX NAME)



● 2 HCl


IT 607373-43-3P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-(6-aminoethyl)amide dihydrochloride 607373-44-4P 607373-45-5P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-((R)-3-aminopyrrolidin-1-yl)methanone dihydrochloride 607373-46-6P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-((S)-3-amino-pyrrolidin-1-yl)methanone dihydrochloride 607373-47-7P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-((R)-pyrrolidin-3-yl)amide dihydrochloride 607373-48-8P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-((S)-pyrrolidin-3-yl)amide dihydrochloride 607373-49-9P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-[(morpholin-2-yl)methyl]amide dihydrochloride 607373-50-2P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-[1-(2-aminoethanoyl)piperidin-4-yl]amide dihydrochloride 607373-52-4P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-[1-(3-aminopropanoyl)piperidin-4-yl]amide dihydrochloride 607373-53-5P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-[1-((S)-1-pyrrolidin-2-ylmethanoyl)piperidin-4-yl]amide dihydrochloride 607373-54-6P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-pyrrolidin-1-ylmethanone 607373-55-7P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-[(S)-2-[(pyrrolidin-1-yl)methyl]pyrrolidin-1-yl]methanone dihydrochloride 607373-57-9P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-((R)-pyrrolidin-3-yl)amide 607373-58-0P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid N-[2-(piperazin-1-yl)ethyl]amide dihydrochloride 607373-61-5P, 4-[7-[(S)-3-Aminopyrrolidin-1-yl)sulfonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-63-7P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-sulfonic acid methylamide 607373-64-8P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-sulfonic acid dimethylamide 607373-66-0P, 4-[1-Ethyl-7-[(piperidin-4-yl)methoxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-68-2P, 4-[1-Ethyl-7-[(piperidin-4-yl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-70-6P, 4-[1-Ethyl-7-[(E)-2-(4-methoxyphenyl)vinyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607373-71-7P, [4-[1-Ethyl-7-[2-(piperidin-4-yl)ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607373-74-0P, [4-(1-Ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine

607373-75-1P, [4-(1-Ethyl-4-methyl-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-yl]amine 607373-77-3P, [2-(4-Aminofuran-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]methanol 607373-80-8P, [4-[1-Ethyl-4-(pyrazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]amine 607373-81-9P, [4-(1-Cyclopropyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-yl]amine 607373-85-3P, [4-(1-Ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-yl]amine 607373-86-4P, [4-(1-Cyclopropyl-6-phenoxy-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-yl]amine 607373-88-6P, [4-(1-Ethyl-6-phenoxy-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-yl]amine 607373-92-2P, [4-[1-Ethyl-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]amine 607373-93-3P, N-[3-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide hydrochloride 607373-94-4P, N-[4-[[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]acetamide hydrochloride 607373-95-5P, 2-(4-Aminofuran-3-yl)-1-ethyl-N-phenyl-1H-imidazo[4,5-c]pyridin-6-amine 607373-97-7P, [4-[1-Ethyl-6-(methylsulfanyl)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]amine 607374-00-5P, [4-[1-[4-(2-Dimethylaminoethoxy)phenyl]-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]amine 607374-03-8P, [4-(1-Cyclopropyl-6-methyl-5-oxo-1H-imidazo[4,5-c]pyridin-2-yl)furan-3-yl]amine 607374-12-9P, [2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanol 607374-13-0P, [[2-(4-Aminofuran-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl][1-(2-methoxyethyl)piperidin-4-yl]amine 607374-18-5P, [4-[1-[2-(Methanesulfonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-1H-imidazo[4,5-c]pyridin-2-yl]furan-3-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazopyridines as kinase inhibitors)

RN 607373-43-3 CAPLUS


CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 N-(6-aminoheptyl)-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 607373-44-4 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(2-piperidinylmethyl)-,
 hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 607373-45-5 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][(3R)-3-amino-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● 2 HCl

RN 607373-46-6 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][(3S)-3-amino-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● 2 HCl

RN 607373-47-7 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(3R)-3-pyrrolidinyl-,
 hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 607373-48-8 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(3S)-3-pyrrolidinyl-,
 hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 607373-49-9 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(2-morpholinylmethyl)-,
hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 607373-50-2 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
N-[1-(2-aminoacetyl)-4-piperidinyll]-2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 607373-52-4 CAPLUS
CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
2-(4-amino-1,2,5-oxadiazol-3-yl)-N-[1-(3-amino-1-oxopropyl)-4-piperidinyll]-1-ethyl-, hydrochloride (1:2) (CA INDEX NAME)




RN 607373-53-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[1-[(2S)-2-
 pyrrolidinylcarbonyl]-4-piperidinyl]-, hydrochloride (1:2) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 607373-54-6 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-
 c]pyridin-7-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 607373-55-7 CAPLUS
 CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl][(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.




● 2 HCl

RN 607373-57-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 607373-58-0 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-carboxamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[2-(1-piperazinyl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



RN 607373-61-5 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[7-[[(3S)-3-amino-1-pyrrolidinyl]sulfonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 607373-63-7 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-methyl- (CA INDEX NAME)




RN 607373-64-8 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-sulfonamide, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N,N-dimethyl- (CA INDEX NAME)




RN 607373-66-0 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinylmethoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607373-68-2 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-(4-piperidinyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607373-70-6 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[(1E)-2-(4-methoxyphenyl)ethenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 607373-71-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-7-[2-(4-piperidiny)ethyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-74-0 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-4-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607373-75-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-4-methyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607373-77-3 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-4-methanol, 2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1-ethyl- (CA INDEX NAME)




RN 607373-80-8 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-4-(1H-pyrazol-1-yl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-81-9 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607373-85-3 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-6-methoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607373-86-4 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-6-phenoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 607373-88-6 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(1-ethyl-6-phenoxy-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)




RN 607373-92-2 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607373-93-3 CAPLUS


CN Acetamide, N-[3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 607373-94-4 CAPLUS


CN Acetamide, N-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 607373-95-5 CAPLUS

CN 1H-Imidazo[4,5-c]pyridin-6-amine, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-phenyl- (CA INDEX NAME)





RN 607373-97-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-ethyl-6-(methylthio)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607374-00-5 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-6-(4-fluorophenoxy)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607374-03-8 CAPLUS


CN 1,2,5-Oxadiazol-3-amine, 4-(1-cyclopropyl-6-methyl-5-oxido-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)





RN 607374-12-9 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanol,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA INDEX NAME)



RN 607374-13-0 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-7-methanamine,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-N-[1-(2-methoxyethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 607374-18-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[1-[1,2,3,4-tetrahydro-2-(methylsulfonyl)-7-isoquinolinyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



IT 607369-58-4P, 3-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]benzaldehyde 607369-99-3P, 2-[4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenoxy]propionic acid methyl ester 607370-04-7P, [4-[1-[4-(2-Bromoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine trifluoroacetate 607370-82-1P, [4-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]benzyl]carbamic acid tert-butyl ester 607370-97-8P, 2-[3-[2-(4-Aminofurazan-3-yl)imidazo[4,5-c]pyridin-1-yl]phenyl]pyrrolidine-1-carboxylic acid tert-butyl ester 607372-30-5P, [4-(7-Bromo-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607372-39-4P, 4-[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]benzaldehyde 607372-44-1P, [4-[7-Bromo-1-[4-(2-dimethylaminoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607372-48-5P, 4-[[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]piperidine-1-carboxylic acid tert-butyl ester 607372-52-1P, 4-[Acetyl[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]piperidine-1-carboxylic acid tert-butyl ester 607372-95-2P, 4-[7-[(1,4-Dioxo-8-azaspiro[4.5]dec-8-yl)methyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-ylamine 607372-96-3P, 1-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]piperidin-4-one 607373-03-5P, 4-[3-[[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]propyl]piperazine-1-carboxylic acid 9H-fluoren-9-ylmethyl ester 607373-18-2P, [4-[7-Bromo-1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]amine 607373-19-3P, 2-(4-Aminofurazan-3-yl)-1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridine-7-carboxaldehyde 607373-26-2P, 2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridine-7-carboxylic acid 607373-27-3P, 4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazine-1-carboxylic acid tert-butyl ester 607373-32-0P, [2-[4-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]piperazin-1-yl]-2-oxoethyl](methyl)carbamic acid tert-butyl ester 607373-51-3P, [2-[4-[[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]amino]piperidin-1-yl]-2-oxoethyl]carbamic acid tert-butyl ester 607373-56-8P, 1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1-imidazol-1-ylmethanone 607373-59-1P, 4-[2-[1-[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methanoyl]amino]ethyl]piperazine-1-carboxylic acid benzyl ester 607373-62-6P, [4-[7-[(S)-3-[(tert-Butoxycarbonyl)amino]pyrrolidin-


1-yl]sulfonyl]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]furazan-3-yl]carbamic acid tert-butyl ester 607373-67-1P,
 4-[[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]piperidine-1-carboxylic acid tert-butyl ester 607373-69-3P, 4-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]piperidine-1-carboxylic acid tert-butyl ester 607373-78-4P, [4-(7-Bromo-1-ethyl-4-methyl-5-oxo-1H-imidazo[4,5-c]pyridin-2-yl)furazan-3-yl]amine 607373-79-5P, Acetic acid [2-(4-aminofurazan-3-yl)-7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-4-yl]methyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridines as kinase inhibitors)


RN 607369-58-4 CAPLUS

CN Benzaldehyde, 3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]- (CA INDEX NAME)



RN 607369-99-3 CAPLUS

CN Propanoic acid, 2-[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenoxy]-, methyl ester (CA INDEX NAME)




RN 607370-04-7 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[1-[4-(2-bromoethoxy)phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 607370-03-6


CMF C16 H13 Br N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2





RN 607370-82-1 CAPLUS

CN Carbamic acid, [[4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607370-97-8 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1H-imidazo[4,5-c]pyridin-1-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)





RN 607372-30-5 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 607372-39-4 CAPLUS
 CN Benzaldehyde, 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-7-yl]- (CA INDEX NAME)




RN 607372-44-1 CAPLUS
 CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607372-48-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 607372-52-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[acetyl[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 607372-95-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-(1,4-dioxo-8-azaspiro[4.5]dec-8-ylmethyl)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)



RN 607372-96-3 CAPLUS


CN 4-Piperidinone, 1-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]- (CA INDEX NAME)




RN 607373-03-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]methyl]amino]propyl]-, 9H-fluoren-9-ylmethyl ester (CA INDEX NAME)


PAGE 1-A






RN 607373-18-2 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-[7-bromo-1-(2-methoxyphenyl)-1H-imidazo[4,5-c]pyridin-2-yl]- (CA INDEX NAME)




RN 607373-19-3 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxaldehyde, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-(2-methoxyphenyl)- (CA INDEX NAME)




RN 607373-26-2 CAPLUS

CN 1H-Imidazo[4,5-c]pyridine-7-carboxylic acid, 2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl- (CA INDEX NAME)




RN 607373-27-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 607373-32-0 CAPLUS

CN Carbamic acid, [2-[4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]-1-piperazinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 607373-51-3 CAPLUS

CN Carbamic acid, [2-[4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]amino]-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 607373-56-8 CAPLUS

CN Methanone, [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]-1H-imidazol-1-yl- (CA INDEX NAME)




RN 607373-59-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]carbonyl]amino]ethyl]-, phenylmethyl ester (CA INDEX NAME)




RN 607373-62-6 CAPLUS
 CN Carbamic acid, [(3R)-1-[[2-[4-[(1,1-dimethylethoxy)carbonyl]amino]-1,2,5-oxadiazol-3-yl]-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]sulfonyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 607373-67-1 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 607373-69-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 607373-78-4 CAPLUS

CN 1,2,5-Oxadiazol-3-amine, 4-(7-bromo-1-ethyl-4-methyl-5-oxido-1H-imidazo[4,5-c]pyridin-2-yl)- (CA INDEX NAME)



RN 607373-79-5 CAPLUS
 CN 1H-Imidazo[4,5-c]pyridine-4-methanol,
 2-(4-amino-1,2,5-oxadiazol-3-yl)-7-bromo-1-ethyl-, 4-acetate (CA INDEX
 NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

139.36

325.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-19.68

-19.68

STN INTERNATIONAL LOGOFF AT 21:41:00 ON 17 FEB 2009